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Abstract
Acinetobacter baumannii is a multi-drug resistant nosocomial pathogen known for
causing wound related- and respiratory-infections. It is currently on the WHO’s list of
critical pathogens due to its broadly drug resistant nature and the constant appearance
of pan-resistant isolates. A majority of the infections caused by this organism are biofilm
associated, however there is limited existing knowledge regarding the mechanisms used
to engage in this multicellular lifestyle. As such, we set out to explore the factors
influencing this behavior using an 10,000+ isolate transposon mutant library of A.
baumannii strain AB5075. Of the strains tested, 6.45% demonstrated some level of
change to their biofilm forming capacity (either increased or decreased). The screen,
coupled with more in-depth (extracellular matrix) ECM analyses and real-time biofilm
tracking, allowed us to further characterize 16 of the most influential strains. During this
investigation, the most significant biofilm phenotype was observed for a tn mutant of a
universal stress protein, which demonstrated an 8-fold increase in biofilm formation
compared to the wildtype strain. This led us to investigate the function of this protein.
Through this, we have named the protein UspG based on structure prediction tools and
demonstrate its essentiality in the survival of AB5075 in whole human blood; likely
mediated at least in part by aiding in protection against oxidative stress. In addition, we
reveal its importance during exponential growth through expression monitoring and RNA
sequencing analysis. These studies reveal that UspG broadly influences cellular
behavior, and specifically the processes of virulence, metabolism, and cell envelope
ix

homeostasis. Collectively, these studies provide a deeper understanding of pathways
important in the formation and maintenance of biofilms in A. baumannii. Further
examination of the factors highlighted herein will provide promising insight into potential
targets for therapeutic intervention in the clinical setting.

Towards the latter point, the rising rates of multi-drug resistant bacterial infections
demonstrate a pressing need for the development of new antibacterial agents with novel
mechanisms of action. Medicinal plants are a viable source for antimicrobial peptides and
therefore we have worked with collaborators on development of the PepSAVI-MS pipeline
for bioactive peptide discovery. This platform uses mass spectrometry coupled with
statistics to create a highly versatile approach to isolating bioactive peptides from complex
multi-cellular systems. Our primary focus in this regard is ribosomally synthesized posttranslationally modified peptides (RiPPs), which have been largely overlooked in standard
AMP fractionation techniques. We have validated this approach through the screening of
Viola odorata fractions and thereafter assessing the bioactivity of purified AMPs of
interest, including cycloviolacin O2, against the ESKAPE pathogens. Herein we report the
bioactivity of several additional ethnobotanical species, many of which possess profound
and broad-spectrum activity against an array of multi-drug resistant bacterial pathogens.
With the evident promise of our preliminary analyses based on bioactivity alone, we are
confident that this pipeline will reveal novel antimicrobial peptides with potential as future
therapeutics.

x

Chapter 1: Introduction

Bacterial Biofilms

What is a biofilm? Bacterial biofilms are a collection of cells encompassed by a
protective matrix largely composed of macromolecules such as proteins, eDNA and
polysaccharides. The formation of a biofilms is ubiquitous in nature. They serve as a
means of protection and allow for survival from harsh surrounding environments and
external threats. Biofilms can exist on a variety of abiotic or biotic surfaces or as freefloating aggregates. In addition, bacteria can form mono-culture biofilms, however, many
times multi-species biofilms are formed. These can include bacteria exclusively or
bacteria and fugal mixtures. Based on reports of fossilized formations within rock and
from deep sea hydrothermal vents, it is estimated that biofilms have been forming for
billions of years[1]. The first description of a live biofilm was recorded as early as 1683
when Antoni van Leeuwenhoek observed a scraping from his teeth using his famous
primitive microscope[2]. Since then, biofilms have been attributed to a variety of diseases
and will be discussed in depth in the following sections.

Biofilm Forming Bacteria and Associated Disease Manifestations. It has been
estimated that 80% of bacterial infections are biofilm associated[3]. In addition, there are
currently no FDA approved antibiotic or chemical treatments with the ability to eradicate
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biofilms. This is further exacerbated by the fact that biofilms can be up to 1000x more
resistant to antibiotic intervention than their planktonic counterparts. Of equal concern, is
the lack of standardized practices for the study of biofilms in the laboratory setting[3],
which leads to variations in experimental results, yielding studies that cannot be directly
related and thus slows progress in the field.

Bacteria within biofilms are protected from the external environment, which leaves them
adept at evading parts of the immune system; however, there are disadvantages to this
state that the bacteria must overcome. For example, nutrients are not as readily available,
and resources become scarce quickly. This leads to metabolically distinct populations
within the biofilm based on location. Levels of oxygen within the biofilms are limited within
the center which forces bacteria to adapt[2]. Some bacteria are dormant, while others
become persisters, and yet others demonstrate a stationary phase-type lifestyle. Thus,
inevitabilities such as nutrient limitation greatly influence cellular behavior. Bacteria are
able to overcome some of these limitations by forming structures that allow channels of
water and nutrients to access more of the biofilm population and provide routes for waste
elimination to avoid toxicity. In addition, cells have mechanisms to communicate and
signals to dictate when the biofilm should disperse and relocate.

There are, however, other advantages to bacteria living in a biofilm state within, say, the
human body. One such advantage to cells becoming metabolically inactive and dormant
is the subsequent downregulation of a variety of systems that antibiotics rely on to
properly function and eliminate target bacteria[2]. Therefore, they are much more tolerant
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to antibiotic treatment. Biofilms within the body induce the innate and adaptive immune
responses depending on their growth phase, however, bacterial clearance is usually
unsuccessful, and instead results in host tissue damage as a byproduct of the immune
response[3, 4].

Biofilm associated disease manifestations of the body include: otitis media, infective
endocarditis,

atherosclerosis,

salivary

duct

stones,

recalcitrant

typhoid

fever,

inflammatory bowel disease, colorectal cancer, wound infections, bacterial vaginosis,
chronic endometritis, pharyngitis, laryngitis, pertussis, cystic fibrosis, chronic bacterial
prostatitis, gingivitis and urinary tract infections [2]. In addition, biofilms can be formed on
a variety of indwelling medical devices and can often result in bloodstream infections that
are then considered biofilm associated[5]. The same is true for ventilator associated
pneumonia. Some examples of medical devices on which biofilms are known to grow
include central venous catheters and their needleless connectors, contact lenses,
endotracheal tubes, intrauterine devices, medical heart valves, pacemakers, peritoneal
dialysis catheters, prosthetic joints, tympanostomy tubes, urinary catheters, and voice
prostheses[5, 6]. The kind of bacteria typically associated with indwelling devices is
dependent upon the location of the device. In some instances, they are able to form single
organism biofilms, however, multi-species biofilms are also common. Staphylococcus
aureus may be the most commonly isolated bacteria from biofilms with typical isolations
from central venous catheters, prosthetic heart valves, diabetic foot infections, artificial
hip prosthetics, and intrauterine devices[5]. Klebsiella pneumoniae and Escherichia coli
are commonly isolated from central venous catheters as well as urinary catheters, while
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Pseudomonas aeruginosa is commonly found on artificial hip prosthetics[5]. Both Gramnegative and Gram-positive bacteria are able to from the same type of biofilm associated
infections, many times, together[7]. Examples include biofilms of the oral cavity, otitis
media, diabetic foot infections and cystic fibrosis[8].

The most well studied co-culture biofilm is demonstrated by cystic fibrosis patients that
go through cycles of colonization with S. aureus and P. aeruginosa. Typically, children
are predominantly colonized with S. aureus and as they age P. aeruginosa becomes the
primary organism, however, they continue to coexist. The secretion and sensing of
bacterial byproducts and signaling molecules by each organism can result in exacerbated
disease symptoms for the host[9, 10]. Specifically, P. aeruginosa produces a variety of
anti-staphylococcal virulence factors such as proteases and toxins that can target S.
aureus, but also host cells[11].

Impact of Bacterial Biofilms in the Clinic and the Environment. Bacterial biofilms not
only influence and lead to chronic, persistent infections, but they present problems in
other areas. For example, biofilms formed by bacteria such as Listeria monocytogenes
and Salmonella spp. can cause food poisoning and are commonly found in food
processing plants with below-average sanitation practices[12, 13]. Bacteria such as
Escherichia coli are very prominent biofilm formers in humans, but also cause food borne
illness due to growth on produce such as lettuce[14]. Instances such as this not only pose
a threat to human health, but cause significant economic costs due to necessary recalls
and associated food spoilage[13]. Another example of a strong biofilm forming organism
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is Vibrio cholera, which exists as a biofilm within its natural environment, water, but readily
colonizes the gut of humans upon ingestion[15]. Biofilms are also associated with manmade structures where they can cause the disruption of waterways or pipes, which is
referred to as biofouling.

Biofilms are not all bad, however, as some populations are able to fix nitrogen and
bioremediate wastewater. Further, biofilms have recently been used for biomass
production from N2 through microbial electrosynthesis which could be the next approach
in creating sustainable biofuels[16, 17].

Biofilm Formation, Effectors and Regulation. Typically, biofilm formation has been
described as a cycle that includes four to five steps and will be described in the form of a
summary of these references and in Figure 1[18-20]. For surface associated biofilm
formation, the first step includes the reversible attachment of planktonically growing
bacteria to a surface. This is accompanied by the downregulation of motility genes and
the upregulation of adhesins. The next step is the irreversible attachment of the bacterial
community which starts to accumulate in the form of a microcolony. Bacteria are actively
growing during this stage, and cell-cell adhesion starts to occur with production of
extracellular matrix (ECM) components also accumulating. The ECM continues to form
and mature during the third step, referred to as maturation I. During this step, the cells
are still growing, and the biofilm structure starts to take form as microcolonies merge to
form a macrocolony. The fourth step is maturation II, or full maturation, which is the most
resistant to chemical or immune cell exposure. A biofilm structure can be flat or form a
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mushroom like configuration containing fluid filled channels that transport nutrients to
various locations within the biofilm. Finally, once a certain threshold is met and resources
are exhausted, signaling triggers the dispersion of the biofilm where cells re-enter a
planktonic state and disseminate to other parts of the body. This is step five and initiates
the cycle to start again and form a biofilm at a different location.

Figure 1. Stages of Biofilm Formation. 1) Bacteria in a planktonic state reversibly attach
to a surface and start to accumulate. 2) Cells adhering near each other start to form
microcolonies and ECM is starting to form. 3) Microcolonies start to merge into
macrocolonies and ECM continues to grow. 4) Mature biofilm is formed where cell growth
is minimal and ECM is established. 5) Dispersal is initiated and cells re-enter a planktonic
state to find new location to restart biofilm cycle. Created using Biorender.com.
Surface composition can greatly influence the speed and efficiency of attachment for
biofilms. In general, bacterial cell surfaces are negatively charged and therefore the
attachment to positively charged surfaces is more likely[6]. However, factors such as
adhesins are important and can promote binding to biotic surfaces that may have similar
charges[6]. There are differences between Gram-positive and Gram-negative bacteria
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when it comes to surface charge although they are both negatively charged overall. For
example, wall teichoic acids contribute to charge in Gram-positive organisms while
lipopolysaccharide (LPS) is this component in Gram-negative organisms[6]. In addition to
charge, hydrophobic surfaces are typically better for the attachment of bacteria to
surfaces as compared to hydrophilic surfaces[21, 22].

The regulation of biofilms is unique to each bacterium, however there are some universal
triggers to initiate the process. One regulator of biofilm formation is the secondary
messenger cyclic di-GMP, produced by diguanylate cyclase enzymes. This molecule is
accumulated in biofilms and promotes several biofilm effectors such as adhesins and
capsule production[23]. Other initiators include two component systems, small RNAs,
secreted signaling molecules, and quorum sensing systems[24].

Acinetobacter baumannii

Background. Acinetobacter baumannii is a Gram-negative, coccobacilli bacterium that
is ubiquitous in nature. It has been recovered from sources such as water, soil, animals,
and humans[25]. A. baumannii is considered the most pathogenic of the Acinetobacter
genus and similarly most commonly causes infections in humans[26]. A. baumannii has
high similarity to A. calcoaceticus and until recently their distinction was very difficult.
Therefore, reporting on and studies of these pathogens likely overlapped, thus literature
reflects a combination of these species[26]. The same is true for two other species that
are known to cause both community acquired and nosocomial infections: A. pittii and A.
nosocomialis[27]. These species are often collectively referred to as A. baumannii[28].
7

Further, many times Acinetobacter genomic species 3 and 13TU are also referred to as
A. baumannii complex or simply A. baumannii. There are over 50 species within the
Acinetobacter genus, however, it was estimated by the CDC in 2004 that 80% of
infections are caused by A. baumannii specifically.

A. baumannii has a particularly dire association with war, as it was one of the most
common Gram-negative organisms isolated from traumatic injuries of wounded soldiers
in Vietnam[25], and was commonly isolated from wounded soldiers during the Iraq and
Afghanistan War[29]. Indeed, the species is sometimes referred to as “Iraqibacter” due to
this association. Although it is tempting to presume that the correlation of infections and
wartime stems from the exposure of wounded soldiers to environmental isolates of A.
baumannii, this is highly unlikely. Instead, it is the unique ability of A. baumannii to exist
for extended periods of time on a variety of surfaces that results in the transfer of infecting
A. baumannii strains from hospital to hospital and patient to patient[29]. Specifically, A.
baumannii isolates are able to persist for days on inanimate surfaces such as medical
equipment, in sinks, on pillows and mattresses, on stainless steel trolleys, bedrails, and
tables[25]. The hypothesis that persistence and transmission of A. baumannii in hospitals
leads to higher infection rates of soldiers during wartime instead of the presumed
environmental soil exposure hypothesis was validated by a study of soil samples within a
region of war that yielded only one A. baumannii isolate, clonally distinct from those found
in soldiers[30]. Further supporting this notion was the isolation of A. baumannii from every
health care facility on the evacuation route from both Afghanistan and Iraq[30].
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Outside of human-to-human transmission, an additional source of A. baumannii isolation
is food, which may serve as an additional source for exposure of hospital patients.
Specifically, A. baumannii can be found on a variety of vegetables including apples,
potatoes, lettuce, sweet corn and mushrooms, among others[31]. In addition,
transmission to humans via body lice has also been reported[32]. With standard medical
equipment, food, and insect vectors all serving as sources for A. baumannii exposure, it
is easy to visualize how quickly this organism can spread within health care facilities. This
also highlights how important it is to maintain a hygienic environment if transmission
control is to be effective.

A. baumannii is considered an opportunistic pathogen that is extremely adept at
colonization. This species is regularly isolated from hospitalized patient urine samples
and respiratory secretions without being associated with disease[25]. Within the body, it
is able to colonize a variety of locations including the digestive tract[33]. Although
Acinetobacter species such as A. lwoffi are commonly found on the skin of healthy
individuals as normal flora, it is rare to find A. baumannii on the skin[34] particularly
outside of urban areas[35]. Therefore, the most likely mode of colonization is ingestion or
inhalation with patients who are immunocompromised at much higher risk for infection.

Disease Manifestations. According to the CDC, patients at most risk for A. baumannii
infection are those within healthcare facilities with ventilators, catheters, open surgical
wounds, patients of the intensive care unit (ICU) or those who have extended hospital
stays. Further there has been a correlation between infection and organ type. Infections
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tend to manifest in areas where organs are liquid filled such as the respiratory tract, the
peritoneum, or the urinary tract. In the United States between 2009-2010 it was estimated
that A. baumannii was the cause of 1.8% of all healthcare associated infections (HAIs)
with an average of 45,000 per year becoming infected[36, 37]. Globally it was estimated
that 1 million infections were caused by A. baumannii annually[37]. By 2013 the
estimation of multidrug resistant infections reached 7,300 per year in the US, which
resulted in 500 deaths. In a report published in 2020 discussing the infections of 2017,
Acinetobacter species were ranked as the 14th most reported pathogen within long term
acute care facilities and hospital ICUs[38]. Carbapenem and multi-drug resistant isolates
accounted for a large majority of strains identified within long-term healthcare facilities,
particularly those causing ventilator associated pneumonia (VAP) and blood stream
infections[38].

Types of infection caused by A. baumannii include pneumonia, bacteremia, urinary tract
infections, wound infections, exudates and abscess formation, meningitis, endocarditis,
osteomyelitis, and endophthalmitis. The highest number of infections seems to occur
between the months of July-October[25, 39]. Although the reasoning behind this is
unclear there has been an association with heat and high humidity (tropical
environments)[40] which could result in higher chances for colonization. This is based on
evidence that A. baumannii can be transmissible through the air and lead to
colonization[41].The highest number of infections are nosocomial, but community
acquired infections do occur[40]. Most A. baumannii infections occur within the ICU of
hospitals with up to 54% mortality reported[25]. One example comes from the study of
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bacteremia caused by A. baumannii which showed a mortality rate of 42.2% in the ICU
while bacteremia caused by other organisms had a mortality rate of 34.4%[42]. This
suggests that morbidity due to blood stream infections is slightly elevated for A.
baumannii. However, an additional study of pneumonia infections concluded that A.
baumannii infection outcomes were similar to that of the same infection type caused by
other organisms[43]. More studies with higher patient pools are needed to accurately
associate morbidity due to A. baumannii infection types compared to other organisms in
addition to the reasoning behind the differences. However, the increasing use of
collaborative reporting and advancements in bioinformatic analyses will undoubtedly lead
to more accurate infection surveillance very soon.

Antibiotic and Antiseptic Resistance. A. baumannii has the ability to resist a variety of
antimicrobial treatments including but not limited to fluoroquinolones, aminoglycosides,
tetracyclines, beta-lactams, glycylcyclines, and polymyxin antibiotics. The strains of most
concern, however, are those considered resistant to the newest class of beta-lactam,
carbapenems. Carbapenem resistance is defined as a strain with the ability to resist
exposure to one or more of the carbapenem antibiotics such as imipenem, doripenem, or
meropenem. According to one study, it was estimated that carbapenem resistant A.
baumannii infects 22,950 people annually in the United States with 75,000 estimated
infections globally[37]. This estimated resistance in turn contributes to almost 5,000
excess deaths per year at an excess cost of $389,000,000 in the United States[37]. This
valuation is slightly off of the CDC estimation of 8,500 infections, 700 deaths and
$281,000,000 in costs annually due to carbapenem resistant A. baumannii infections[44].
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Regardless of the source of reporting, it is clear that this organism causes detrimental
impacts on both human health and the economy that need to be addressed.

The last line of treatment for carbapenem-resistant strains is the use of colistin, a
membrane disrupting antibiotic, however, A. baumannii has a variety of ways to resist this
antibiotic. Colistin acts by targeting and binding the lipid A anchor of LPS or
lipooligosaccharides (LOS) and the outer membrane phospholipids which leads to
membrane disruption and ultimately cell death. A. baumannii is able to resist colistin
treatment through the modification of lipid A by the addition of galactosamine[45] or
phosphoethanolamine[46, 47]. Bacterial strains can accomplish this through forming
mutations in the pmrAB two-component system, which leads to the overexpression of
pmrC, encoding a lipid A modifying enzyme[48]. Alternatively, mutations in the lpxACD
operon can result in the deletion of LOS[49], therefore, colistin binding is prevented
altogether.

Another means of resistance to a variety of antibiotics comes in the form of efflux pumps.
These allow the bacterium to resist antibiotic exposure by expelling the drug and
preventing its accumulation within the cell, thus resulting in an increased minimum
inhibitory concentration (MIC). A. baumannii produces a multitude of efflux pumps some
of which are yet to be characterized. In particular, A. baumannii possesses pumps of the
major facilitator superfamily (MFS), small multidrug resistance (SMR) family, multidrug
and toxic compound extrusion (MATE) family, proteobacterial antimicrobial compound
efflux (PACE) family, and most importantly, the resistance-nodulation cell division (RND)

12

family[50]. RND family pumps are known for their ability to expel a variety of antibiotics
as well as antiseptics, biocides, detergents, and dyes[50].One of the best studied
examples is the RND efflux pump in A. baumannii is encoded by adeABC, which is under
the control of a two-component system AdeRS. This pump is responsible for expelling a
variety of antibiotics including aminoglycosides, fluoroquinolones, and tigecycline while
concurrently contributing to better fitness in vivo[51]. In addition, the AdeAB and AceI
efflux pumps of A. baumannii are responsible for the expulsion of chlorohexidine, a
commonly used antiseptic that targets bacterial membranes[52] thus, in part, contributing
to the persistence of this organism on hospital surfaces. Resistance to other antiseptics
such as ethanol and hydrogen peroxide have also been reported. Additional mechanisms
of

resistance

by

A.

baumannii

include

the

production

of

beta-lactamases,

cephalosporinases, carbapenemases, antibiotic modifying enzymes, shifts in membrane
permeability, and alterations of antibiotic target sites[50].

Treatment Options. Colistin is primarily used when dealing with pan-resistant isolates,
or for the treatment of severe infections, such as meningitis, and has shown to be very
effective[53, 54]. The combination of colistin and sulbactam has also been used for the
treatment of VAP[55]. The use of colistin and similar polymyxins is effective, however,
many patients present with negative side effects such as nephrotoxicity following
treatment and resistance does occur. Difficult to treat A. baumannii strains causing
intraabdominal infections are commonly successfully treated with the glycylcycline
tigecycline,

however,

more

studies

are

necessary

before

it

is

universally

recommended[56]. The safest options to treat A. baumannii infections with minimal
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patient side effects include the use of beta-lactams or fluoroquinolones. However, a
multitude of resistance mechanisms exist and therefore A. baumannii strains must be
tested to ensure susceptibility to the antibiotic of choice prior to treatment of the patient.

There have been attempts made to develop vaccines targeting A. baumannii, however
these efforts have remained unsuccessful thus far. This is in part due to the high amount
of genetic diversity seen for A. baumannii strains. For example, within the species, nearly
40 serotypes have been identified. Therefore, vaccines are not likely to be a functional
option for treatment of A. baumannii infections now or in the foreseeable future. There is
however hope, as two novel antibacterial agents are showing promising anti-A. baumannii
activity. First, cefiderocol, a catechol-substituted siderophore cephalosporin was recently
approved (2019) by the FDA to treat complicated urinary tract infections caused by Gramnegative bacteria and is now being evaluated for its ability to treat VAP and sepsis with
promising results[56]. Second, is the FDA approved synthetic fluorocycline, eravacycline,
recommended for the treatment of complicated intraabdominal infections. It is similar to
tigecycline, but more potent against A. baumannii[56]. These drugs will serve as reliable
first-line treatments of A. baumannii infections allowing for more limited use of toxic
salvage therapies such as colistin.

The CDC has been surveilling carbapenem resistant infections in the United States
through the Emerging Infections Program. Recently, in 2021, they have extended this
surveillance to track the occurrence of carbapenem resistant A. baumannii from normally
sterile sites, such as urine specimens, lower respiratory tracts, and wounds. This effort is
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tracking the presence of these pathogens in nine states within the US and will give better
insights into the best way to treat resistant infections. However, the overall consensus is
that by tailoring an antibiotic regimen to a particular clinical isolate through laboratory
testing prior to antibiotic treatment, resistance can be mitigated, and overall better patient
outcomes will result.

Contributors of Virulence in A. baumannii

Regulators of Virulence. One of the global virulence regulators in A. baumannii has
been identified as the two-component system GacSA, which regulates motility, pili
synthesis, biofilm formation, amino acid metabolism and survival within the host[57].
Another regulator of virulence is the transcriptional regulator Fur (ferric uptake regulator),
which controls systems for iron acquisition, an essentiality for survival in vivo. Another
similar regulator of virulence controlling metal homeostasis is Zur, which controls two
distinct zinc acquisition systems within A. baumannii[58].An additional, rather unique
regulator of virulence is BlsA, which responds to light and temperature to influence
virulence through iron metabolism via direct interactions with Fur[59]. Photoregulation is
a unique feature in A. baumannii virulence that is not yet fully understood. However, it is
tempting to speculate that this regulator, BlsA, contributes to the shifts in cell behavior
outside of the host that require persistence on surfaces, and within the host, where light
is absent, but iron scavenging and virulence factor production are necessary.
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Virulence Factors. The most well studied virulence factor produced by A. baumannii is
OmpA, an outer membrane protein that facilitates the adherence to host cells, mediates
their invasion and promotes cell death. A. baumannii also produces a variety of porins
(Omp22, Omp33, Omp36, CarO) similar to OmpA that induce host cell death. Other
membrane associated factors are also essential and contribute to virulence in A.
baumannii. For example, type two secretion systems (T2SS) secrete factors that are
required for virulence such as the lipoyl synthases LipA [60]and LipH as well as proteases
such as CpaA[61]. Phospholipase C as well as LPS and penicillin binding proteins also
serve as virulence factors by contributing to resistance to serum and promoting survival
in vivo[62].

Although Acinetobacter translates to non-motile rod, it is now known that A. baumannii is
capable of two forms of motility- twitching motility and surface associated motility.
Specifically, A. baumannii demonstrates twitching motility through the use of type IV pili,
allowing the organism to travel on wet surfaces in a flagella-independent manner. Surface
associated motility is in part controlled by quorum sensing, however, a mechanism for
this is unclear[63]. These forms of motility are considered virulence effectors as they
contribute to survival within the host and certain components such as PilA serve to assist
in immune evasion[62].

Another mechanism of virulence is the ability of A. baumannii to scavenge metals from
the host such as zinc, iron, copper, and manganese. These metals are necessary to serve
as structural cofactors for a variety of proteins and essential systems and are therefore
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important for the survival of A. baumannii. Zinc acquisition is accomplished via the
expression of the ZnuABC system, which is regulated by the Zur transcription factor and
allows for resistance to calprotectin zinc sequestration by the host when levels of zinc are
low[64]. Another Zur regulated system induced following zinc starvation is the
metallochaperone ZigA, which sequesters zinc from histidine-zinc complexes with the
help of HutH[65].

Copper resistance is also a major contributor of virulence in A. baumannii. This is
achieved through the production of a variety of proteins that function to regulate copper
transport, oxidation, sequestration, and homeostasis. Copper is used by the immune
system as a means for bacterial clearance due to its toxicity and therefore these
resistance mechanisms are vital to ensure survival in vivo[66]. The regulation of iron is
equally important, and homeostasis is regulated in some part by Fur. A. baumannii also
possesses a variety of heme oxygenase enzymes which remove iron from hemin. Other
uptake systems for iron are present in A. baumannii as well as the production of
siderophores that chelate iron[67]. Iron uptake can also be regulated by a membrane
porin, OmpW that also contributes to antibiotic resistance through colistin binding[68].

A. baumannii also produces a variety of putative efflux pumps, fimbriae systems, pili
components and membrane proteins that are yet to be characterized, but likely contribute
to virulence. In addition, this species has a variety of stress response proteins that protect
the cell from external threats such as DNA damage, exposure to reactive oxygen species
(ROS) and nutrient starvation.
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Capsule and Immune Evasion. A significant way that A. baumannii can avoid detection
by the immune system is through the production of glycoconjugates: bacterial
carbohydrates that act as a line of defense against host cells and the environment. One
such glycoconjugate is a capsule consisting of polysaccharides. Specifically, capsule
formation can protect against complement mediated killing[69]. Immune evasion also
comes in the form of glycosylation of type IV pili to render them undetectable by host cell
antibodies[70]. Capsules also play a role in the formation of biofilms which protect A.
baumannii and allow them to persist within the infected host.

Desiccation Tolerance. One of the reasons A. baumannii is able to thrive within the
hospital environment is its ability to survive for extended periods of time without water or
nutrients[71]. Its ability to persist on objects such as medical equipment and bed rails for
longer than a week allows for a variety of opportunities for secondary infections and
patient exposure[72, 73]. Depending on the strain, A. baumannii isolates such as AB5075
can survive desiccation for over 90 days[74]. Based on this study, desiccation tolerance
was attributed to the function of BfmR, a response regulator that controls the production
of oxidative stress response genes as well as other factors following nutrient starvation
or high osmolarity. In general, tolerance is thought to be due to the expression of capsular
polysaccharides, which can assist in retaining water for extended periods of time[70]. In
addition, changes in the cell envelope that induce a thicker cell wall, a shift from rod shape
to cocci shape cells and higher electron density occur following desiccation[75].
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Acinetobacter baumannii Biofilms

Types of Biofilms. Acinetobacter baumannii is able to form biofilms as free-floating
aggregates, at the surface-liquid interface of cultures or at the air-liquid interface in the
form of a pellicle. Surface associated biofilms are able to form on a variety of surfaces
typically found within a clinical setting such as glass, rubber, porcelain, polypropylene,
stainless steel, and polycarbonate[21]. Of these, polycarbonate and stainless steel
promote the most biomass accumulation. Polycarbonate is hydrophobic, which is a
characteristic that is common for the promotion of bacterial attachment. Biofilms can also
form under static conditions or within flow cell systems such as bioreactors where
nutrients are continually replenished and the biofilm is under sheer stress[76]. Flow cell
systems attempt to mimic the environment that would be experienced within the body and
therefore serve as a good model for biofilm characterization in vitro. Importantly, the
system of study dictates the biofilm structure and cell behavior which is very different
when parameters such as media, temperature, length of incubation, and stasis are
changed[44]. Therefore, it is important to continue to investigate multiple forms of biofilms
produced by A. baumannii. Thus, we will understand the major regulators controlling
biofilms residing within the hospital on surfaces as well as those causing persistent
infections in vivo that are increasingly difficult to treat.

Regulators and Known Effectors of Biofilm Formation. BfmRS is one of the best
characterized regulators of biofilm formation in A. baumannii, particularly due to its control
of the csu-operon-encoded usher pili system essential for the formation of biofilms on
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abiotic surfaces[77]. In addition, GacSA has been shown to regulate this operon and
indirectly influence biofilm formation[57].

Other than the expression of the csu operon, other factors exist that contribute to biofilm
formation. For example, Bap encodes a very large biofilm associated protein that assists
in maintaining a stable mature biofilm structure[78]. Further, a type I secretion system
exists to export Bap, and thus assists in maintaining biofilm stability[79]. In addition, the
production of an autotransporter adhesion (Ata) assists in adherence of biofilms to
membranes of the host[80]. Another essential component of a successful biofilm is the
production of poly-β-1,6-N-acetylglucosamine (PNAG) encoded by the pgaABCD
locus[81]. The production of capsule in the form of polysaccharides has also been
attributed to better biofilm formation[69]. In addition, O-linked glycosylation is important
for virulence as well as biofilm formation[82].

Pili systems are also known to be upregulated during biofilm formation, specifically filF,
fimA, and papC transcripts are universally upregulated regardless of the time of
incubation or differing growth conditions of A. baumannii[44]. In addition, RND efflux
pumps and iron acquisition systems are upregulated in A. baumannii biofilms, which links
antibiotic resistance to biofilm formation[44]. This connection has been explored for a
variety of antibiotics. More recently, connections have been drawn between the presence
of biofilm associated genes such as pili and the presence of a CRISPER/cas system,
however the details behind their involvement remains unclear[83].
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Antimicrobial Peptides

Origins and Properties. Antimicrobial peptides (AMPs) are produced by every domain
of life. The first AMP was isolated from a soil bacterium, Bacillus brevis in 1939 following
experiments that showed protection of mice against pneumococcal infection[84, 85]. The
peptide was later identified as a mixture collectively named gramicidin. Since then, a
variety of peptides have been identified in plants, animals, protozoa, fungi, and insects.
In addition, many have been synthetically derived.

Humans produce AMPs as a first line of defense against invading pathogens. The most
important and best studied human AMP is the cathelicidin LL-37 that functions to kill
invading bacteria, but also modulates the immune system and ensures it does not
overreact to the exposure of bacterial components such as LPS[86]. LL-37 can protect
against infection in a variety of areas, including the pulmonary and digestive systems, the
genitourinary system, salivary glands, skin, and ocular surfaces[86].

AMPs are characteristically small, typically cationic, and amphipathic. According to the
peptide database, ADP3, (aps.unmc.edu/classification) however, they can be classified
as either cationic, neutral, or anionic. Further they can be hydrophobic, amphipathic, or
hydrophilic. Peptides within this database are considered to be AMPs if they consist of
between 2-100 amino acids. AMPs made up of greater than 100 amino acids are instead
considered antimicrobial proteins which includes lysozyme or histones, for example. In
addition, if the AMP composition consists of at least 25% of a single amino acid (X), they
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are termed X-rich peptides. For example, proline-rich or glycine-rich peptides have been
discovered to have antimicrobial properties[87-89]. They can be classified based on their
biological function, for example some are antibacterial or antifungal, while others are
chemotactic, insecticidal or mediate wound healing. Another form of classification is
termed the universal classification system (UC) which separates AMPs into four classes:
class I (UCLL) are linear one-chain peptides or two linear peptides not connected
covalently; class II (UCSS) are sidechain-sidechain linked peptides; class III (UCSB) are
polypeptide chains with a sidechain to backbone connection; and class IV (UCBB) are
circular polypeptides with a peptide bond between both termini[90]. Examples of class II
include disulfide containing defensins or ether-bond containing lanthibiotics, while class
III include bacterial lasso peptides and fuscaricidins[90]. Finally, class IV peptides include
cyclotides from plants or theta-defensins from animals[90]. An additional layer of
classification is the distinction between peptides based on the presence or absence of
beta sheets or alpha helices in their secondary structure. For example, AMPs within the
alpha family contain helical structures, while those within the beta family are composed
of beta-strands and those within the alpha-beta family have both. The final family within
this classification is the non-alpha-beta family, with AMPs that do not possess helices or
beta-strands.

These numerous forms of classification allow for quick insights into the characteristics of
a particular peptide. This is necessary to readily distinguish between each AMP as the
number of sequences within the databases rapidly rises. As of October 20, 2021, there
are 3,273 AMPs within APD3, 2,756 of which are considered antibacterial
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(aps.unmc.edu). There are a variety of other AMP databases, however, ADP3 is the
largest that is specific to AMPs. For example, there is a biofilm AMP database, but only
221 peptides are present (baamps.it). This is likely due to the juvenescence of this niche
field. Databases such as these are a great resource to promote the understanding of
AMPs and to collectively compare newly identified peptides to those reported within the
databases.

Methods for Discovery. Natural products drug discovery has had many successes over
the years, however, approaches to identify new environmental compounds is not always
as easy as screening large synthetic small molecule libraries. For example, fractionation
and purification are considered far more laborious than the high-throughput screening of
combinatorial libraries[91, 92]. However, new advancements in biotechnologies have
resulted in a better understanding of genomics, natural product biosynthesis, synthetic
biology, transcriptomics, and post-translational modifications. These advancements have
propelled us towards what we hope to call the New Golden Age of natural products drug
discovery[91]. For example, platforms have emerged that are aimed at targeting
druggable proteins and peptides and predicting ligands through chemoproteomics
resulting in target specific identification from a variety of natural product sources[93].

A number of approaches have been considered the gold standards for AMP discovery,
such as bioassay guided fractionation. This includes the isolation of peptides through
solvent extraction followed by fractionation using chromatography. These crude fractions
are then tested for bioactivity and bioactive fractions are then reassessed to identify the
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component within contributing to activity. Bioactive components are then isolated,
purified, and retested, while their structure is simultaneously elucidated. Unfortunately,
this requires multiple rounds of fractionation and subsequent bioactivity screening before
a single peptide can be isolated. A disadvantage to this approach is the inability to isolate
active peptides from a crude fraction of peptides. There are multiple reasons for this,
including the degradation of bioactive components during purification due to its instability,
the existence of bioactive peptides at too low of a concentration, thus preventing isolation,
or the interdependence of multiple peptides within a fraction working synergistically to
exhibit bioactivity[94]. Further to this, there is a disappointingly high rate of reisolating
peptides that have previously been discovered using such approaches.

A way in which to avoid this repetition is through the use of dereplication or the preanalysis of partially purified (fractionated) samples using NMR or mass spectrometry. The
efficiency of this step is also growing as dereplication databases such as the Dictionary
of Natural Products for spectral alignments is expanding. Resources such as the Global
Natural Product Social molecular networking platform (GNPS) is also growing rapidly and
allows for the annotation of bioactive products. Certain groups have proposed the use of
a workflow termed bioactive molecular networking which integrates bioactivity scoring and
MS/MS data to assist in bioassay guided fractionation processes[94]. This approach is
similar to the novel pipeline that was created by our collaborators at the University of
North Carolina, Chapel Hill -the statistically guided bioactive peptides prioritized via mass
spectrometry (PepSAVI-MS) approach. This allows for bioactivity to be attributed to
peptides through simultaneous mass spectrometric analysis with bioassay guided
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statistics to identify peptides with bioactivity[95]. This pipeline aims to identify cationic
peptides of medicinal plants, but it has proven as successful in identifying novel AMPs
from other sources as well.

When considering experimental design for assessing bioactivity there are additional
challenges. The cationic nature of AMPs can cause off-target binding to certain assay
materials that make screening a extensively thought out process. Peptides can bind to
components within the media being tested, other experimental materials, compound vials,
or even transport material, such as pipette tips. Therefore, testing must account for the
physiochemistry of the AMPs to be tested. Common laboratory consumables are
composed of polypropylene, polystyrene, or borosilicate glass, each of which elicit some
level of AMP binding[96, 97]. Experimental design, however, can limit this interaction,
leading to more representative results. Another feature of AMPs that is their tendency to
be unstable. To overcome this limitation, AMPs should be tested within the same day,
freeze-thaw cycles should be minimized, and AMP concentrations should be increased
to account for loss due to binding. In addition, selecting a media that allows for the AMP
being tested to remain soluble within the testing range is essential.

The advantageous approach of testing the bioactivity of AMPs within the same day to
ensure peptide stability can be achieved by tracking bacterial respiration instead of
implementing traditional overnight MIC assays. Fluorescent dyes have been used for this
purpose, however, the nontoxic dye, resazurin is superior to most for a multitude of
reasons.
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AMPs in Plants. Plant derived natural products have been used since ancient times to
cure common ailments such as inflammation, sickness, and nausea. Documentation of
plant based medicinal systems can be found in the histories of almost every human
civilization[92]. Today, it is estimated that more than 70% of the global population rely on
the use of medicinal plants and herbs for their health due to the inability to afford western
medicines[92]. However, there are some disadvantages to the use of herbs and plants in
this regard, including the observation that certain components of plants are toxic, and that
manufacturing of herbal supplements is not regulated by the FDA. It is important to
consider that natural does not equal safe.

Distinct from humans, plants do not possess a form of adaptive immunity, and therefore
rely on factors such as AMPs for protection against bacteria and fungi[98]. A general
characteristic of plant derived AMPs that makes them unique is their high cysteine
content, which results in multiple disulfide bonds[99]. The best studied groups of plant
AMPs are thionins, defensins, and cyclotides, however there are many other classes. In
addition, each portion of a plant is known to contain AMPs. Previous research has shown
that plant based peptides can even work synergistically to combat bacterial biofilms, the
most concerning form of infection[100].

AMPs as Antibiotics. Natural products have long been a successful source for medicinal
discovery over synthetic compounds. In fact, a majority of FDA approved drugs are
natural products, or synthetic derivates of natural products[92]. Peptides serve as
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advantageous options for therapeutic treatments due to their reduced immunogenicity,
better tissue penetration, and relatively low manufacturing costs compared to antibody or
protein therapies. In addition, advances in biotechnology have allowed for better systems
for AMP production. For example, the recombinant expression of AMPs in plants for
molecular farming has been proposed as a sustainable approach to upscaling AMP
production[101].

Although AMPs are not always bioactive, they are universally produced leaving vast
opportunities for discovery. In addition, their scaffolds can serve as inspiration for semior wholly synthetic derivatives with improved bioactivity. For example, peptide length and
composition can be altered to enhance target specificity. Other methods to enhance
pharmacokinetic properties can be achieved through peptide modification or
encapsulation.

To date there are 3,273 AMPs within the antimicrobial peptide database, however, only
a few AMPs have FDA approval for use in humans: gramicidin, daptomycin, colistin,
vancomycin, oritavancin, dalbavacin, nisin, polymyxin, bacitracin and telavancin. One of
the main features of these AMPs is their stability- their long half-lives give them greater
therapeutic potential. The first, Gramicidin, was isolated from Bacillus brevis as a mixture
of pore forming peptides in 1939[84, 85]. Original testing was unsuccessful as the peptide
was toxic within the peritoneum of mice[102]. However, topical applications led to FDA
approval in 1955, and gramicidin was introduced as a component of Neosporin. This
topical antibiotic is used for everyday applications, such as skinned knees and minor cuts.
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Bacitracin is also only approved for topical use, however, several of the other AMPs with
FDA approval such as polymyxin B, colistin and daptomycin are bioavailable and
approved for use via injection[103]. Thus, peptides such as colistin that are bioavailable
and very effective are held in reserve as antibiotics and are considered very valuable.
There are also a variety of AMPs undergoing clinical trials, and with the biotechnological
advances discussed in earlier sections, we expect to see more enter the market each
year.

AMP Mechanisms of Action. The most common mechanism of action for antibacterial
AMPs relies on their cationic nature. Specifically, they target bacterial cell membranes
and cause disintegration of the lipid bilayer which results in lysis[104]. These are referred
to as membrane-active AMPs. The ability to integrate into membranes is based on their
amphipathic nature, which means they possess a cationic portion as well as a
hydrophobic portion. This feature ensures cationic interaction with the negatively charged
membranes, and the integration into these membranes via their hydrophobic portion.
There are a variety of mechanisms in which this can occur depending on the properties
of the AMP. For example, some peptides aggregate and bind to the surface of cells as a
cluster, which results in a large gapping of the membrane and subsequent pore formation.
This mechanism mimics surfactants and is referred to as the carpet method[105]. Another
mechanism of pore formation comes when a disordered peptide contacts a lipid
membrane and then becomes ordered, which alters its secondary structure in a way that
ultimately leads to membrane penetration[105].
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More recent reports, however, have shown that some AMPs can target intracellular
functions, such as protein synthesis, without any membrane damage. These are referred
to as cell penetrating peptides. In addition, others such as buforin II have demonstrated
the ability to bind DNA and RNA intracellularly without membrane disruption, instead
functioning via diffusion into cells[106].

Project Aim

This work will cover three distinct (but important) topics associated with both the virulence
of A. baumannii, and antimicrobial therapies for other major human pathogens. Chapters
2-3 aim to further our understanding of biofilm formation and virulence in a highly
pathogenic and clinically relevant A. baumannii strain, AB5075. Chapter 2 will address
the biofilm population as well as describe our approach for the identification and
characterization of factors important for A. baumannii biofilm formation. Within Chapter 3,
UspG (a newly identified negative effector of biofilm formation) will be characterized for
its roles in A. baumannii virulence and stress adaption. Finally, Chapter 4 aims to describe
how we use natural products discovery to combat antimicrobial resistance. Our
successes in plant-derived AMP discovery will be outlined with focus on the evolution of
our collaborator’s novel pipeline and demonstratable antibacterial activity against a panel
of multi-drug resistant bacteria.
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Chapter 2: Identification and Characterization of Factors Required for Biofilm
Formation in Acinetobacter baumannii

Introduction

Acinetobacter baumannii is a dangerous pathogen often referred to as “Iraqibacter” due
to its emergence in wounded soldiers during the Iraq war[27]. It is commonly known for
causing myriad diseases, such as ventilator associated pneumonia, wound infections,
diabetic foot infections, peritonitis, and urinary tract infections, as well as meningitis and
bacteremia[107-109]. In 2019, the CDC released a list of multi-drug resistant
microorganisms and presented carbapenemase producing A. baumannii as a highest
priority pathogen for drug resistance. Additionally, a substantial number of A. baumannii
clinical isolates are also extended spectrum beta-lactamase (ESBL) producers, rendering
even the most recent generations of beta-lactam antibiotics ineffective[110, 111].
Unfortunately, most strains of A. baumannii are resistant to common clinical antibiotic
classes, such as aminoglycosides, fluoroquinolones, and tetracyclines, among
others[112]. The resistance capacity of this organism is further exacerbated when
growing in a biofilm as tolerance to environmental stressors and antimicrobial agents
becomes significantly increased when in this state[70]. This problem is magnified when
one considers that a majority of the infections caused by A. baumannii are likely mediated
through biofilm formation[70].
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Bacterial biofilms cause up to 80% of chronic infections[113], and are defined as dense,
aggregated communities with a population(s) of bacteria encased within a protective layer
(extracellular matrix, ECM). They can form by attachment to host tissues or abiotic
surfaces, can exist as free-floating aggregates, or form pellicles at air liquid interfaces.
This serves as a line of defense against external stress, the immune system, and
antibiotics, among other factors. A. baumannii has the unique ability to form various types
of biofilms dependent on the environment in which it is grown. For example, unlike other
Acinetobacter species, A. baumannii strains can form biofilms at air-liquid interface and
can survive for days in a desiccated environment, making a hospital setting ideal for it to
thrive[114-116].

A number of factors have already been identified as being essential for biofilm formation
in A. baumannii thus far. It has been demonstrated that nutrient availability, pili, flagella,
outer membrane proteins, adhesins, quorum sensing systems, metals and secreted
macromolecules all play a role in biofilm formation[117]. One of the better studied factors
influencing biofilm formation in A. baumannii is the membrane embedded biofilm
associated protein (Bap), a giant protein (469kDa) that is highly conserved in A.
baumannii strains and shares similarity to Bap produced by Staphylococcus aureus[78,
118]. This protein is highly abundant within A. baumannii biofilms [119], and is predicted
to play a role in cell-cell adhesion to support mature biofilm structure[78, 118]. In order to
stabilize biofilms, Bap monomers self-assemble into amyloid like formations important for
altering the hydrophobicity of cell surfaces, so as to attach to biotic (human cells) and
abiotic surfaces[120, 121]. In terms of Bap expression and regulation, little is known,
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however, low iron concentrations increase Bap production during biofilm formation[122].
A. baumannii has also been known to produce Bap like proteins (Blp1 and Blp2) that
influence biofilm formation and architecture, sharing Ig-like domains, N-terminal motifs,
and expression profile similarities[123, 124].

In addition to Bap, OmpA, an outer membrane protein, is believed to possess a biofilm
associated role in vivo through attachment to epithelial cells, and also in vitro through
attachment to polystyrene[125, 126]. Studies have suggested that ompA is present in
both strong biofilm forming strains and non-biofilm forming strains, indicating that its role
in virulence through host cell cytotoxicity following adherence may be its primary
function[122]. Another surface associated factor essential for biofilm formation in vitro
and in vivo is the Acinetobacter trimeric autotransporter adhesin (Ata). This adhesin has
the ability to bind to various host extracellular matrix and basal membrane components,
such as collagen and laminin, in addition to plastic [80, 127]. As collagen I is the most
abundant ECM component in the lung, it is predicted that this trimeric autotransporter can
take advantage of exposed collagen to initiate and maintain a biofilm in this niche during
infection[80]. That being said, there is evidence to suggest that ata is only present in
certain clonal lineages of A. baumannii (78%), such as ATCC 17978, and thus its role is
clearly not conserved across all strains [128, 129]. In addition to these factors, the wellstudied usher pili system made up of the Csu proteins A/B,A-E is very important for
attachment to abiotic surfaces[130], and is considered key to biofilm formation.
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When considering polysaccharides, the production of Poly-β-1-6-N-Acetylglucosamine
(PNAG) is critical for biofilm formation in A. baumannii[81]. The pgaABCD locus encodes
genes for the production of PNAG, which is a major component of biofilm ECM in many
species of bacteria and is universally conserved among A. baumannii isolates[81, 131,
132]. In general, polysaccharides act to assist in biofilm adhesion, providing protection
from the host, and maintaining structural integrity of the biofilm. In A. baumannii it seems
that PNAG production occurs in biofilms at the liquid-surface interface when under shear
force (S1 strain)[81], while it is produced within pellicles formed at the air-liquid interface
under static conditions (ATCC 17978 strain)[133]. In addition, the process of O-linked
glycosylation, which is a part of capsule production, has been shown to be important in
surface-liquid biofilms, as defects are observed in biofilms formed without a functioning
PglC protein, which typically initiates glycosyltransferase activity[134]. Furthermore, Olinked protein glycosylation of biofilm associated polysaccharides through the OOligosaccharyltransferase (O-OTase) PglL has been shown to be important for proper
biofilm formation in this organism[82]. It is also known that eDNA is required for ECM
formation, however there is little to no evidence regarding the mechanics of this process.
One suggestion is that eDNA is transported from the cell through membrane vesicles,
however this contention still requires validation[135].

In terms of regulating the biofilm process, much less information is available, however, a
few global transcriptional regulators have been identified. First, the two-component
system BfmRS has been shown to regulate the csu operon and the K-locus for capsule
production[136-138], both of which are required for biofilm formation. Similarly, the TCS
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GacAS influences biofilm formation via regulation of the csu operon, as well as ompA
[57]. This TCS has also been found to be highly expressed within pellicles indicating
involvement in various types of biofilms formed by A. baumannii[133]. Quorum-sensing
has also been implicated in influencing biofilm formation in A. baumannii, as deletions in
the autoinducer synthase abaI lead to impaired biofilm forming capabilities[139-141].
Importantly, inhibition of the quorum-sensing receptor, AbaR, by non-native N-acyl
homoserine lactones has been shown to reduce biofilm formation in A. baumannii[142].

Although a number of studies have explored the contribution of various factors to A.
baumannii biofilm formation, there is still a paucity of information on this important topic
(given the relevance this lifestyle plays in disease causation for this organism). As such,
herein we sought to uncover in a global, unbiased manner, factors contributing to biofilm
formation at the surface liquid interface in the highly virulent A. baumannii strain
AB5075[143]. To do so, we make use of an ordered transposon mutant library to screen
for biofilm impaired or biofilm enhanced phenotypes compared to the wildtype strain. In
so doing, we identified a wealth of novel factors that influence biofilm formation, including
those important for transcriptional regulation, transport, stress response and metabolism.
Mutants for these genes were comprehensively characterized, quantifying biofilm
biomass, eDNA production, ECM composition and adhesion capabilities. As such, this
work shines new light on the process of biofilm formation in A. baumannii, providing new
avenues for further investigation, and the potential to serve as future targets for
antimicrobial therapeutic intervention.
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Materials and Methods

Strains and Growth Conditions. Transposon mutant strains used in this study were
obtained from the University of Washington transposon mutant library of A. baumannii
AB5075-UW[144]. All strains were stored at -80°C in Lysogeny Broth (LB) with 25%
glycerol. Mutants containing the T26 transposon were grown on LB agar (LBA)
supplemented with 12.5 µg/mL tetracycline or LB containing 5 µg/mL tetracycline.
Mutants containing the T101 transposon were grown in LBA and LB containing 160 µg/mL
hygromycin B.

Screening Transposon Library Mutants for Biofilm Production. For screening
purposes, 96 well plate glycerol stocks of the A. baumannii transposon library were
defrosted, and 20 µL was removed and added to 180 µL tryptic soy broth (TSB) in tissue
culture treated 96 well plates (Falcon). Plates were then sealed with parafilm and masking
tape and incubated for 24 hours under static conditions at 37°C. After this time, OD600
values were recorded and wells were gently aspirated, prior to fixing with 100% ethanol.
Once dry, cells were stained for 15 minutes using 0.3% crystal violet (CV) and then rinsed
three times in PBS, before being allowed to air dry. CV was eluted by a 10 min incubation
with 100% ethanol and their OD550 was recorded using a Synergy 2 plate reader (BioTek).
All liquid handling processes were performed using of a viaflo 96-well pipetting robot
(INTEGRA Biosciences Corp.). For every assay plate, data was subjected to normal
distribution statistics to establish a list of leads due to the absence of a wildtype control
within the transposon mutant library plates. The CV values for each assay plate was
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averaged, with maximum and minimum values determined. Thereafter a Z-score was
calculated for each strain by subtracting the raw CV value for each well from the mean of
the assay plate. This value was divided by the standard deviation of each sample plate
to obtain a Z-score. To generate a prioritized list of mutants within a given plate, a cutoff
was established as ±12.5th percentile from the mean for each assay plate.

Secondary Screening of Mutant Strains. Each mutant identified in the primary screen
was rescreened alongside the wild-type strain in technical sextuplicate, using methods
outlined above, to ensure retention of phenotype. Mutants were narrowed by quantifying
fold change from the parental strain, and only those whose biofilm was altered ±2-fold
were considered for further study.

Complement Strain Generation. All cloning strains, plasmids and primers are listed in
Supplemental Tables A1 and A2. Flanking primers were designed for target genes to
include the native promotor as well as 100-200 nt of DNA 3’ of translational stop codons.
Each fragment was amplified by PCR and products were cloned into pMQ557. Strains
were confirmed by PCR and Sanger sequencing (GeneWiz) prior to transformation into
the relevant mutant strain. Mutant strains containing complementation plasmid were
again confirmed by PCR and Sanger sequencing (GeneWiz). Assays were performed
using Hygromycin B at a concentration of 160 µg/mL to maintain the plasmid. Empty
vector controls for each mutant strain and the wildtype strain were included for
complementation assays.
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Real-Time Biofilm Analysis. An xCELLigence Real Time Cell Analysis (RTCA)
instrument was used to evaluate biofilms, according to manufacture protocols (ACEA
Biosciences Inc.). Each strain was grown overnight with shaking at 37°C in TSB
supplemented with antibiotics relevant to the transposon marker being used. Prior to each
assay, cells were standardized to an 0D600 of 0.5 in PBS. Antibiotic free TSB (180µL) was
used to blank the system before 20µL of each strain was added to each well leading to a
final OD600 of 0.05 (~5x107 CFU). Plates were incubated statically in the RTCA device at
37°C, and electrode output readings were taken every 5 minutes for up to 72 hours. Each
strain was seeded in biological triplicate and technical duplicate for n=6 for each strain.
Units are expressed as cell-sensor impedance (CI), which is automatically calculated at
each time-point as (Xn-Xb)/5 with Xn indicating the impedance at said time-point and Xb
representing the background impedance recorded prior to the addition of cells into the
assay plate.

eDNA Quantification. Extracellular DNA was evaluated for planktonic and biofilm
populations of each strain using the Quant-iT™ PicoGreen® biofilm kit (Invitrogen).
Biofilms were prepared as detailed above, and a standard curve was generated using λ
DNA according to the manufacturer’s protocols. Planktonic cells were carefully removed
from wells before biofilms were disrupted and resuspended in 100µL TE buffer. Each
sample was then transferred to a black walled 96 well plate before 100µL of TE +
PicoGreen® reagent was added to each well. Plates were incubated for 4 minutes in the
dark before reads were taken using a Synergy 2 plate reader (BioTek). Measurements
were recorded at an excitation of 480nm and 520nm emission. Controls of TE alone and
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TE + PicoGreen® were included in each assay. Background was subtracted prior to
calculation of eDNA concentration. A standard curve was generated using manufacturer
provided DNA and a slope equation (Y=mX+B) was used to determine eDNA
concentrations present in samples. Each strain was tested in biological triplicate and
technical duplicate giving n=6 for each mutant.

Extracellular Matrix Component Inhibition Assays. Assays were performed similar to
Sager et. al. with the following modifications[145]. In brief, overnight cultures were
standardized to an OD600 of 0.5 in PBS before 96-well tissue culture treated plates were
seeded with 180µL TSB with or without proteinase K (25µg/mL) or sodium periodate
(2.5mM). Wells were then inoculated with 20µL of each standardized strain giving a final
sample volume of 200µL. Proteinase K was solvated in 20mM Tris-HCl (pH 7.5) and
100mM NaCl, while sodium periodate was solvated in deionized water. Plates were
incubated for 24 hours at 37°C under static conditions. After this time, plates were
analyzed using the CV procedure described above. For each strain, no-treatment wells
were averaged and used to calculate fold change from treatment groups. All data is
presented based on testing each mutant in biological triplicate.

Extracellular Matrix Component Disruption Assays. Biofilms were seeded as
described above and allowed to form for 24 hours. After this time, they were treated with
either 25µg/mL proteinase K, 2.5mM sodium periodate, or solvent, and were then allowed
to incubate for an additional 24 hours prior to processing. Processing and analysis were
performed using methods described in the previous section.
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Results

An Unbiased Global Screen to Identify Novel Components Influencing Biofilm
Formation in A. baumannii. Although a number of genes have previously been shown
to influence biofilm formation in A. baumannii [117, 146], to our knowledge there has not,
to date, been a large scale, unbiased approach to identifying them. Accordingly, we made
use of the ordered transposon library previously reported in strain AB5075 [144] by
randomly selecting twenty-eight 96-well plates from this collection (~25%) and assessing
the biofilm formation capacity of mutants contained within. Each plate was used to
generate biofilms in a replica 96-well plate format, before being subjected to crystal violet
(CV) staining after 24 hours of incubation. Because transposon mutant library plates do
not contain a wildtype strain, each plate was subjected to normal distribution statistics to
establish a list of leads. The CV values for each assay plate were averaged with the
maximum and minimum values determined. Thereafter each well of the plate was given
a Z-score that allowed a cutoff to be established by identifying strains that ranked furthest
from the mean (Supplemental Tables A3 and A4 Supplemental Figures A1 and A2).
For ease of processing, the cutoff used was ± 12.5th percentile from the mean of each
plate. From this initial screen, we identified 171 (6.46%) isolates demonstrating differential
biofilm biomass from the total of 2,648 screened (40 total wells were empty in the 28
plates screened) (Supplemental Figures A1 and A2). Of these, 79 showed significantly
increased biofilm formation and 92 demonstrated a decrease in biofilm formation.
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Following the initial screen, our 171 strains were validated using CV staining in sextuplet
in direct comparison to the wildtype to establish a rigorous, quantitative cutoff. Using a
baseline of ± 2-fold alteration, along with statistical significance (Figure 2), we found 30
mutants demonstrating an increase in biofilm biomass, and 19 mutants with a decrease
in biofilm biomass, when compared to the parental strain (Table 1). Of note, a presiding
characteristic that eliminated mutants with decreased biofilm capacities at this stage was
the presence of a growth defect (data not shown).

Figure 2. Mutants Identified as Demonstrating Altered Biofilm Biomass Following
Secondary Screening. Shown is the crystal violet analysis of biofilms for mutant strains
identified in the secondary screen as having significantly altered biomass as compared
to the wild-type strain. Data is derived from 6 replicates per strain after 24h growth. Error
bars are shown ±SEM. Statistical significance was assessed using Student’s t-test. Pvalue: * =0.01 ; ** =0.001 ; *** = 0.0001.
40

Table 1. Lead Transposon Mutant Strains Confirmed to Significantly Alter Biofilm
Formation.
ID
Gene
Description
CV
Fold
ABUW_1763 usp
UspA domain protein
8.05
ABUW_2194 Acyl-CoA dehydrogenase, middle domain protein
7.43
ABUW_3242 fadL
FilD
5.34
ABUW_0582 Phage-related capsid scaffolding protein (GPO5.04
like)
ABUW_2431 umuD
DNA polymerase V component
5.00
ABUW_4114 TraH family protein
4.56
ABUW_1555 ppsA
Phosphoenolpyruvate synthase
4.37
ABUW_3809 Transcriptional regulator, GntR
4.00
ABUW_1974 adeA
Multidrug efflux protein AdeA
3.98
ABUW_3694 Protein YegH
3.47
ABUW_0715 mreB
Rod shape-determining protein MreB
3.46
ABUW_0182 Two-component system hybrid histidine
3.38
kinase/response regulator
ABUW_2925 pit
Phosphate transporter
3.27
ABUW_2276 Transcriptional regulator, ArsR family
3.20
ABUW_3391 gntK
Shikimate kinase
3.09
ABUW_0133 Ribosomal protein S30EA/sigma 54 modulation
2.94
protein
ABUW_0932 Non-ribosomal peptide synthetase
2.77
ABUW_2717 3-oxoacyl-(acyl carrier protein) synthase
2.62
ABUW_2655 Hypothetical protein
2.60
ABUW_0983 hda
DnaA family protein
2.59
ABUW_3133 coax
Pantothenate kinase, type III
2.43
ABUW_1808 Hypothetical protein
2.39
ABUW_2874 Hypothetical protein
2.33
ABUW_0539 Hypothetical protein
2.29
ABUW_1791 Hypothetical protein
2.20
ABUW_2921 Formylglycine-generating sulfatase enzyme
2.18
domain-containing protein
ABUW_1244 mrdB
Rod shape-determining protein RodA (EsvE3)
2.17
ABUW_1658 Hypothetical protein
2.16
ABUW_0625 Sporulation related domain-containing protein
2.11
ABUW_0192 Hypothetical protein
2.07
ABUW_1352 ygiW1
Bacterial OB fold domain-containing protein YgiW -2.03
ABUW_0201 gabP
GABA permease
-2.04
ABUW_3421 folA
Dihydrofolate reductase
-2.04
ABUW_1189 ErfK/YbiS/YcfS/YnhG family
-2.05
ABUW_2988 Transcriptional regulator, LysR family
-2.24
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Table 1. Lead Transposon Mutant Strains Confirmed to Significantly Alter Biofilm
Formation. (Continued)
ABUW_3725 Transporter, drug/metabolite exporter family
-2.44
ABUW_1340 hisQ
Histidine transport system permease protein HisQ -2.48
ABUW_3387 Leucine carboxyl methyltransferase
-2.99
ABUW_1016 cbl
Transcriptional regulator, LysR family
-3.11
ABUW_3390 gapN
Aldehyde dehydrogenase
-3.37
ABUW_0885 Biofilm associated protein
-3.53
ABUW_0885 Biofilm associated protein
-3.64
ABUW_0570 Phage-related baseplate assembly protein (GPJ-3.66
like)
ABUW_0643 cysI
Sulfite reductase
-3.73
ABUW_3783 mmsA1 Methylmalonate-semialdehyde dehydrogenase
-4.15
ABUW_0885 Biofilm associated protein
-4.27
ABUW_0999 ruvB
Holliday junction DNA helicase RuvB
-5.70
ABUW_3326 copC
Copper resistance protein CopC
-16.28
ABUW_0711 Intracellular protease, PfpI family
-18.70

Each biofilm was tested in technical sextuplicate for biofilm formation. CV Fold refers to the calculated fold
change in biomass of the indicated mutant strain compared to wildtype AB5075. Positive fold changes were
calculated by dividing the average CV of the mutant / the average CV of AB5075. Negative fold changes
were calculated by dividing the average CV of AB5075 / the average CV of the mutant then multiplying by
-1. CV: crystal violet staining.

Ontological Assessment of Factors Identified as Influencing Biofilm Formation. We
next took the 49 genes from our secondary screen and organized them ontologically,
based on predicted or known function (Figure 3). Importantly, when reviewing this list,
we identified three different mutants in ABUW_0885 (bap::tn) as having a marked
decrease in overall biofilm production (≥3.5 fold). Bap plays an important role in A.
baumannii biofilm formation by assisting in cell-cell and cell-host adherence and
maintaining mature biofilm structure on biotic and abiotic surfaces[118-121]. The
substantial defects in biofilm formation observed for all three tn mutants thus serves as
proof of principle for the efficacy of this study. Beyond this, the majority of strains fell into
the categories of general metabolism or hypothetical proteins. Specifically, 13 of the 49
strains contribute to some form of metabolism within the cell, with seven found to exhibit
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a stronger biofilm while six showed a biofilm defect. The metabolic pathways associated
with each group were broad with no clear correlation, however this is potentially due to
the nature of our randomized screen. Of interest, all six genes within the hypothetical
protein category demonstrated increased biofilm formation, highlighting various potential
new targets influencing biofilm formation. Each of these uncharacterized genes encode
proteins ranging from 38 to 356 amino acids in length. Otherwise, nothing is known about
these proteins in terms of function or homology, with no clear domains detectable from
multiple different bioinformatic interrogations[147].

Number of Tn Mutants
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Figure 3. Ontological Grouping of Mutants Identified as Having Differential Biofilm
Forming Capacities. Mutants altered in their ability to form a biofilm from our secondary
screen were categorized ontologically based on known or predicted function.
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Another abundant ontological grouping, transcription factors, contained five strains, three
of which demonstrated increased biofilm formation. Of these, one was a hybrid twocomponent system component of unknown function, ABUW_0182. The other two mutants
belong to the ArsR (ABUW_2276) and GntR (ABUW_3809) transcription factor families.
Both of the regulatory factors within the decreased biofilm group were members of the
LysR family (ABUW_1016 & ABUW_2988), the most abundant class in A.
baumannii[148]. The first of these, ABUW_1016, is annotated as cbl, and would appear
to be a homolog of CysB, which is involved in sulfur metabolism in Escherichia coli[149];
whilst the second is uncharacterized in terms of function, but demonstrates homology
with the OxyR transcriptional regulator of P. aeruginosa (HHPred search [147]).

Further to this, we identified two mutants with enhanced biofilm formation that are
predicted to engage in the general stress response, ABUW_1763 (usp::tn) and
ABUW_2431 (umuDAb::tn)[150, 151]. We also identified disruption of an uncharacterized
membrane gene/protein as producing a defect in biofilm formation. Interestingly,
bioinformatic analysis of this gene product reveals a peptidoglycan binding domain and
an ErfK domain, the latter of which is a conserved lipo-protein anchoring transpeptidase
domain. Several other membrane/transporter mutants were identified, two of which had
reduced biofilm forming abilities (ABUW_1340, ABUW_3725), while the other three had
an increased ability to form a biofilm (ABUW_2874, ABUW_2925, ABUW_3694).
ABUW_1340 encodes HisQ, a histidine transport system permease protein, while
ABUW_3725 is an uncharacterized member of the drug/metabolite exporter family. As for
the mutants with increased biofilm forming capacities, ABUW_2925 (pit) is involved in the
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transport of phosphate while ABUW_3964 is not yet characterized, but putatively has a
role in ion transport based on the presence of a TlyC domain. ABUW_2874, also
uncharacterized, is a hypothetical membrane protein of unknown function.

Of interest, two mutants found to have enhanced biofilms had disruptions in genes
associated with cell shape determination. Specifically, ABUW_0715 encodes the rodshaped determining factor MreB whilst ABUW_1244 encodes the rod shape determining
factor MrdB. Two phage related genes were also identified, with ABUW_0582 disruption
leading to an increased biofilm phenotype and ABUW_0570 presenting a decrease.
ABUW_0582 encodes a GPO-like phage related capsid scaffold protein, whilst
ABUW_0570 encodes a GPJ-like phage related base plate assembly protein.

Real-Time Profiling of Biofilm Formation. To explore our findings more fully, we next
sought to understand the specific mechanisms behind altered biofilm formation using an
array of analyses. To facilitate and streamline this, we elected to proceed with only those
factors/strains that were the most underexplored and/or had the most striking phenotypic
changes. As such, we narrowed the list to 16 mutants: 8 with increased biofilm forming
capacities, and 8 with diminished formation (Supplemental Figure A3, Table 2).
Table 2. Lead Mutant Strains Selected for ECM Profiling.
Gene No.
Description
Ontology Group
ABUW_1763
ABUW_2431
ABUW_4114
ABUW_3809
ABUW_3391
ABUW_0133

usp, uspA domain containing protein
umuD, DNA polymerase V
traH, TraH domain containing protein
Transcriptional regulator GntR
gntK, shikimate kinase
Ribosomal S30EA/sigma 54 modulator
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Stress Response
Stress Response
Pili-Conjugation
Transcriptional R
Metabolism
Translation

Fold
CV
8.05
5
4.56
4
3.09
2.94

Table 2. Lead Mutant Strains Selected for ECM Profiling. (Continued)
ABUW_2655 Hypothetical protein
Uncharacterized
ABUW_0983 hda, DnaA
DNA replication
ABUW_3421 folA, dihydrofolate reductase
Metabolism
ABUW_0201 gabP, GABA permease
Transport
ABUW_1189 ldtJ, ErfK/YbiS/YcfS/YnhG family
Membrane
ABUW_3390 gapN, aldehyde dehydrogenase
Metabolism
ABUW_0570 Phage base plate assembly protein
Phage
ABUW_3783 mmsA1, methylmalonate-semialdehyde Metabolism
dehydrogenase
ABUW_0885 bap, biofilm associated protein
Biofilm Associated
ABUW_0999 ruvB, holiday junction DNA helicase
DNA binding

2.6
2.59
-2.04
-2.04
-2.05
-3.37
-3.66
-4.15
-4.27
-5.7

Each biofilm was grown in technical sextuplicate and Fold CV was calculated the same as shown in Table1.
Transcriptional R: Transcriptional regulator

First, to confirm the integrity of our screen, one strain was selected for complementation
analysis to confirm that alterations in biofilm forming capacities observed were the result
of the expected transposon disruption (Supplemental Figure A4). The expected result
was observed, and complementation restored phenotypes to that of the parent strain.
Following this, we next chose to measure the attachment and adherence of strains in
real-time using an xCELLigence RTCA instrument (ACEA Biosciences). This technology
works by monitoring electrical flow across a series of gold-plated networks at the bottom
of modified 96-well plates. Any shift in overall charge caused by disruption of the signal
(i.e. attachment to the bottom of the well) is measured and calculated in the context of
control readings to establish a Cell Index (CI)[152]. For this assay, each mutant was
tested in biological triplicate and technical duplicate (n=6), with reads taken automatically
every 5 minutes for a 72-hour period (Supplemental Figure A5 and A6). Four of the
strains demonstrating the most unique phenotypes are represented in Figure 4.
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Figure 4. Real-Time Profiling of Biofilm Formation Mirrors that Obtained via CV
Staining. Each mutant was seeded into the wells of gold-plated 96-well plates in
biological triplicate and technical duplicate at an OD600 of 0.05. Reads were taken every
five minutes over a 72h growth period. Blue indicates strains with increased biofilm
formation during CV staining, whilst pink indicates strains that had a defect in biofilm
formation. Wildtype is shown in black in each case. Error bars are shown ±SEM.
When reviewing this data, we noted that all strains experienced a decrease in impedance
during the first 6h with the RTCA instrument, which is common for bacterial biofilms grown
within this system; it is believed to indicate the initial attachment phase of biofilm formation
[153-155]. For wildtype, this decline reached a CI of -0.04 before demonstrating a
continual increase that registered positive values at 10.5h and plateaued at around 26h;
remaining relatively stable through 40h. At this point the wildtype strain demonstrated a
continual decline through the remainder of the assay. It is suggested that this decline
indicates detachment of the biofilm in this system[154, 156].
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Looking at the mutant strains, the first observation is that the RTCA assays were
consistent with the end-point crystal violet studies, with the vast majority of mutants
demonstrating identical results. There were exceptions to this, however, as ABUW_4114
(traH::tn), ABUW_0983 (hda::tn), and ABUW_3391(gntK::tn) were categorized as
enhanced biofilm formers using CV assays, but at intervals demonstrated a lower CI
compared to the parent (Supplemental Figure A5). With that said, however, all four of
these mutants did complete the RTCA experiments with a greater CI than the wild-type,
thus explaining why our end-point CV assays ultimately assigned them as having
enhanced biofilm formation. Conversely, ABUW_0999 (ruvB::tn) demonstrated a biofilm
deficiency during end-point CV studies, but had a higher impedance value compared to
the parental strain through the first 20h of growth (Supplemental Figure A6A). Akin to
that for the four previously listed mutants, however, the final CI values for this strain were
ultimately lower than the parent, again explaining why this was ascribed as a reduced
biofilm forming strain in our end-point assays.

Reviewing individual mutant data, we note that each demonstrated a unique phenotype
as compared to the parent strain. For example, ABUW_1763 (usp::tn) displayed a less
severe decrease in impedance during the initial hours of assessment, and rapidly
exceeded the CI of the parent strain thereafter, with a maximum value of 0.43 reached
(compared to the wild-type at 0.25, Figure 4A). The profound ability of this mutant to form
a biofilm is particularly interesting as this mutant demonstrates impaired cellular density
during planktonic growth (Supplemental Figure A7A). Another mutant of interest was
ABUW_2431 (umuDAb::tn), which mirrored the wildtype during early growth, albeit at a
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slightly higher CI, however, thereafter it demonstrated relative stasis whilst the parental
strain exhibited decline indicating there is some defect in the transition to detachment
phase for this mutant (Figure 4B).

When looking at mutants with impaired biofilm formation, ABUW_3783 (mmsA1::tn) had
the most severe defect in impedance, with a maximum CI value ≤0.06 (Figure 4C). When
reviewing the RCTA data for this strain, it appears that this mutant is defective in the initial
attachment phase of biofilm formation as it is unable to generate a positive CI until at least
24h of growth. Indeed, even after this time, it barely registers on the Cell Index, indicating
strongly impaired ability for biofilm formation, which is in agreement with our CV studies.
Another similarly impaired biofilm forming mutant was ABUW_0885 (bap::tn), although it
was able to register a positive CI at a timeframe similar to that of the wildtype (Figure
4D). After this time, however, the mutant reached its maximum CI more quickly than WT
and thereafter declined more rapidly, reaching a negative CI around 67h. This supports
previous literature on the biofilm associated protein (Bap), which is known to play a role
in stabilizing the structure of mature biofilms instead of being involved in the initial
attachment phase [78, 118]. Collectively, our real-time cell analysis studies provide a
useful companion to the end-point CV assays, generating unique insight into the biofilm
formation process during attachment, development, and dispersal phases.

Characterization of eDNA Abundance in Mutant Strains. We next set out to
investigate the composition of the extracellular matrix (ECM) for the wild-type and mutant
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strains. First, eDNA was quantified as it is known to be a major component of A.
baumannii biofilms[135]. Thus, biofilms were allowed to establish in 96 well plates under
static conditions at 37°C for 24 hours, before planktonic populations were removed, and
biofilm cells were assessed for eDNA production. Upon analysis (Figure 5) we noted that,
for at least a subset of mutants, there was a clear correlation with decreased biofilm
formation and significantly reduced eDNA production. The most substantial difference
was observed for ABUW_3783 (mmsA1::tn) which contained ~18-fold less eDNA within
its ECM than wildtype. Another mutant with substantially less eDNA was ABUW_0885
(bap::tn) with 3.85-fold less eDNA within its ECM. This is of particular interest, and
perhaps provides insight into how Bap mediates stabilization of structure for mature
biofilms. Beyond the bap mutant, ABUW_0201 (gabP::tn) and ABUW_0999 (ruvB::tn)
possessed 7.89-fold and 2.59-fold less eDNA respectively in their biofilms, again likely
explaining why deficiencies were observed for these strains. Additional to these strains,
some of our mutants with enhanced biofilms also had increases in eDNA production,
including ABUW_0983 (hda::tn) and ABUW_0133. It is clear, however, that these are only
modest changes, and thus, although they perhaps contribute to the phenotypes observed,
they clearly are not a definitive explanation.
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Figure 5. Probing the Contribution of eDNA to Mutant Biofilm Formation. Biofilms
for each strain were seeded in biological triplicate and technical duplicate at an OD600 of
0.05 prior to incubation for 24h. Blue indicates a strain that had increased biofilm
formation during CV staining, whilst pink indicates strains that had a defect in biofilm
formation. eDNA concentrations were calculated using a standard curve prior to
normalization based on cell density. Error bars are shown ±SEM. Significance was
calculated using Student’s t-test. *, p<0.05; **, p<0.01;***, p<0.001.

Beyond this we were able to discern no other correlation between biofilm phenotype
observed during CV screening, and the amount of eDNA produced by each mutant.
Indeed, for some mutants, findings that are in opposition to that expected were seen. For
example, four of the eight mutants demonstrating a biofilm deficiency had greater levels
of eDNA in their biofilms when compared to wildtype. Specifically, ABUW_0570 showed
the highest amount of eDNA in its biofilm ECM of all strains tested. ABUW_1189 (ldtJ::tn),
ABUW_3390 (gapN::tn) and ABUW_3421 (folA::tn) also displayed higher levels of eDNA
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within their biofilms, although these were relatively modest increases. Additionally, seven
of the strains that were biofilm proficient had less eDNA within their biofilms compared to
wildtype. Of those, ABUW_2431 (umuDAb::tn) produced a biofilm containing the least
amount of eDNA (~3-fold less). Collectively, this data provides insight, and in some cases,
obvious explanation for our CV and RTCA findings. For others, however, this is not the
case, and thus a consideration of additional ECM components is required.

Exploring the Impact of Protease on Biofilm Initiation of Mutant Strains. To consider
other components of the ECM produced by our mutant strains, we next tested the impact
of proteinase K to determine which strains produce protein-mediated biofilms (Figure 6).
Our first approach was to explore the impact of proteolysis on initial biofilm development;
thus biofilms were allowed to establish as detailed above but in the presence of 25µg/mL
proteinase K. Upon analysis of the wild-type biofilm we noted that it was impaired by 1.4fold, indicating that, at least to some degree, proteins play a role in AB5075 biofilm
initiation. Beyond this, of our 16 strains, nine were negatively impacted by preincubation
with protease, whilst seven actually demonstrated increased biofilm formation.
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Figure 6. ECM Profiling Reveals Differential Contribution of Protein to Biofilm
Initiation. Biofilms were seeded in biological triplicate at an OD600 of 0.05 prior to
incubation for 24h with or without 25 µg/mL Proteinase K. Blue indicates a strain that had
increased biofilm formation during CV staining, whilst pink indicates strains that had a
defect in biofilm formation. Fold change was calculated by comparing an individual
strain’s treated biofilm to non-treated. Error bars are shown ±SEM. Significance was
calculated using Student’s t-test. *, p<0.05; **, p<0.01.

The two most profoundly affected strains by protease addition were ABUW_0570 and
ABUW_2431(umuDAb::tn). Interestingly, the former displayed a diminished biofilm forming
capacity in CV and RTCA assays, whilst the latter had an enhanced capacity. Given that
protease addition made the biofilm of ABUW_0570 worse, this suggests that either: the
already diminished ECM protein levels in this strain were further reduced by protease
addition (reducing biofilm biomass), or that the biofilm formed by this strain is due to the
loss of other ECM components, and that presence of ECM proteins in this strain facilitated
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some level of biofilm formation, albeit to a reduced level. Regardless of outcome, it is
clear that the presence of ECM proteins is important to the biofilm forming capacity of the
ABUW_0570 mutant. In line with this, three other biofilm impaired strains (ABUW_0201
gabP::tn, ABUW_3783 mmsA1::tn, and ABUW_3421 folA::tn) also demonstrated
diminished biofilms when challenged with proteinase K.

With respect to the biofilm proficient ABUW_2431(umuDAb::tn) strain, it is apparent that
biofilm initiation in this mutant is dependent on ECM proteins based on the reduced
biofilms produced by this mutant under proteinase K challenge. Similarly, four additional
strains (ABUW_3391, gntK::tn; ABUW_0983, had::tn; ABUW_1763, usp::tn; and
ABUW_3809) had reduced biofilm forming capacities in the presence of proteinase K, but
enhanced biofilm in CV and RTCA assays. Although not to the same level as the umuDAb
mutant, it seems likely that they too derive their enhanced biofilm forming abilities, at least
in part, due to ECM proteins. In the case of the enhanced biofilm forming mutants
ABUW_2655, ABUW_4114 (traH::tn), and ABUW_0133, none were impacted by
protease K addition, with all displaying modest increases in formation compared to no
treatment controls; indicating their enhanced biofilm forming capacity is not protein driven.
Finally, four biofilm deficient mutants (ABUW_0999, ruvB::tn; ABUW_0885, bap::tn;
ABUW_3390, gapN::tn; and ABUW_1189, ldtJ::tn) actually had enhanced biofilm
formation in the presence of proteinase K, suggesting proteinaceous inhibition of their
respective biofilms.
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Investigating the Dispersive Effects of Proteinase K on Established Biofilms. While
observing the inhibitory effects of proteolysis in the context of biofilm development
delivered useful insight, we also found it important to explore the effects of proteinase K
on established biofilms. Thus, we measured biofilm strength/dispersal by allowing biofilms
of our strains to form for 24 hours without treatment (Figure 7). After this time, undisturbed
biofilms were treated with 25µg/mL of proteinase K for an additional 24 hours. Here, the
wildtype strain showed a small reduction in biofilm mass, with a 1.31-fold decrease in
biofilm observed following treatment of the established biofilm. In line with this, four of our
16 strains (ABUW_0570; ABUW_1189, ldtJ::tn; ABUW_3783, mmsA1::tn; and
ABUW_0885, bap::tn) followed the same trend as the parent, indicating limited impact of
ECM proteins on their biofilm strength/dispersal.

An additional eight strains had significantly diminished biofilm biomass as compared to
the parental strain, with three previously demonstrating impaired biofilm formation using
CV/RTCA tests (ABUW_0999, ruvB::tn; ABUW_3390, gapN::tn; and ABUW_0201,
gabP::tn), whilst the other five displayed enhanced biofilm biomass (ABUW_4114,
traH::tn; ABUW_0133; ABUW_3809; ABUW_3391, gntK::tn; and ABUW_2431,
umuDAb::tn). For the former three strains, this is similar to the scenario outlined above;
namely, that either diminished ECM protein levels in these strains are further reduced by
proteinase K in a mature biofilm, or that the weakened biofilms formed by these strains is
due to the loss of other ECM components, and that presence of ECM proteins in this
strain facilitated some level of biofilm formation, albeit at a reduced level. Regardless,
ECM proteins would appear to be important to the strength of biofilm forming capacity in
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these mutants. Similarly, for the latter five mutants, ECM proteins are clearly important to
the strength of biofilms formed by these strains. The five other remaining strains all
displayed resistance to proteinase K, with no biofilm dispersal observed, and in fact a
modest increase in their CV levels was noted. Thus, in each case, it is clear that ECM
proteins play no role in their altered biofilm formation from CV/RTCA tests.
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Figure 7. The Importance of Proteins to Mature Biofilm ECM Differs Between Lead
Strains. Biofilms were seeded in biological triplicate at an OD600 of 0.05 prior to incubation
for 24h. After this time strains were treated with 25 µg/mL Proteinase K (or not) and
incubated for an additional 24h. Blue indicates a strain that had increased biofilm
formation during CV staining, whilst pink indicates strains that had a defect in biofilm
formation. Fold change was calculated by comparing an individual strain’s treated biofilm
to non-treated. Error bars represent ±SEM. Significance was calculated using Student’s
t-test. *, p<0.05; **, p<0.01;***, p<0.001.
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Dissecting the Contribution of Polysaccharide to Differential Biofilm Formation.
The final step in considering alterations in ECM components of our selected mutants was
to explore the contribution of polysaccharide to our observed phenotypes. To do this we
treated biofilms of our various strains with sodium periodate, which targets the 1-6 β
linkage of extracellular polysaccharides such as N-acetylglucosamine[157]. Biofilms were
seeded as with our other experiments, with or without 2.5mM of sodium periodate,
followed by incubation for 24 hours (Figure 8).
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Figure 8. ECM Profiling of Lead Mutants Indicate the Importance of
Polysaccharides During Biofilm Development. Biofilms were seeded in biological
triplicate at an OD600 of 0.05 prior to incubation for 24h with or without 2.5 mM Sodium
Periodate. Blue indicates a strain that had increased biofilm formation during CV staining,
whilst pink indicates strains that had a defect in biofilm formation. Fold change was
calculated by comparing an individual strain’s treated biofilm to non-treated. Error bars
represent ±SEM. Significance was calculated using Student’s t-test. *, p<0.05; **,
p<0.01;***, p<0.001.
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Upon analysis we observed that biofilms produced by all strains were negatively impacted
by the presence of sodium periodate, but to varying degrees. Of the 16 strains, 10 of them
followed the same trend as the parental strain, whilst the remaining six all had significantly
enhanced declines in biofilm biomass beyond the wildtype strain. Of these latter strains,
two (ABUW_0999, ruvB::tn; and ABUW_0570) already demonstrated reduced biofilm
formation in CV/RTCA tests, whilst the remaining four (ABUW_1763, usp::tn;
ABUW_0983, hda::tn; ABUW_3391, gntK::tn; and ABUW_0133) had enhanced biofilm
formation. For these latter strains, it is clear that polysaccharide plays an important role
in the altered biofilm formation phenotype of these mutants. For the former, however, the
suggestion is that either polysaccharide is the driving force behind their impaired biofilm
formation, which the addition of sodium periodate only magnifies, or that loss of other
ECM components is the explanation of their impaired biofilm biomass, and that
polysaccharide was enabling, albeit in a limited way, some level of biofilm formation.
Regardless of the explanation, is it is clear that polysaccharides are important to the
biofilm forming capacities of these strains.

Evaluation of Polysaccharide Content in Established Biofilms via Dispersal
Experiments. As with proteinase K, the effect of sodium periodate on dispersing
established biofilms was also assessed. To our surprise, 12 of the 16 strains followed the
wild-type phenotype of a modest increase in biofilm biomass (Figure 9). The remaining
four strains did have a decrease in biofilm formation in these tests, with two (ABUW_1189,
ldtJ::tn; and ABUW_3421, folA::tn) previously demonstrating impaired biofilm formation
in CV/RTCA assays, and two (ABUW_4114, traH::tn and ABUW_3809) proving
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increased. The explanation for these findings is likely the same as in the previous test,
that for the latter two, polysaccharide plays a major role in the enhanced biofilm strength
at later stages of growth, whilst for the former two polysaccharide is an important
component of their diminished biofilms, but perhaps not the driving force behind the
phenotypes observed in the original screen.
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Figure 9. The ECM of Mature Biofilms is Less Dependent on Polysaccharides for
Integrity. Biofilms were seeded in biological triplicate at an OD600 of 0.05 prior to
incubation for 24h. After this time strains were treated with 2.5 mM Sodium Periodate (or
not) and incubated for an additional 24h. Blue indicates a strain that had increased biofilm
formation during CV staining, whilst pink indicates strains that had a defect in biofilm
formation. Fold change was calculated by comparing an individual strain’s treated biofilm
to non-treated. Error bars represent ±SEM. Significance was calculated using Student’s
t-test. *, p<0.05; ***, p<0.001.
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Discussion

A. baumannii is known for its multi-drug resistant capacity and its ability to survive in a
hospital setting. In addition, the ability to form biofilms allows for this organism to cause
serious complications during infection. Herein, we have taken a non-biased, global
approach to identify factors important for biofilm formation in A. baumannii AB5075.
Through the screening of >2,500 Tn mutant strains we have identified 171 factors
contributing to biofilm formation, with 49 of them influencing biofilm formation greater than
2-fold. Herein, we have investigated 16 of those targets in depth, uncovering unique
phenotypes that provide insight into the intricacies of biofilm formation in A. baumannii.
Through biofilm mass assessment and analysis of the ECM, our work has uncovered
specific characteristics for the 16 mutants as summarized in Table 2 and discussed in
depth below.

During our investigation, we identified a mutation in ABUW_0885 (bap::tn) as being
impaired for biofilm formation. Importantly, this is a well-known membrane associated
factor that has been widely documented for its role in biofilm formation in A. baumannii.
Importantly, multiple bap::tn mutants were uncovered in our screen, each demonstrating
a defect in biofilm forming capabilities (Table 1), thus validating the approach and data
associated. Of these individual mutants, one was chosen to investigate more fully,
producing a biofilm with 4.15-fold less biomass. In addition, RTCA analysis showed a
severe attachment defect that was consistent throughout the 72-hour assay. This is in
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line with previous studies identifying Bap as one of the major contributors to mature biofilm
stability and structure[78, 118, 119]. In addition, the idea that Bap influences biofilm
maturation and not the initial stages of biofilm formation are validated by RTCA where the
trends of wildtype and the mutant were virtually identical for the first 10-15 hours of the
assay.

Another mutant demonstrating a defect in biofilm formation was ABUW_0201 (gabP::tn),
a membrane transporter/permease responsible for the uptake of GABA (gammaaminobutryic acid). This mutant was able to form a biofilm with 2.04-fold less biomass
than the parent strain. Of note, GABA exposure has varying effects on biofilm formation,
inducing formation in some species[158], but inhibiting formation in others[159]. It is likely
that the A. baumannii version of this permease does in fact play a positive role in biofilm
formation as the expression of gabP was increased 9.74-fold in four-day old static biofilms
as compared to planktonic growing cells in a study by another group[160]. Of interest, in
the same study, genes involved in GABA catabolism were expressed at lower levels in
biofilms, while genes associated with GABA metabolism were increased in expression.
This indicates that GABA is utilized in biofilms and is likely not broken down, but instead
is transformed into other metabolites during biofilm formation. Indeed, in other organisms
such as Bacillus subtilis, this permease is able to uptake GABA and proline, both of which
are utilized in nitrogen metabolism[161]. Therefore, in A. baumannii it is not unreasonable
to suggest that GabP may be importing other substrates important in biofilm formation
and that the mutant may have an altered ability to metabolize nitrogen. In fact, nitrogen
metabolism has been linked to various aspects of biofilm formation, including the
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production of ECM components[162]. Based on our findings, it is clear that GabP is
influencing critical components of the biofilm such as protein production and eDNA
secretion, however, without further experimentation we cannot be certain of the specific
mechanism behind this phenomenon.

We also observed a defect in biofilm formation for an ABUW_1189 (ldtJ::tn) mutant, which
specifies a periplasmic protein of the ErfK/YbiS/YcfS/YnhG (YkuD) family[163].
ABUW_1189 was initially annotated as YkuD[163], but more recently as LdtJ in A.
baumannii[164]. The STRING database along with Uniprot, identified a signal peptide,
coiled coil region, peptidoglycan binding domain, and YkuD domain within this protein
[165]. The YkuD family of proteins are known for their L-D transpeptidase (LDT) activity
and are involved in peptidoglycan cross-linking within the cell envelope. In E. coli, YnhG
(LdtE) specifically induces meso-DAP to meso-DAP crosslinking (33) instead of the
penicillin binding protein controlled meso-DAP to D-alanine crosslinking (34)[166]. The
same is true for LdtJ of A. baumannii (homolog of LdtE) which is also responsible for
peptidoglycan editing through LD-carboxypeptidase activity, incorporating D-amino acids
into peptidoglycan stem peptides during stationary phase[164]. Further, it has been
determined that peptidoglycan editing during stationary phase is dependent on RacK
(racemase) via the secretion of D-lysine for incorporation during the editing process[167].
Of interest, racK has been shown to be upregulated in biofilms of ATCC 17978 indicating
that peptidoglycan editing is in fact occurring during biofilm formation in A.
baumannii[140]. Since we also know that LdtJ is responsible for incorporating the amino
acids necessary for peptidoglycan editing into the cell wall (D-Asn, D-Arg, D-Lys, and D62

Met) it is logical that LdtJ would have a role in the biofilm formation process in A.
baumannii[164]. In our study, ldtJ::tn demonstrated a 2.05-fold decrease in biomass
accumulation in CV assays which is likely due to the lack of peptidoglycan editing in the
absence of the ldtJ. With an altered cell wall, it is conceivable that the components making
up the extracellular matrix are also altered. This is shown in Figure 6 where more eDNA
is found within this mutant as compared to the wildtype strain, perhaps as a result of more
transient autolysis occurring in the ldtJ mutant strain.

The next lead mutant analyzed, ABUW_3390 (gapN::tn), demonstrated a 3.37-fold
decrease in biofilm formation. GapN encodes an aldehyde dehydrogenase, specifically
non-phosphorylating NADP+ dependent glyceraldehyde-3-phosphate dehydrogenase
(EC 1.2.1.9) (KEGG) that functions to irreversibly convert glyceraldehyde-3-phosphate to
3-phosphoglycerate without the need of inorganic phosphate while reducing NADP+ to
NADPH[168, 169]. This is different from the standard housekeeping gene, GAPDH, which
can reversibly convert NAD+ and NADP+ to NADH and NADPH while oxidizing
glyceraldehyde-3-phosphate into diphosphoglyceric acid[169]. GAPDH also differs from
that of GAPN by the fact that GAPN is not associated with glycolysis flux, but instead
allows for the production of NADPH that can be used by the cell when levels of inorganic
phosphate are low[170]. In addition, GapN allows for the use of a modified version of the
Entner-Doudoroff pathway and glycolysis to produce NADPH and NADH to be used in
anabolic processes in the cell[171]. Although this gene has not be functionally
characterized in A. baumannii specifically, our group has observed an increase in
expression of this gene by almost 2-fold in the biofilm population of AB5075 as compared
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to their planktonic counter parts (Tomlinson & Shaw, unpublished data). This is in line
with the inability of this strain to form a biofilm to the degree of the wildtype strain (this
study). In addition, GapN was shown to be more abundant in biofilms formed by
Clostridium acetobutylicum[172], further supporting our finding. In all, to the best of our
knowledge this is the first time GapN has been implicated as a positive regulator of biofilm
formation in A. baumannii and highlights a unique mechanism of the Embden-MeyerhofParnas (EMP) pathway of carbon metabolism that is prevalent within biofilm populations.

Another biofilm deficient mutant, ABUW_3783 (mmsA1::tn) is also connected to
metabolism. MmsA1 is a CoA-acylating methylmalonate semialdehyde dehydrogenase
that is associated with propanoyl-CoA production, which is linked to the citrate cycle as
well as the synthesis of type II polyketide backbones and 12-16-membered macrolides
(KEGG). In this study, we found that this mutant was able to form a biofilm with 4.27-fold
less biomass than the parent strain. In addition, disruption of this gene led to the formation
of a thick, hypermucoviscous pellicle type structure at the air-liquid interface
(Supplemental Figure A6). This is also supported by the RTCA assay that showed a
significant inability to adhere throughout the length of the experiment. Further, mmsA1::tn
biofilms were found to contain lower eDNA concentrations within the ECM (3.85-fold).
Hypermucoviscosity is typically associated with the overproduction of polysaccharides
[18, 173], however, our mutant did not demonstrate large differences in the presence of
sodium periodate. On the other hand, it is possible that the pellicle produced at the airliquid interface contains high levels of polysaccharide that would not be detected using
the methods employed as, upon aspiration, the gelatinous biofilm is removed as one
64

globular unit for this strain. It has been shown that pellicles of A. baumannii contain
cellulose like polymers high in glucose units[174], which has been associated with a
gelatinous phenotype[175] as seen with our mutant strain. In all, this mutant demonstrates
the inability to form a surface-liquid biofilm and instead forms a gelatinous pellicle that
contains low levels of eDNA within the ECM. This unique phenotype is likely due to the
overproduction of polysaccharides due to methylmalonate semialdehyde being
transformed into 3-aminoisobutyrate instead of propionyl-CoA. It is unclear how this shift
leads to excess polysaccharide production, however, MmsA1 likely acts as a negative
regulator of pellicle formation under normal conditions.

An ABUW_3421 (folA::tn) mutant, which encodes a dihydrofolate reductase, also
demonstrated a biofilm defective phenotype. FolA is responsible for reducing
dihydrofolate to tetrahydrofolate which is an intermediate used in dTPM synthesis, purine
synthesis, the production of folic acid and the initiation of protein synthesis[176]. In terms
of biofilm formation, folA::tn had 2.04-fold less biomass than the wildtype strain, indicating
FolA to play a positive role in biofilm formation. In support of this finding, others have
shown that AB5075 biofilms formed for 6 days under flow conditions had a 2.94-fold
increase in expression of folA as compared to wildtype[177]. FolA is involved in central
systems in bacteria, which would lead one to believe that the mutant would have a growth
defect; however, this is not the case (Supplemental Figure A7O). Indeed, many other
bacterial species are able to survive without a functional folA gene[176]. In terms of biofilm
formation, folate metabolism has been connected to the well characterized biofilm
associated pili system, the csu operon. Specifically, under folate stress induced via the
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treatment of ATCC 17978 with subinhibitory concentrations of trimethoprim, which targets
FolA, inhibition of the csu operon was observed coupled with a decrease in the ability to
form a biofilm[178]. It is not unreasonable to predict that a transposon insertion disrupting
this gene could lead to a similar outcome as we see for our mutant strain.

The most substantially reduced biofilm forming capacity was found for a mutant of
ABUW_0999 (ruvB::tn), which encodes RuvB, a component of the RuvAB Holliday
junction DNA helicase. The Holliday junction helicase is one of the core SOS genes in
gamma proteobacteria[179]. In fact, a recent report identified extracellular DNA within
bacterial biofilms of multiple species that was similar to the DNA Holliday junction
intermediates produced by RuvB’s protein partner RuvA[180]. This is in line with the
decrease in eDNA (2.59-fold less) observed in the biofilm of this mutant and the overall
reduced biofilm forming capacity of the ABUW_0999 (ruvB::tn) strain (5.70-fold less).
Further, work by others reveals that six day old biofilms of AB5075 under flow conditions
show ruvB expression levels 1.49-fold higher than planktonic cells, which also validates
our findings herein[177].

The final mutant demonstrating a biofilm deficient phenotype (3.66-fold less) was
ABUW_0570, which encodes a putative GPJ-like phage base-plate assembly protein.
Within the genome of AB5075, ABUW_0570 is part of an operon containing 14 genes
associated with bacteriophage assembly, 10 of which overlap with the Pseudomonas
phiCTX phage (PHASTER search[181]). Although the phage present in AB5075 is
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uncharacterized, general characteristics associated with lysogenic phages have been
connected to biofilms. Lysogenic phages have been shown to spontaneously enter a lytic
cycle in both planktonic and biofilm populations. Within the biofilm, higher levels of phage
are released thus inducing cell lysis, which leads to the release of cellular components
that can be recycled or incorporated into the ECM of biofilm populations[182-184]. In
addition, the spontaneous release of phage is predicted to be universal for all lysogenic
phages[185]. One specific example from Streptococcus pneumoniae revealed that strains
carrying lysogenic phages had an enhanced capacity to form biofilms through phage
mediated cell lysis and release of eDNA[185]. As noted above, this mutant did produce
more eDNA than wildtype, however, it was not greater than 1.5-fold. Thus, we can predict
that the inability of the ABUW_0570 strain to generate a substantial biofilm is perhaps
due to the absence of intact phage and that the ECM phenotypes associated are likely
due to a cellular response to the phage components attempting to assemble, albeit
unsuccessfully.

In terms of potential negative regulators of biofilm formation, ABUW_3809 was identified.
ABUW_3809 encodes an uncharacterized transcriptional regulator of the GntR family.
The increase in biofilm formation observed for this mutant (4-fold) suggests that this is
indeed a negative regulator of biofilm formation when intact. This is supported by two
separate studies finding the gene adjacent to this regulator are upregulated in A.
baumannii biofilms. Specifically, levels of ABUW_3809 were not detected in RNA
sequencing experiments, but prpB (located directly adjacent) transcription was 3.29 and
6.6-fold higher in six day and 18-hour A. baumannii biofilms respectively[140, 177]. It is
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highly likely that ABUW_3809 itself negatively regulates the expression of the biofilm
associated PrpB during exponential growth, while during biofilm formation it is itself
downregulated via an unknown mechanism.

Another seemingly negative regulator of biofilm was ABUW_2431 (umuDAb), which
produced a biofilm with 5-fold more biomass than the parent strain and had consistently
higher adherence via RTCA (Figure 6B). UmuDAb encodes a LexA type repressor protein
that is dependent on RecA and controls the response to DNA damage and mitomycin C
treatment[179, 186]. UmuDAb has been proven to be a direct regulator of the DNA damage
response in A. baumannii ATCC 17978 and oversees the activity of at least eight different
DNA damage response genes, four of which are present in AB5075[187]. Each of the
genes present in AB5075 as well as ATCC 17978 were shown to be derepressed when
umuDAb was disrupted, including ddrR, a described co-regulator[179]. This signifies that
in our umuDAb::tn mutant ddrR would be derepressed and constitutively expressed
without the need for inducing conditions. This is of note because DdrR has been shown
to regulate the biofilm impacting efflux pump AdeFGH[188] as well as A1S_1147, which
is only expressed in biofilms[140] in a manner independent of UmuDAb[189]. Therefore,
our mutant’s increased capacity to form biofilms is likely a result of the de-repression of
ddrR which in turn activates biofilm associated genes under its control without the need
for a DNA damage inducing stimulant. In addition, umuDAb transcription was found to be
expressed 1.4-fold less in AB5075 biofilms growth under flow for 6 days[177], further
supporting the role of UmuDAb as a negative regulator during biofilm formation.
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ABUW_0983 (hda::tn) disruption resulted in the ability of AB5075 to form a biofilm with
2.59-fold more biomass than the wildtype strain. Hda has been characterized in detail in
Escherichia coli as a inactivator of DnaA, which helps to prevent the unnecessary reinitiation of replication, an activity known as regulatory inactivation of DnaA (RIDA)[190].
In Acinetobacter species, Hda is conserved, sharing ~30% sequence similarity to its E.
coli counterpart, but is predicted to share functional similarity in engaging with DnaA[191].
In E. coli, the loss of hda leads to the over-initiation of replication resulting in replication
fork stalling and slower growth (and sometimes death)[190]. It is known that replication
fork stalling leads to higher levels of DNA within the cell that in turn are secreted out of
the cell in the form of eDNA. In terms of biofilm formation, there is limited knowledge on
the influence of over-initiation of replication on the formation of biofilms in Gram negative
organisms specifically. However, a negative regulator of replication in Bacillus subtilis,
YabA, has been shown to negatively regulate biofilms when in-tact. Specifically, without
YabA, over-initiation of replication occurs and a more substantial biofilm is formed, which
is in line with the results of our study[192]. YabA is not an analog of Hda and each protein
differs mechanistically, however, the outcome of their inhibitory influence on DnaA and
the outcome of over-initiation is the same. Therefore, the phenotypes observed in our
analysis are likely due to an over-initiation of replication that influence biofilm formation
via a mechanism in line with that in B. subtilis. In addition, the loss of hda has been shown
to increase the production of ribonucleotide reductases[193], which results in stronger
biofilms; while deleting the genes responsible for their synthesis reduces biofilm
formation[194]. This connection reveals yet another potential mechanism by which this
mutant is able to form a better biofilm than the parent strain.
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ABUW_0133::tn was another mutant demonstrating an enhanced capacity to form
biofilms, demonstrating a 2.94-fold more biomass than AB5075. ABUW_0133 is
annotated as a putative sigma-54 modulator, however this appears to be a historical
misnomer (BLAST analysis, this study). Instead, the protein has strong homology to the
ribosome hibernation factor (RHF) family, derived from Pfam, InterPro, and HHPred
bioinformatic searches[147, 195, 196]. Ribosome hibernation factors are known to inhibit
translation by helping to stabilize and promote 70S dimerization under stressful conditions
leading to an inactive 100S ribosome. In addition, they function in preventing ribosomal
turnover[197] meaning cells lacking ABUW_0133 would theoretically undergo higher
levels of this process. There have been multiple studies suggesting that ribosomal
turnover is higher in biofilms produced by A. baumannii suggesting biofilms form more
readily in the absence of ABUW_0133[140, 177, 198]. Specifically, without the normally
triggered inhibition of ribosomal activity, higher levels of protein would accumulate and
could result in higher levels of protein being secreted, becoming a part of the ECM. This
idea is supported by the 2.93-fold decrease in biofilm biomass for this mutant following
the addition of proteinase K to mature cultures. Furthermore, in a study conducted in A.
baumannii strain ATCC 17978, ABUW_0133 was expressed at lower levels within
biofilms as compared to planktonic or stationary phase cells[140]. Additionally, a six-day
old AB5075 biofilm produced under flow conditions showed 5.57-fold lower expression of
ABUW_0133 in biofilms as compared to planktonic growing cells[177]. Each example is
in line with our study highlighting that ABUW_0133 plays an inhibitory role in biofilm
formation.
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In this study we have identified numerous metabolically linked negative regulators of
biofilm formation. One such example is ABUW_3391 (gntK), which encodes a gluconate
kinase enzyme (gluconokinase); disruption of which resulted in a 3.09-fold increase in
biofilm biomass. GntK is responsible for converting D-gluconate into 6-phospho-Dgluconate[199]. 6-P-Gluconate is used as an intermediate for the Entner-Doudoroff
pathway. Therefore, in the absence of gntK, the Entner-Doudoroff pathway cannot
generate pyruvate from 2-hydro-3-dexoxygluconate. In, a study in Streptococcus
pneumoniae, disrupting various components of the Entner-Doudoroff pathway led to
increased polysaccharide production[200]. As polysaccharides are a major component of
bacterial biofilms, this finding corroborates our data, which indicates a higher level of
polysaccharides produced during biofilm formation by the gntK::tn mutant, as shown in
Figure 9. Indeed, a strain of A. baumannii lacking gntK was shown to respond to the
presence of glucose by overproducing lipopolysaccharide[201] - further suggesting a shift
towards biofilm formation upon loss of GntK, as mutants lacking LPS form weaker
biofilms[202-204].

The identification of ABUW_4114 (traH::tn) strain in our screen was unique as this gene
is encoded on a large plasmid (p1AB5075) yet has a profound influence on biofilm
formation. Specifically, traH::tn was able to form a biofilm with 4.56-fold more biomass
than AB5075. In terms of function, ABUW_4114 encodes a putative TraH domain
containing protein. This type of domain within proteins is predicted to be a part of a
relaxasome accessory protein of an F-like Type IV secretion system associated with
conjugation. It is known that plasmid transfer via conjugation is more efficient within
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biofilms regardless of nutrient availability and it is suggested that conjugation could itself
induce biofilm formation[205]. Therefore, it would be assumed that without a functional
TraH domain containing protein, a less robust biofilm would be formed. This is
contradictory to our endpoint CV assay that demonstrated an increase in biofilm biomass
(Figure 4), however, the RTCA demonstrated a delayed induction of adherence for this
mutant that was ultimately overcome at the end of the assay (Supplemental Figure
A4C). In addition, mutations in other components of the F-type type IV pilus, such as traD
and traX in E. coli, lead to a more robust biofilm being formed - as seen for our A.
baumannii traH::tn mutant[206]. Further, it is known that in E. coli the pilus cannot fully
assemble in the absence of traH, but there is still expression of the pilus tip, and other
outer membrane proteins such as TraN, which is responsible for the aggregation of cells
[207, 208]. The increased biofilm forming capacity of this mutant is thus likely due to two
things: the accumulation of proteinaceous products that are not able to assemble, and
closer contact/aggregation of cells due to a truncated pilus. The truncated pilus would
also explain why we see a lag in adherence via RTCA as less cells are aggregating
initially, due to an inability to actively search for each other. In addition, the accumulation
of proteins produced by this operon line up nicely with the sensitivity of this mutant to
proteinase K challenge after the biofilm is established (Figure 8).

Another candidate identified, ABUW_2655 encodes a 195-residue protein of unknown
function that, when disrupted, leads to an increase in biofilm formation of 2.60-fold.
Although it is unclear how loss of ABUW_2655 produces this phenotype, it has been
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shown to be expressed at levels 2.07-fold lower in six-day old AB5075 biofilms as
compared to planktonically growing cells[177], which is in line with this study.

Finally, the mutant identified as having the most profound effect on AB5075 biofilm
formation herein was ABUW_1763 (usp::tn), which demonstrated a 8.05-fold increase in
biomass. This phenotype, along with the drastically higher CI values via RTCA (Figure
4A) support the idea that Usp is a profound negative regulator of biofilm formation in A.
baumannii when intact. In line with this, various other studies have shown decreased
expression of universal stress proteins in A. baumannii biofilms[140, 177]. Universal
stress proteins are generally known to help circumvent various forms of stress
encountered by bacteria, including but not limited to: protection from reactive oxygen
species, acidity, and toxins. However, a direct mechanism of Usp’s functioning on a
biochemical level remains elusive. In A. baumannii a paralog of usp::tn, UspA, is generally
known for playing a role in virulence and survival within the host[209]. In other organisms,
there are unique roles that UspA plays some of which are biofilm associated. Specifically,
UspA and UspA-like proteins seem to be positive regulators of anaerobic biofilm formation
in Pseudomonas aeruginosa[210, 211] and Porphyromonas gingivalis[212, 213].
Therefore, it is clear that we have uncovered a unique functional role for Usp in biofilm
formation that is specific to A. baumannii, which merits further investigation and will be
explored in depth in the following chapter.
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In summary, using a high-throughput screening approach we have identified factors that
influence biofilm formation in A. baumannii AB5075. This screen is the first step in finding
new candidates that are likely to play a role in the complex regulatory cascade known as
biofilm formation. Future studies into the specific mechanisms at play within these
mutants will be critical to our understanding of this process in this dangerous organism
and may provide new and novel candidates that could be used for future anti-biofilm
based therapeutic strategies.
.
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Chapter 3: Characterization of Universal Stress Protein G in the Oxidative Stress
and Cell Envelope Stress Response of Acinetobacter baumannii

Introduction

Universal stress proteins are known for their role in protecting organisms from various
forms of stress. They act as global regulators to allow organisms to respond to external
threats. The first universal stress protein, UspA was discovered in Escherichia coli in
1992. It was described as a 13.5kDa cytoplasmic protein that accumulates following
nutrient starvation, or exposure to toxic chemicals such as heavy metals, oxidants, acids
and antibiotics[214]. Its induction was found to be independent of many stress-induced
global regulators such as OmpR, PhoB or H-NS[214]. Since then, thousands of universal
stress proteins have been documented within all three kingdoms of life, in such diverse
organisms as fungi, archaea, protozoa, and plants[215]. In such organisms, they have
been characterized as protecting against starvation of nutrients such as: carbon, nitrogen,
phosphate, sulphate, amino acids[216-219]. In bacteria, this means that expression is
often induced during stationary phase where nutrient limitation naturally occurs[220]. A
role in protection against oxidative stress, acidity, heat exposure, osmotic stress,
chemical stress, exposure to heavy metals and DNA damage has also been
described[221-224]. Evidence has shown that some bacterial Usp proteins are also
involved in regulating motility, adhesion, and biofilm formation[222, 225, 226]. Finally,
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within organisms such as A. baumannii, they are important for survival and virulence in
vivo[209, 221, 224].

Proteins containing the UspA (or Usp) family domain (Pfam PF00582) can be composed
solely of a Usp domain, or such a domain can be one amongst many. Members of this
family have a Usp domain with an average length of 136 amino acids. Based on the nearly
60,000 sequences available (59,455 to be exact), the average percent sequence identity
of full alignments is only 17%, indicating a high level of diversity among members of the
Usp domain family. Indeed, within the Pfam database there are thousands of examples
of protein sequences containing Usp domains, with a variety of domain organizations.
With that said, the most common arrangement is a lone USP domain, as >31,000 protein
sequences within databases contain just this configuration, whilst a further 10,000 or so
proteins contain two tandem Usp domains. Further, there are 272 additional groups with
unique architectures each containing a Usp domain[227]. For example, there are over
1,000 sequences that contain a Usp domain followed by a protein kinase domain. In
addition to the high prevalence of Usps in nature demonstrated by Pfam alone, there are
many organisms that harbor multiple Usp proteins within their genome.

In the best studied organism, E. coli, there are five paralogs of UspA that exist: UspC,
UspD, UspE, UspF, and UspG. UspE is unique such that the protein contains two
adjacent Usp domains, one of which has similarity to UspG and UspF and the other
resembles UspA, UspC, and UspD[228]. Other bacteria also often have a variety of Usp
proteins, for example Streptococcus coelicolor encodes 12 usp genes, Mycobacterium
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tuberculosis possesses eight or nine and Micrococcus luteus has three[216, 228, 229].
Conversely, some species, such as Xanthomonas campestris only encode one[216]. The
best examples to date that explain the connection between paralogs within a single
species have been performed in E. coli. Synthesis of UspA, UspC, UspD, UspE, and
UspG is induced by glucose or phosphate starvation, exposure to dinitrophenol and heat,
and extended growth in nutrient rich media[215]. The overlap in expression demonstrates
a form of functional redundancy between them. However, when separated into classes,
distinct functions can be assigned to each set of proteins and even individuals within a
class. For example, one class consists of UspA, UspC, and UspD, another consists of
UspF and UspG; whilst UspE is broken into two classes. There is overlap and specificity
between classes in terms of function. For example, UspA and UspD are important for
protection against superoxide and DNA-damaging agents, while UspC and UspE are
essential for motility and UspG and UspF promote adhesion[222]. However, UspA, UspC,
UspD, and UspE play a role in protection against UV-irradiation[228]. Therefore, each
Usp can function within the same pathway, but their functions are not explicitly redundant:
the deletion of one does not allow for another to compensate. Additionally, although there
are conditions that lead to a similar induction of each Usp, the level of induction of each
Usp can be specific to the stressor. For example, UspA is induced >3-fold when exposed
to low level heat shock, while UspC, UspD, and UspE, although also induced, are at levels
less than 3-fold[228].

There is also diversity in terms of regulators of specific Usps. In E. coli, UspA is negatively
regulated by FadR[230] while UspA, UspC, UspD, and UspE are negatively regulated by
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FtsK[231], and positively regulated by RecA[231] and ppGpp[232]. UspG of E. coli is
regulated by the two component system NtrB/NtrC[233] and is likely a substrate of
GroEL[234]. The response regulator of a two-component system, DevR, is also important
for regulating some of the Usps of Mycobacterium smegmatis[235]. In Burkholderia
glumae, RpoS and the quorum sensing transcriptional regulator QsmR are known to
transcriptionally regulate the expression of its various usp genes[236]. Conversely, uspA
induction is not dependent on RpoS in E. coli[214]. In E. coli all usp genes are predicted
to be under the control of σ70 (RpoD), the housekeeping sigma factor, based on the -10
and -35 regions upstream of uspA[218]. However, uniquely, UspD within the same
organism is under the regulation of RpoE (σE), the extracytoplasmic stress sensing sigma
factor[237]. In another species, Listeria monocytogenes, RpoB is predicted to regulate
usp genes based on σB boxes upstream of these genes[221].

Following translation, another form of regulation is present for Usps. Post-translational
modifications such as ATP binding and phosphorylation, dimerization and protein-protein
interactions also mediate the functionality of Usps. For example, UspA of E. coli can be
detected in three different isoforms, two of which are phosphorylated[238]. This
phosphorylation is induced upon entry into stationary phase and is dependent on the
phosphotyrosine protein TypA. UspF and UspG of E. coli undergo post-translational
modification through ATP binding while UspG can also autophosphorylate[239, 240]. This
is also shown in the UspFG homolog MJ0577 of Methanococcus jannaschii, which can
form homodimers that tightly bind ATP[241]. There is also evidence that an additional
factor is required to release ATP from MJ0577. In addition to phosphorylation or substrate
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binding, evidence of the formation of homo and heterodimers exist. For example, UspA,
UspC, and UspD of E. coli are shown to interact with themselves as well as with each
member of their class[242]. The same was found for UspF and UspG[242]. Further, UspE
was found only to interact with itself, an interaction that is dependent on the presence of
both Usp domains[242]. Therefore, interactions between different Usps would result in a
different cellular response compared to Usp homodimers in vivo. Evidence for interactions
between Usps and other protein complexes also exists. For example, Rv2623 of M.
tuberculosis

interacts

with

an

ATP-dependent

ABC

transporter

of

lipooligosaccharides[243] and UspC of E. coli interacts with the Usp domain of KdpD
under osmotic stress[244].

Usp proteins have a unique ability to exist in a variety of forms to influence cellular
processes and function as global regulators in bacteria and other organisms. They can
form complexes with themselves, bind substates, interact with other proteins, and change
phosphorylation state depending on their environment. The complexity increases within
organism such as A. baumannii that possess multiple Usps that are yet to be
characterized fully. Thus far in A. baumannii, only one Usp has been characterized
phenotypically. The homolog of ABUW_0890 in ATCC17978 (A1S_2692) has been
shown to have a role in oxidative stress tolerance, survival in the presence of 2,4-DNP,
growth under acidic conditions, and survival in vivo[209]. Herein we show that in the
absence of uspG, a paralog of uspA, A. baumannii is impaired in growth, energy
metabolism, lipid metabolism, membrane integrity and the expression/function of various
transporters. We also show that, like many other Usp proteins, the uspG::tn strain
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demonstrates increased sensitivity to DNA-damaging agents, H2O2, and a variety of
different antibiotics.

Materials and Methods

Bacterial Strains and Growth Conditions. Bacteria were maintained on agar plates for
no longer than 48 hours prior to assay and were stored at 4°C. All plasmids and strains
used within this chapter are listed in Table 3. Bacterial strains were grown with shaking
at 250 rpm and 37°C. Unless otherwise specified strains were grown in Luria Broth (LB)
or Luria Broth Agar (LBA). For experiments using strains containing the pMQ557 plasmid,
cultures were supplemented with 160µg/mL of Hygromycin B. Transposon mutants were
grown on LBA containing 12.5µg/mL of tetracycline or in LB containing 5µg/mL of
tetracycline.
Table 3. Bacterial Strains and Plasmids.
Strain
Description
A. baumannii
AB5075
Wildtype Strain
uspG::tn
AB5075 with tn insertion in ABUW_1763 (uspG)
WT EV
AB5075 containing pMQ557 (JLA2887)
uspG (M)
uspG::tn containing pMQ557 (JLA2878)
uspG+ (C)
uspG::tn containing pMQ557::uspG-His6
(JLA2879)
Plasmids
pMQ557
Cloning vector for complementation
pLSJA1

pMQ557::uspG

Source
[143]
[144]

This study
This study
This study

Gift, Dr. R. Shanks,
University of Pittsburgh
This study

Growth Curve Analysis. Bacterial strains were grown at 37°C shaking at 250 rpm for 15
hours with antibiotic supplementation. Strains were then synchronized by adding 50µL of
culture to 5mL of fresh media and incubating while shaking for 3 hours. Each sample was
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then standardized to an optical density at 600nm (OD600) of 0.05 in fresh media containing
antibiotic. A 96-well polystyrene plate was seeded with each strain in biological triplicate
and technical duplicate. Each well contained 200µL total. Measurements were taken at
OD600 every 15 minutes for 18 hours with continuous double-orbital shaking in between
(Citation 5, BioTek). The temperature was maintained at 37°C.

Construction of a uspG Complementing Strain. To generate the complementing strain
of uspG, flanking primers were designed for the ABUW_1763 gene that included the
promotor as well as 100-200 nt of DNA 3’ of the translational stop codon. The fragment
was PCR amplified and cloned into pMQ557. Primers for this can be found in
Supplementary Table A1. The plasmid containing uspG and the uspG::tn strain were
verified using PCR and sanger sequencing (GeneWiz) prior to transformation. uspG+ (C)
was generated by transforming the pMQ557::uspG plamid into uspG::tn. uspG- (M) was
created by transformation with the empty plasmid (pMQ557). Finally, AB5075 underwent
transformation with empty vector (pMQ557) to generate the AB5075 WT strain. Strains
and plasmids are listed in Table 3. Each strain containing plasmid was then confirmed by
PCR amplification followed by Sanger sequencing (GeneWiz). Prior to setting up
overnight cultures for each assay, colony PCRs were performed to confirm the integrity
of the transposons and plasmids within each strain. Assays were performed using
Hygromycin B at a concentration of 160µg/mL to maintain the plasmid. Each
complementation assay included uspG- (M), uspG+ (C), and AB5075 (WT).
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Western Blot Analysis. The uspG::tn complement strain was synchronized and
standardized as detailed above in biological triplicate, before 5mL samples were collected
hourly for 8 hours. An 18-hour and 24-hour timepoint were also collected. Samples were
harvested at 4150 x g for 10 minutes before supernatant was removed and pellets were
stored at -80°C prior to normalization. Cytosolic proteins were harvested by resuspending
each pellet in 500µL of PBS containing protease inhibitor cocktail (Thermo Fisher
Scientific) followed by the inclusion of glass beads. Samples were lysed mechanically by
bead beating 3 times for 30 second intervals. Samples were then centrifuged for 5
minutes at 17000 x g and supernatant was transferred to a fresh tube. Samples were then
normalized to 100µg/mL using the ProteinQuant 660nm Kit (Thermo Fisher Scientific)
and a BSA standard curve. Samples were separated using SDS-PAGE on a gradient 420% SDS precast gel (BioRad). The samples were subject to 90V for 2 hours prior to
blotting on polyvinylidene difluoride (PVDF) membranes using a semi-wet transfer at 20V
for 45 minutes (BioRad). Immunoblotting was performed using anti-6xHis polyclonal
rabbit primary antibody (Invitrogen) incubating overnight at 4°C in blocking buffer. The
secondary antibody was HRP-conjugated mouse anti-rabbit IgG (Cell Signaling
Technologies) incubated for 1 hour at 27°C. HRP activity was assessed using the
SuperSignal West Pico Chemiluminescent substrate kit (Thermo Fisher Scientific) and
was visualized using X-ray film.

RNA Sequencing. Collection of AB5075 wildtype and AB5075 uspG::tn mutant samples
was performed using the synchronization and standardization methods described above.
Samples were tested in biological triplicate. Once cells were standardized to OD600 0.05,
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they were grown for 3 additional hours. Samples were then harvested, added to an equal
volume of ice-cold phosphate buffered saline (PBS), and centrifuged at 4°C. An RNeasy
Kit (Quiagen) was used to isolate total RNA from cell pellets as previously described[245].
A TURBO DNA-free kit (Ambion) was used for DNA removal. DNA removal was confirmed
using 16s rRNA specific primers. An Agilent 2100 Bioanalyzer system and Agilent RNA
6000 nano kit were used to assess sample quality and ensure RNA integrity. Samples
used in this study measured an RIN of ≥9.9. Biological replicates for each strain were
pooled and normalized prior to rRNA removal using a Ribo-Zero Kit for Gram Negative
Bacteria (Illumina). This was followed by mRNA enrichment using the MICROBExpress
Bacterial mRNA enrichment kit (Agilent) before removal efficiency of rRNA was checked
using a bioanalyzer and nano kit. These samples were then used for RNA sequencing
on an Illumina NextSeq sequencer. RNA sequencing and Library preparation were
performed using the Truseq Stranded mRNA Kit (Illumina) method but omitting the mRNA
enrichment step. Prior to sequencing the quality, concentration, and average fragment
size were measured and assessed using an Aglient 2100 Bioanalyzer system and a
corresponding RNA 6000 Nano kit. The library concentration for pooling barcoded
samples was evaluated via qPCR with a KAPA Library Quantifiaction kit (KAPA
Biosystems) to ensure high sensitivity. The Illumina NextSeq was used to run samples
with a 150-cycle NextSeq mid Output Kit v2.5.

RNA Sequencing Bioinformatics. Data sets were exported from BaseSpace (Illumina)
to CLC Genomics Workbench 20 (Quiagen Bioinformatics) for analysis in the fastq format.
Reads were imported and failed reads removed using the Illumina Paired Importer tool.

83

Quality score parameter options were set to Illumina Pipelines 1.8 and later. rRNA reads
were filtered and removed by aligning to known rRNA sequences. Remaining reads were
then aligned using the RNA-seq Analysis Tool (v0.1) under default parameters. Strand
specificity was defined through alignment to A. baumannii AB5075 NCBI reference
genome (CP008706.1). The Expression Browser tool (v1.1) was used to calculate gene
expression with transcripts per million (TPM) as the output value. To determine differential
expression values, the Differential Expression in Two Groups tool (v1.1) for whole
transcriptome samples was used. Fold change values of the uspG::tn mutant to wildtype
samples were reported. Library size normalization was taken into account using the
trimmed mean of M values (TMM) generated using the Differential Expression in Two
Groups tool. Genes were classified ontologically using the Kyoto Encyclopedia of Genes
and Genome (KEGG) database[246-248] for the related AB57 strain.

Minimum Inhibitory Concentration Determination. MIC assays were performed
according to CLSI guidelines[249] using either LB or Mueller Hinton II (Ca-MHB) media.
MICs were performed in 96-well polystyrene plates with a final volume of 200µL/well.
Overnight cultures were diluted to a final OD600 of 0.05 in fresh media containing the
stressors to be tested alongside the appropriate solvent only controls. Media only controls
were also included in each assay plate. Samples were wrapped in parafilm to prevent
evaporation and incubated for 18 hours, shaking at 37°C. The following day, assay plates
were measured at OD600 (Cytation 5 Plate Reader, BioTek) and percent inhibition was
calculated for each compound comparing treated samples to solvent only controls for
each strain. MICs were verified on at least two separate days. Percent inhibition was
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calculated following the subtraction of background from each well (average of OD600 of
media only wells) using the following formula: %inhibition = (1 - (OD600 treated/average
OD600 solvent only controls)) x 100. Fold change was then calculated for each stressor
tested by dividing the MICs of AB5075 and uspG::tn.

Motility Assessment. Overnight cultures of uspG- (M), uspG+ (C), and AB5075 (WT)
were synchronized in the presence of 160µg/mL hygromycin to maintain the plasmid.
Following three hours of growth, samples were standardized to an OD600 of 0.1 in fresh
LB. Each strain was grown in biological triplicate and plated onto LBA+hygromycin by
adding 10µL to the center of each agar plate. Samples were wrapped in parafilm and tape
to prevent evaporation and were placed (without inversion) at 37°C and 27°C for
incubation in the dark. The diameter of each sample was measured and recorded. Plates
were incubated at 37°C and 27°C for 48 hours prior to recording the first measurement.
Samples at 27°C were allowed to incubate for an additional 15 days prior to recording the
final measurement. The same approach was taken to assess uspG::tn and wildtype
AB5075 strains. Plates were poured without antibiotic prior to incubation for 14 days in
the dark.

Survival in Whole Human Blood. Bacterial strains were grown overnight, synchronized
and standardized according to the methods above and the assay was performed as
previously described[250] with modifications. Each strain was grown in biological triplicate
and following 3 hours of synchronization, samples were centrifuged at 4150 x g.
Supernatant was then removed and samples were resuspended in 1mL of PBS prior to
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standardization to an OD600 of 0.5. Cells were then diluted in 3mL of whole human blood
(BioIVT) to an OD600 of 0.05. PBS samples were also prepared at OD600 0.05 to serve as
a control for timepoint 0. An additional control for 0 minutes was taken immediately after
inoculation in blood. Timepoints were then taken following 30 minutes, 1 hour, 2 hours, 3
hours, 4 hours, 5 hours and 6 hours of incubation. CFU/mL were calculated for each strain
at each timepoint by serial dilution in PBS and plating on LBA. Blood cultures were
incubated between collections at 37°C, rotating.

Results

Bioinformatic Considerations of Usps in A. baumannii 5075. In Chapter 2 we
identified a variety of genes/proteins in A. baumannii as being important for biofilm
formation. One of the most profoundly impaired mutants from these was for gene
ABUW_1763, which contains a Universal Stress Protein (Usp) domain. A search of the
AB5075 genome for other universal stress proteins revealed six genes encoding proteins
with the Usp domain: ABUW_0890, ABUW_1661, ABUW_1763, ABUW_2639,
ABUW_3660, and ABUW_3666 (Table 4).
Table 4. Usp Paralogs in AB5075
Gene
ABUW_0890
ABUW_1661
ABUW_1763
ABUW_2639
ABUW_3660a
ABUW_3666b

Bp Length
438bp
444bp
444bp
843bp
351bp
528bp

AA Length
145aa
147aa
147aa
280aa
116aa
175aa

% Seq ID
50.34%
45.58%
27.03%
0%
27.34%

GenBank
AKA30650.1
AKA31399.1
AKA31499.1
AKA32361.1
KGP64547.1
KGP64480.1

Bp: base pair, AA: amino acid, %Seq ID: Percent identity to ABUW_1763 based on NCBI Blastp alignment,
GenBank: ID from NCBI database. aNo longer annotated as such, non-redundant protein ID
WP_000034558.1, alternate annotations: A591_A3583/ABUW_RS17825. bNo longer annotated as such,
protein ID WP_000451088.1 record removed, alternate annotations: A591_A3588/ABUW_RS17850
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Sequences of each Usp protein were aligned using CLC Genomics Workbench as
visualized in Figure 10. When observing this alignment we note that ABUW_2639 is
much longer than the other proteins, which is evident by the large gaps in alignment within
Figure 10. Indeed, according to the UniProt database, ABUW_2639 possess two Usp
domains, and therefore resembles UspE of E. coli. However, UspE of E. coli has been
shown to possess the ATP binding domain G-2X-G-9X-G-N[251] while ABUW_2963 does
not. Further, ABUW_3360 is similarly unlikely to bind ATP, as the sequence do not
possess the characteristic G-2X-G-9X-G-S/T nor G-2x-G-9x-G-N sequence[216]. The
remaining four Usps, do in fact possess this sequence (highlighted in Figure 1, black box)
and are therefore likely to bind ATP. In addition, although ABUW_1763 and ABUW_1661
are of the same number of amino acids, their sequences are very different, which
indicates they are of different classes of Usp with distinct functions.

Figure 10. Universal Stress Proteins of AB5075 Show Little Sequence Similarity.
Each protein sequence was downloaded from the NCBI database as a fasta file and input
into CLC genomics workbench to create the alignment.
Performing bioinformatic analysis with each of the Usp proteins in A. baumannii we note
that each of the six proteins are strictly cytoplasmic. According to the Protter protein
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visualization database, none of the sequences possess transmembrane domains nor
signal peptide sequences and are therefore located within the cell following
translation[252]. In addition, a blastp search was conducted and found that the A.
baumannii Usp showing the greatest similarity to ABUW_1763 was ABUW_0890, with
50.34% identity (Table 4). The homolog of ABUW_0890 has been phenotypically
characterized in A. baumannii ATCC 17978 (A1S_2692) and has the highest level of
similarity to Usp2 of Staphylococcus aureus at ~ 49%[209].

To gain structural insights, the ABUW_1763 protein sequence was submitted to two
separate protein folding predictive software platforms (I-TASSER [253] and Phyre2[254]).
The outcome of these searches was in agreeance: demonstrating ABUW_1763 as having
the highest level of structural similarity to UspA of Lactobacillus plantarum (PDB: 3S3T)
and MJ0577 of Methanocaldococcus jannaschii (PBD: 1MJH). However, sequence
similarity of ABUW_1763 to L. plantarum was 21.3% while alignments indicated 29.8%
similarity to the Usp of M. jannaschii. The predicted structure of ABUW_1763 is
characterized by the Usp domain which spans amino acids 3-145 of the 147 amino acid
sequence, according to the UniProt database. Structurally, ABUW_1763 possesses 4
alpha helices making up 48% of the sequence and 5 beta sheets that account for 19% of
the sequence according to the Phyre2 database analysis. In addition, it is predicted that
10% of the structure is disordered. The largest area of disorder is predicted to be between
residues 43 and 54 in addition to the terminal amino acids on either end of the protein,
not predicted to be part of the Usp domain. According to the RCSB protein database
(rcsb.org), each protein is predicted to bind ATP while UspA of L. plantarum is also likely
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to bind glycerol, acetate, and calcium. ATP binding is highly likely since the sequence
G(2X)G(9X)G(S/T), characteristics of ATP binding[216], is present within the sequence
of ABUW_1763 and was predicted with 0.93/1.0 confidence in the I-TASSER prediction
data for ligand binding sites. Further, GSHG-9X-GSV specifically is present within the
ABUW_1763 sequence and mirrors that of M. jannaschii’s usp, which is a proven ATP
binding protein[255]. The Phyre 2 generated structure of ABUW_1763 and the predicted
binding site for ATP are shown in Figure 11.

Figure 11. Rendering of Predicted ABUW_1763 Protein Structure. (A) Predicted
structure of ABUW_1763 with 99% confidence generated using Phyre2 software modeled
after 1mhj from Methanocaldococcus jannaschii with 95% coverage. N-terminus red to Cterminus blue in rainbow scheme. Pink arrow indicates predicted ATP binding region. (B)
Structure indicates predicted pocket for ATP binding created using BioRender.com. UspA
domain covers residues 3-145 of 147 amino acid sequence.
To identify Usp proteins of other organisms with similar sequence homology to
ABUW_1763, an additional NCBI blastp search was conducted. The ABUW_1763 fasta
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sequence aligned perfectly, with two partial sequences of Usp domain containing proteins
of E. coli and P. aeruginosa. The alignment for these sequences and the next top 9
sequences showing the highest similarity are shown in Figure 12. The partial sequences
could not be traced back to a specific class of Usp for each species and it is difficult to
classify them simply based on sequence, however, based on the predicted ATP-binding
activity that is typical for UspG class Usps, ABUW_1763 with be referred to as UspG
hereafter.

Figure 12. Top 11 Species with Usp Proteins Sharing Similarity to ABUW_1763. An
ncbi blastp search was conducted and the alignment was exported to CLC genomics
workbench to generate the alignment presented. Black box outlines the sequence
indicative of ATP binding capacity (G-2X-G-9X-G-S/T). ABUW_1763 sequence is listed
first.
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Universal Stress Protein G Disruption Results in a Growth Defect. Based on previous
connections between Usp function and growth, an analysis was performed to determine
the impact of uspG::tn on A. baumannii growth. Cultures were synchronized to midexponential phase and were then standardized to an OD600 of 0.05 in fresh media prior
to measurement over time. It was found that uspG- (M) has a slight growth defect and an
extended lag phase (Figure 13) that is partially complemented in the uspG+ (C) strain.
Growth defects have been observed in other A. baumannii strains lacking usp
analogs[209, 256]. However, this seems to be unique to A. baumannii, as single usp
mutants of other organisms in nutrient rich conditions grow indistinguishable from the WT
strains[221, 257]. In addition, complementation of uspA in A. baumannii has only been
demonstrated for a strain created to harbor two chromosomal copies of the gene and
expression values of 20-fold that of the wildtype strain[209]. Therefore, it is perhaps
unsurprising that our complement strain was unable to fully restore growth to wild-type
levels.

Figure 13. uspG::tn Strain Exhibits a Growth Deficit When Compared to Wildtype
AB5075. Each strain was synchronized and standardized to an OD600 of 0.05 prior to
analysis. Measurements were taken every 15 minutes for 15 hours. Error bars represent
±SEM of three biological replicates.
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UspG Baseline Protein Expression Increases Over Time and Remains Stable. Many
Usps are expressed following the induction by stressors, but they are also known to
accumulate as cells enter stationary phase as nutrients become limited[220]. In order to
determine whether UspG of AB5075 is similarly accumulated during stationary phase, it
was important to evaluate protein expression. To do this, our complement strain uspG+
(C), which bears a C-terminally included his-tag was tested for expression. The strain was
synchronized standardized before growth over 24 hours at 37°C shaking in LB. An empty
vector control of AB5075 (WT) was used and was grown in concert with the uspG+ (C)
expression strain. As shown in Figure 14, UspG accumulates with expression seen from
2-24 hours. Expression could be detected following 2 hours of growth indicating UspG is
present in exponential phase, which is unique for Usps and could indicate a novel role for
UspG of AB5075. In line with Usp accumulation in other organisms during stationary
phase, UspG is in high abundance at the later time points. This data also indicates that
protein is likely stable over time. The highest level of expression seen after 24 hours of
growth is, again, not surprising as uspA and uspG of E. coli are shown to be expressed
under conditions of growth arrest[234, 238]. Further, the control samples (WT) were
treated with the same conditions and no banding was observed (data not shown),
verifying that the band seen within Figure 13 is specific to His-tagged UspG.

Figure 14. UspG Expression is Stable Over Time. Samples of uspG+ (C) were taken
at described timepoints and normalized to 100µg/mL prior to gel loading. Western blot
exposed using histidine-6 antibody. Image represents results observed for three
biological replicates.
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RNA-sequencing Analysis Reveals Vast Changes in uspG::tn. With protein
expression seen within exponentially growing cells in the absence of stress, it is clear that
UspG is employed by the A. baumannii cell during standard growth. Given the importance
of these enzymes in other organisms, we decided to explore UspG function using
transcriptomic analyses. These were performed on 3-hour synchronized cultures of
uspG::tn and the wildtype AB5075 strain. Upon analysis, a substantial number of genes
were differentially expressed and therefore a cutoff of ≥4-fold was established. Overall,
326 genes fell within this cutoff and were organized ontologically (Figure 15).

Figure 15. Disruption of uspG Leads to Vast Changes in Transcriptome. Overall
number of genes changed (left). Genes with changes in expression greater than or less
than 4-fold as compared to wildtype were grouped ontologically based on KEGG
searches (right). Genes with higher expression within uspG::tn are shown in blue, genes
with lower expression are shown in pink. Categories: metabolism (purple), genetic
information and processing (green), environmental processing (orange), cellular
processing (teal), human disease (dark green), and unclassified (black).
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Specifically, 261 genes were downregulated by greater than 4-fold in the uspG::tn mutant
strain compared to the wildtype AB5075 strain (Table 5). Conversely, 65 genes had
increased expression greater than 4-fold in the mutant strain (Table 6). Ontological
groupings were established using the KEGG orthology database, however AB5075 is not
specifically represented within the system. To overcome this, gene identifiers were
converted to homologous genes in the closely related AB57 A. baumannii strain prior to
the search. Genes were then organized into six categories with relevant subcategories
as shown in Figure 15: metabolism (carbohydrate, energy, lipid, nucleotide, amino acid,
glycan, cofactor, terpenoid/polyketide, xenobiotic degradation), genetic information
processing (transcription, translation, folding/sorting/degradation, replication/repair),
environmental information processing (membrane transport, signal transduction), cellular
processing (cellular community), human diseases (antimicrobial drug resistance), and
unclassified. While a majority of the genes identified are considered unclassified based
on the comparative cross-referencing of homologs of AB57 within KEGG, some
correlations could be deduced based on genomic location or gene annotations and
protein descriptions found utilizing the UniProt knowledgebase[258].
Table 5. Ontological Grouping of Genes with Decreased Expression in the uspG::tn
Mutant Strain
ABUW_
Annotation
Metabolism
Amino Acid Metabolism
ABUW_0066 hpd hppD
ABUW_0069

maiA hmgC

ABUW_0077

hutU

ABUW_0078

hutH

Description

Fold

4-hydroxyphenylpyruvate dioxygenase (EC
1.13.11.27) (HppD 4-hydroxyphenylpyruvate
dioxygenase)
MaiA maleylacetoacetate isomerase
(Maleylacetoacetate isomerase)
(Maleylacetoacetate isomerase (MAAI)) (EC
5.2.1.2)
Urocanate hydratase (Urocanase) (EC 4.2.1.49)
(Imidazolonepropionate hydrolase)
Histidine ammonia-lyase (Histidase) (EC 4.3.1.3)
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-7.49
-4.18

-6.03
-9.75

Table 5. Ontological Grouping of Genes with Decreased Expression in the uspG::tn
Mutant Strain (Continued)
ABUW_0080

hutI

ABUW_0081

hutG

ABUW_1635

ligE_2 ligE
ligE_1

ABUW_1726
ABUW_2410

yfcF

ABUW_2452

clbF_14 ivd

ABUW_2453

ABUW_2454

mgh

ABUW_2455

accA1_2

ABUW_2526

paaF paaK

ABUW_2529

paaG paaB

Imidazolonepropionase (EC 3.5.2.7)
(Imidazolone-5-propionate hydrolase)
Formimidoylglutamase (EC 3.5.3.8)
(Formiminoglutamase) (Formiminoglutamate
hydrolase)
Glutathione S-transferase (Glutathione Stransferase family protein) (Glutathione Stransferase, N-terminal domain protein)
D-amino acid dehydrogenase 3 small subunit
Glutathione S-transferase (Glutathione Stransferase family protein) (Glutathione
transferase) (Putative glutathione S-transferase)
(EC 2.5.1.18)
Acyl-CoA dehydrogenase (EC 1.3.8.1) (Colibactin
biosynthesis dehydrogenase ClbF) (IsovalerylCoA dehydrogenase) (EC 1.3.8.4) (Isovaleryl-CoA
dehydrogenase (IVD))
Acetyl-CoA carboxylase (EC 2.1.3.1)
(Methylcrotonoyl-CoA carboxylase)
(Methylcrotonoyl-CoA carboxylase beta chain)
(Methylcrotonyl-CoA carboxylase carboxyl
transferase subunit) (EC 6.4.1.4)
3-methylglutaconyl-CoA hydratase (Enoyl-CoA
hydratase) (EC 4.2.1.17) (Enoyl-CoA
hydratase/isomerase family protein)
(Methylglutaconyl-CoA hydratase) (EC 4.2.1.18)
Acetyl-CoA carboxylase biotin carboxylase
subunit (Acetyl/propionyl/methylcrotonyl-CoA
carboxylase subunit alpha) (Acyl-CoA carboxylase
alpha chain protein) (Methylcrotonoyl-CoA
carboxylase subunit alpha) (MethylcrotonoylCoenzyme A carboxylase 1 (Alpha))
(Methylcrotonyl-CoA carboxylase biotin-containing
subunit) (EC 6.4.1.4)
Phenylacetate-coenzyme A ligase (EC 6.2.1.30)
(Phenylacetyl-CoA ligase)
2-(1,2-epoxy-1,2-dihydrophenyl)acetyl-CoA
isomerase (EC 5.3.3.18) (Enoyl-CoA hydratase)
(EC 4.2.1.17) (Enoyl-CoA hydratase, phenylacetic
acid degradation) (PaaB phenylacetate
degradation probable enoyl-CoA hydratase paaB)
(Phenylacetate degradation enoyl-CoA hydratase
PaaB)
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-8.93
-6.94
-4.97
-5.11
-6.29

-10.98

-25.05

-31.71

-36.01

-7
-7.19

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_2531

paaK hmp_2

ABUW_2532

paaJ paaD

ABUW_2533

paaI2 paaC
paaI

ABUW_2534

paaB paaH

ABUW_2535

paaA paaG

ABUW_2537
ABUW_3473

sdaA
yfcG_1
yfcG_2
yfcG_3

ABUW_3782

mmsB Hgd

Carbohydrate Metabolism
ABUW_2099 thlA_2 thlA_1

Flavodoxin reductase (EC 1.17.1.-)
(Phenylacetate-CoA oxygenase/reductase)
(Phenylacetate-CoA oxygenase/reductase subunit
PaaK) (Phenylacetate-CoA oxygenase/reductase,
PaaK subunit) (Phenylacetic acid degradation
protein) (Putative phenylacetic acid degradation
NADH oxidoreductase paaE)
Metal-sulfur cluster biosynthetic protein (PaaJ
phenylacetate-CoA oxygenase, PaaJ subunit)
(Phenylacetate-CoA oxygenase) (PhenylacetateCoA oxygenase subunit PaaJ) (PhenylacetateCoA oxygenase, PaaJ subunit) (Putative 1,2phenylacetyl-CoA epoxidase, subunit D)
Phenylacetate-CoA oxygenase (PhenylacetateCoA oxygenase subunit PaaC) (PhenylacetateCoA oxygenase subunit PaaI) (PhenylacetateCoA oxygenase, PaaI subunit) (Phenylacetic acid
degradation protein paaC) (Subunit of
Phenylacetate-CoA oxygenase)
1,2-phenylacetyl-CoA epoxidase subunit B (EC
1.14.13.149) (1,2-phenylacetyl-CoA epoxidase,
subunit B) (PaaB) (Phenylacetate-CoA
oxygenase) (Phenylacetate-CoA oxygenase
subunit PaaB) (Phenylacetate-CoA oxygenase,
PaaH subunit) (Phenylacetic acid degradation
protein paaB)
1,2-phenylacetyl-CoA epoxidase subunit A (1,2phenylacetyl-CoA epoxidase, subunit A) (EC
1.14.13.149) (AAA family ATPase) (ATPase AAA)
(Phenylacetate-CoA oxygenase) (PhenylacetateCoA oxygenase subunit PaaA) (PhenylacetateCoA oxygenase, PaaG subunit) (Phenylacetic
acid degradation protein paaA)
L-serine dehydratase (EC 4.3.1.17)
Disulfide-bond oxidoreductase YfcG (EC 1.8.4.-)
(Glutathione S-transferase) (EC 2.5.1.18)
(Glutathione S-transferase family protein)
(Glutathione S-transferase, N-terminal domain
protein)
3-hydroxyisobutyrate dehydrogenase (HIBADH)
(EC 1.1.1.31)
Acetyl-CoA C-acetyltransferase family protein
(Acetyl-CoA C-acyltransferase) (Acetyl-CoA
acetyltransferase) (EC 2.3.1.16) (EC 2.3.1.9)
(Acetyl-CoA acetyltransferase(Acetoacetyl-CoA
thiolase)) (Thiolase family protein)
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-7.87

-8.44

-7.55

-6.57

-8.67

-4.4
-6.13

-170.82
-26.47

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_0175
ABUW_1574

acsA_1 acs
acsA acsA_2
mbtA
acsA_2
acsA_1

ABUW_1621

ald1 acoD

ABUW_1624

dhaT_1 dhaT
dhaT_2
lap_2

ABUW_2092

bdhA

ABUW_2096
ABUW_2097
ABUW_2126

atoD scoA
scoB atoA
gutB

ABUW_2127
ABUW_2129

budC
budC_1
acoC

ABUW_2436
ABUW_2456

katE
yngG_1

ABUW_2504
ABUW_2528

srpA
paaC
paaH_2

ABUW_2530

caiD
echA8_4

Acetyl-coenzyme A synthetase (AcCoA
synthetase) (Acs) (EC 6.2.1.1) (Acetate--CoA
ligase) (Acyl-activating enzyme)
AMP-binding protein (Acetyl-CoA
synthetase/AMP-(Fatty) acid ligase) (EC 6.2.1.1)
(Acetyl-coenzyme A synthetase) (Acyl-CoA
ligase) (Acyl-CoA synthetase)
Acetaldehyde dehydrogenase 2(Acetaldehyde
dehydrogenaseII) (ACDH-II) (Ald1) (Aldehyde
dehydrogenase) (EC 1.2.1.3) (Aldehyde
dehydrogenase family protein)
1,3-propanediol dehydrogenase (EC 1.1.1.202)
(Alcohol dehydrogenase) (Alcohol
dehydrogenase, iron-containing) (Iron-containing
alcohol dehydrogenase) (Iron-containing alcohol
dehydrogenase family protein) (L-threonine
dehydrogenase) (Listeria adhesion protein Lap)
(Putative alcohol dehydrogenase) (EC 1.1.1.1)
3-hydroxybutyrate dehydrogenase (BdhA) (Dbeta-hydroxybutyrate dehydrogenase) (EC
1.1.1.30)
3-oxoadipate CoA-transferase (EC 2.8.3.6)
3-oxoadipate CoA-transferase (EC 2.8.3.6)
(R,R)-butanediol dehydrogenase (EC 1.1.1.14)
(EC 1.1.1.4) (2,3-butanediol dehydrogenase)
(Butanediol dehydrogenase) (GutB Sorbitol
dehydrogenase) (Zinc-binding alcohol
dehydrogenase) (Zinc-binding dehydrogenase)
Diacetyl reductase [(S)-acetoin forming] (EC
1.1.1.304)
Dihydrolipoamide acetyltransferase component of
pyruvate dehydrogenase complex (EC 2.3.1.-)
Catalase (EC 1.11.1.6)
Hydroxymethylglutaryl-CoA lyase (EC 4.1.3.4)
(Hydroxymethylglutaryl-CoA lyase(HMG-CoA
lyase))
Catalase-related peroxidase (EC 1.11.1.-)
3-hydroxyacyl-CoA dehydrogenase (EC 1.1.1.35)
(3-hydroxyacyl-CoA dehydrogenase PaaC) (3hydroxybutyryl-CoA dehydrogenase) (EC
1.1.1.157) (PaaC)
2,3-dehydroadipyl-CoA hydratase (Enoyl-CoA
hydratase, phenylacetic acid degradation) (EC
4.2.1.17) (Enoyl-CoA hydratase/isomerase family
protein) (Phenylacetate degradation enoyl-CoA
hydratase PaaA) (enoyl-CoA hydratase)
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-8.98
-24.54

-21.75

-10.71

-10.26
-33.66
-26.44
-87.11

-70.07
-77.77
-6.76
-29.34
-7.2
-6.63

-6.92

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_2603

bccA accC_2

ABUW_2933
ABUW_3122

mro
otsB

ABUW_3779

echA8_8

ABUW_3781

acs

ABUW_3783

mmsA1
mmsA
mmsA3
mmsA_2

ABUW_3806 acnD
ABUW_3807 prpC
Cofactor Metabolism
ABUW_2438 cinA1 cinA

ABUW_3312

pntB

ABUW_3313

pntA pntA2

ABUW_3314

pntAA pntA-1
pntA1
Energy Metabolism
ABUW_2389 cydA_2 cioA
cydA_1

ABUW_0259
ABUW_2122

ychM_1
fccB

BccA (EC 6.3.4.14) (Biotin carboxylase)
(Carbamoyl-phosphate synthase)
Aldose 1-epimerase (EC 5.1.3.3)
Trehalose 6-phosphate phosphatase (EC
3.1.3.12)
Enoyl-CoA hydratase (EC 4.2.1.17) (Putative
enoyl-CoA hydratase) (Short-chain enoyl-CoA
hydratase)
AMP-binding protein (Acetyl-coenzyme A
synthetase) (EC 6.2.1.1)
CoA-acylating methylmalonate-semialdehyde
dehydrogenase (EC 1.2.1.27) (Methylmalonatesemialdehyde dehydrogenase) (Methylmalonatesemialdehyde dehydrogenase (Acylating))
(Methylmalonate-semialdehyde dehydrogenase
(CoA acylating)) (MmsA methylmalonatesemialdehyde dehydrogenase (Acylating)) (NADdependent aldehyde dehydrogenase)
Aconitate hydratase (EC 4.2.1.3)
Citrate synthase

-27.73
-5.07
-20.34
-92.31
-205.98
-118.41

-4.17
-4.96

CinA family protein (CinA-like protein)
(Competence damage-inducible protein A)
(Competence-damaged family protein)
(Competence-damaged protein)
(Competence/damage-inducible protein CinA)
(Damage-inducible protein CinA)
NAD(P) transhydrogenase subunit beta (EC
7.1.1.1) (Nicotinamide nucleotide
transhydrogenase subunit beta)
Proton-translocating NAD(P)(+) transhydrogenase
(EC 7.1.1.1)
Proton-translocating NAD(P)(+) transhydrogenase
(EC 7.1.1.1)

-30.29

Bacterial Cytochrome Ubiquinol Oxidase family
protein (Cyanide insensitive terminal oxidase)
(Cytochrome D ubiquinol oxidase subunit I)
(Cytochrome bd ubiquinol oxidase, subunit I)
(Cytochrome bd-I ubiquinol oxidase subunit 1)
(EC 1.10.3.10) (Cytochrome bd-type quinol
oxidase subunit 1) (EC 1.10.3.-) (Cytochrome
ubiquinol oxidase subunit I) (Putative Cytochrome
bd2)
Sulfate permease (Sulfate transporter)
Oxidoreductase (EC 1.8.2.3) (TIGR01244 family
phosphatase)

-6.84
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-4.69
-4.81
-5.34

-4.31
-5

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
Lipid Metabolism
ABUW_0324 lip
ABUW_0921

glpQ

ABUW_1227
Nucleotide Metabolism
ABUW_3217 add2 add
Terpenoid Metabolism
ABUW_0485 fabG_1

Lactonizing lipase(Triacylglycerol lipase) (Lipase)
(Triacylglycerol lipase) (EC 3.1.1.3)
Glycerophosphodiester phosphodiesterase
(Glycerophosphoryl diester phosphodiesterase)
(EC 3.1.4.46) (Glycerophosphoryl diester
phosphodiesterase(Glycerophosphodiester
phosphodiesterase))
Acyl-coenzyme A dehydrogenase (EC 1.3.8.7)
(EC 1.3.8.8)

-4.28

Adenosine deaminase (EC 3.5.4.4) (Adenosine
aminohydrolase)

-6.87

2,4-dienoyl-CoA reductase (Citronellol and
citronellal dehydrogenase) (Dehydrogenase) (EC
1.1.1.-) (EC 1.1.1.100) (Oxidoreductase shortchain dehydrogenase/reductase family)
(Peroxisomal trans-2-enoyl-CoA reductase)
ABUW_0487
Acyl-CoA dehydrogenase (EC 1.3.8.1) (Acyl-CoA
dehydrogenase family protein) (Acyl-CoA
dehydrogenase, C-terminal domain protein) (AcylCoA dehydrogenase, N-terminal domain protein)
(Citronellyl-CoA dehydrogenase)
Genetic Information and Processing
Translation
ABUW_0231
N/A
ABUW_0906
N/A
Environmental Information Processing
Membrane Transport
ABUW_2331 gltK_2 gltK
ABC transporter permease subunit (Amino ABC
gltK_1
transporter, permease, 3-TM region,
His/Glu/Gln/Arg/opine family domain protein)
(Amino acid ABC transporter permease) (Bindingprotein-dependent transport system inner
membrane component family protein) (Glutamate
Aspartate transport system permease protein
GltK) (Glutamate/Aspartate transport system
permease protein) (Glutamate/aspartate ABC
transporter) (Glutamate/aspartate import
permease protein GltK) (Glutamate/aspartate
transport system permease protein GltK)
(Glutamate/aspartate transporter permease GltK)
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-6.5

-8.01

-4.64

-4.58

-5.67
-10.66

-7.88

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_2332

gltJ gltK_1
gltK_2

ABUW_2333

gltI pebA_1

Signal Transduction
ABUW_0304 pilA1 fimA_1

ABUW_2098

atoE

Cellular Processes
Cellular Community
ABUW_3485
Unclassified
ABUW_0022
ABUW_0053 ytjA
ABUW_0055

ABUW_0057

yfdC

ABC transporter permease subunit (Amino acid
ABC transporter permease) (Amino acid
transporter) (Binding-protein-dependent transport
system inner membrane component family
protein) (Glutamate Aspartate transport system
permease protein GltJ) (Glutamate/aspartate
transport system permease protein GltJ)
(Glutamate/aspartate transport system permease
protein GltK) (glutamate/aspartate transport
system permease protein)
ABC transporter substrate-binding protein (Amino
acid ABC transporter substrate-binding protein)
(Bifunctional adhesin/ABC transporter
aspartate/glutamate-binding protein) (Glutamate
Aspartate periplasmic binding protein GltI)
(Glutamate/aspartate import solute-binding
protein) (Glutamate/aspartate periplasmic-binding
protein) (Glutamate/aspartate transport protein
(ABC superfamily, peri_bind))
(Glutamate/aspartate transport system substratebinding protein) (Transporter substrate-binding
domain-containing protein)

PilA1 (Pilin) (Prepilin-type N-terminal
cleavage/methylation domain-containing protein)
(Prepilin-type cleavage/methylation domaincontaining protein) (Type IV pilin PilA) (Type IV
pilin structural subunit)
Short chain fatty acid transporter family protein
(Short-chain fatty acid transporter) (Short-chain
fatty acid transporter (ScFAT family)) (Short-chain
fatty acids transporter)

-9.1

-6.62

-7.58

-18.56

Integral membrane protein

-5.06

Transporter
UPF0391 membrane protein A7M79_16605
Glucose dehydrogenase (Glucose sorbosone
dehydrogenase) (PQQ-dependent
oxidoreductase, gdhB family) (PQQ-dependent
sugar dehydrogenase)
Formate transporter (Formate/nitrate transporter)
(Formate/nitrite transporter family) (Formate/nitrite
transporter family protein) (Transport)

-4.56
-6.36
-4.28
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-7.11

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_0068

fosB

ABUW_0079

proY

ABUW_0139
ABUW_0166
ABUW_0181
ABUW_0183
ABUW_0184

yjcH yjcH_1
yjcH_2
actP actP_1
actP_2

ABUW_0210

ABUW_0233
ABUW_0339
ABUW_0359

sodC sodCI

ABUW_0360
ABUW_0468
ABUW_0628
ABUW_0646

ahpC_1

Fosfomycin resistance protein FosB (Glyoxalase)
(Glyoxalase family protein) (Glyoxalase/Bleomycin
resistance /Dioxygenase superfamily protein)
(Glyoxalase/Bleomycin resistance
protein/Dioxygenase superfamily protein)
(Glyoxalase/bleomycin resistance
protein/dioxygenase) (Glyoxalase/bleomycin
resistance/dioxygenase family protein)
(Homogentisate 1,2-dioxygenase) (EC 1.13.11.5)
(Metallothiol transferase FosB) (EC 2.5.1.-) (VOC
family protein)
Amino acid permease (Gamma-aminobutyrate
permease) (Proline-specific permease ProY)
DUF2147 domain-containing protein (Signal
peptide)
Membrane protein (Omp25) (Outer membrane
protein) (Putative porin)
Uncharacterized protein
Acetate permease (DUF485 domain-containing
protein) (Membrane protein) (inner membrane
protein YjcH)
Acetate permease (Acetate permease ActP)
(Cation acetate symporter) (Cation/acetate
symporter actP (Acetate transporter actP)
(Acetatepermease)) (Na+/solute symporter)
(Sodium/solute symporter)
Aldehyde-activating protein (GFA family protein)
(Gfa-like protein) (Glutathione-dependent
formaldehyde-activating GFA) (Glutathionedependent formaldehyde-activating enzyme family
protein)
Signal peptide
Superoxide dismutase [Cu-Zn] (EC 1.15.1.1)
Putative signal peptide-containing protein (Signal
peptide protein) (Signal peptide-containing
protein)
Putative signal peptide protein (Putative signal
peptide-containing protein) (Signal peptide
protein)
DUF2789 domain-containing protein (DUF2789
family protein) (Protein of uncharacterized
function (DUF2789))
Alkyl hydroperoxide reductase C (Peroxiredoxin)
(Thioredoxin peroxidase)
Glyoxalase/Bleomycin resistance
protein/Dioxygenase superfamily protein (PhnB
protein) (VOC family protein)
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-6.76

-7.23
-4.3
-4.37
-6.48
-5.29
-4.81

-5.44

-4.98
-5.44
-9.86
-10.71
-4.88
-7.99
-14.75

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_0667
ABUW_0673
ABUW_0734
ABUW_0740
ABUW_0741
ABUW_0742
ABUW_0743
ABUW_0744
ABUW_0985
ABUW_1004
ABUW_1005

yqfO

ABUW_1063
ABUW_1064

icaA

ABUW_1065
ABUW_1066
ABUW_1111

feaB_1

ABUW_1113

ipdC

Activator of HSP90 ATPase (Activator of Hsp90
ATPase homolog 1-like family protein) (SRPBCC
family protein) (Toxin)
DUF1508 domain-containing protein
(Uncharacterized conserved protein) (YegP family
protein)
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
CSLREA domain-containing protein (Outer
membrane protein)
Uncharacterized protein
GTP cyclohydrolase 1 type 2 (GTP
cyclohydrolase 1 type 2-like protein) (NGG1p
interacting factor 3 protein, NIF3) (NGG1p
interacting factor NIF3) (NIF3 1) (NIF3-like protein
1) (Putative GTP cyclohydrolase 1 type 2) (EC
3.5.4.16) (Uncharacterized protein conserved in
bacteria)
Cellulose biosynthesis cyclic di-GMP-binding
regulatory protein BcsB
Dolichol-phosphate mannosyltransferase in lipidlinked oligosaccharide synthesis cluster (EC
2.4.1.83) (Glycosyl transferase) (EC 2.4.1.-)
(Glycosyltransferase) (Glycosyltransferase family
2 protein) (IcaA)
Uncharacterized protein
Membrane protein
Aldehyde dehydrogenase (Aldehyde
dehydrogenase family protein) (NAD-dependent
aldehyde dehydrogenase) (EC 1.2.1.39)
(Phenylacetaldehyde dehydrogenase(PAD))
Alpha-keto acid decarboxylase family protein
(Indole-3-pyruvate decarboxylase) (Indole-3pyruvate
decarboxylase(Indolepyruvatedecarboxylase))
(Pyruvate decarboxylase) (Pyruvate
decarboxylase/indolepyruvate decarboxylase) (EC
4.1.1.74) (Thiamine pyrophosphate enzyme,
central domain protein)
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-8
-4.95
-4.13
-5.48
-4.83
-4.68
-5.35
-7.13
-4.25
-7.63
-7.63

-8.64
-8.94

-10.91
-10.33
-7.26

-8.31

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_1114

aroP3
aroP_3

ABUW_1120
ABUW_1206

dtpT

ABUW_1210
ABUW_1286
ABUW_1287
ABUW_1317
ABUW_1318
ABUW_1332
ABUW_1355
ABUW_1379
ABUW_1416
ABUW_1466
ABUW_1467
ABUW_1468
ABUW_1469

ABUW_1470

ABUW_1471
ABUW_1499

hemP

Amino acid permease (Aromatic amino acid
transport protein) (Aromatic amino acid transport
protein aroP (General aromatic aminoacid
permease)) (Aromatic amino acid transporter)
BapA prefix-like domain-containing protein
(Subtilisin-like serine protease)
Amino acid/peptide transporter (Peptide:H+
symporter) family protein (Di-/tripeptide
transporter) (Dipeptide/tripeptide permease) (MFS
transporter) (Peptide MFS transporter)
Alpha/beta hydrolase (Hydrolase)
(Lysophospholipase) (EC 3.1.1.5)
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Alkaline lipase (Alpha/beta fold hydrolase)
(Lysophospholipase) (EC 3.1.1.5) (Secretory
lipase family protein) (Triacylglycerol lipase)
Complement control module protein (Hemin
transporter HemP) (Hemin uptake hemP family
protein) (Hemin uptake protein HemP)
Putative signal peptide protein (Signal peptide)
Uncharacterized protein
DUF2171 domain-containing protein
(Uncharacterized protein conserved in bacteria)
Acyl-CoA dehydrogenase
GlcNAc-PI de-N-acetylase family protein (LmbE
protein) (LmbE-like protein) (PIG-L family
deacetylase)
Class I SAM-dependent methyltransferase
(Methyltransferase) (Methyltransferase domaincontaining protein) (Methyltransferase type 12)
(Nodulation protein S) (SAM-dependent
methyltransferase)
Glycosyl transferase (Glycosyl transferase 2
family protein) (Glycosyl transferase family 2
family protein) (Glycosyl transferase, family 2)
(Glycosyl transferase, group 2 family)
(Glycosyltransferase)
DNA-binding protein (NirD/YgiW/YdeI family
stress tolerance protein) (Signal peptide) (Signal
peptide protein)
DMT family transporter (EamA family transporter)
(EamA/RhaT family transporter) (Membrane
protein putative) (Permease of the drug/metabolite
transporter (DMT) superfamily)
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-14.02

-4.42
-4.79

-5.97
-18.14
-7.33
-6.71
-7.38
-5.44
-6.36
-5.99
-4.42
-8.95
-13.75
-14.04
-12.57

-14.4

-14.57
-4.38

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_1536
ABUW_1541
ABUW_1542

ABUW_1561
ABUW_1572

fabG_4

ABUW_1573

ABUW_1601
ABUW_1603

ABUW_1629
ABUW_1631

csuB_2
csuB_1

ABUW_1632
ABUW_1633

ABUW_1634

htrE_1

Putative signal peptide-containing protein (Signal
peptide protein) (Signal peptide-containing
protein)
Alpha-E domain-containing protein (Bacterial
domain of uncharacterized function (DUF403))
Protein containing transglutaminase-like domain
(Transglutaminase) (Transglutaminase family
protein) (Transglutaminase-like enzyme, putative
cysteine protease)
Cyclohexanone monooxygenase (EC 1.14.13.22)
(Flavoprotein)
2,5-dichloro-2,5-cyclohexadiene-1,4-diol
dehydrogenase (EC 1.1.1.35) (3-hydroxy-2methylbutyryl-CoA dehydrogenase) (3hydroxyacyl-CoA dehydrogenase) (EC 1.1.1.100)
(SDR family NAD(P)-dependent oxidoreductase)
(Short chain dehydrogenase family protein)
(Short-chain dehydrogenase/reductase)
Acyl-CoA dehydrogenase (Acyl-CoA
dehydrogenase family protein) (Acyl-CoA
dehydrogenase protein) (EC 1.3.8.1) (Acyl-CoA
dehydrogenase, N-terminal domain protein)
Uncharacterized protein
Acetyltransferase (Acetyltransferase (GNAT)
family protein) (Acetyltransferase domain protein)
(Acetyltransferase, GNAT family) (GNAT family Nacetyltransferase) (N-acetyltransferase) (Putative
acetyltransferase)
Uncharacterized protein
Csu pilus subunit CsuB (Fimbrial major subunit
CsuA/B family protein) (Protein U) (Putative
biofilm synthesis protein) (SCPU domaincontaining protein) (Sigma-fimbriae tip adhesin)
(Spore Coat Protein U domain protein) (Spore
coat protein SpoU) (Spore coat protein U domaincontaining protein)
CsuC (Fimbria/pilus periplasmic chaperone)
(Molecular chaperone) (Pilus assembly protein)
(Sigma-fimbriae chaperone protein)
Fimbria/pilus outer membrane usher protein
(Fimbrial biogenesis outer membrane usher
protein) (Fimbrial usher protein) (Putative outer
membrane usher protein yraJ) (Sigma-fimbriae
usher protein)
SCPU domain-containing protein
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-5.08
-6.82
-4.19

-5.68
-26.34

-25.8

-6.63
-6.12

-6.34
-12.32

-14.53
-11.26

-9.63

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_1637

ABUW_1649
ABUW_1651
ABUW_1653
ABUW_1657
ABUW_1659

pliG

ABUW_1692

tetC

ABUW_1693
ABUW_1723
ABUW_1751
ABUW_1753
ABUW_1761
ABUW_1775
ABUW_1787
ABUW_1810
ABUW_1860
ABUW_1861

antA_3
antA_1

Oxidoreductase (Oxidoreductase short-chain
dehydrogenase/reductase family)
(Oxidoreductase, short-chain
dehydrogenase/reductase family) (SDR family
NAD(P)-dependent oxidoreductase) (Short-chain
dehydrogenase)
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
DNA breaking-rejoining protein (Inhibitor of g-type
lysozyme) (Protein ycgK)
Bacterial regulatory protein, tetR family protein
(Putative transcriptional regulator) (TetR family
transcriptional regulator) (TetR/AcrR family
transcriptional regulator) (Transcriptional
regulator) (Transcriptional regulator, TetR family)
(Transposon Tn10 TetC protein)
Heme oxygenase-like protein
Uncharacterized protein
Fels-1 Prophage Protein-like family protein
(Putative prophage protein) (Putative signal
peptide-containing protein)
Uncharacterized protein
Abasic site processing protein (EC 3.4.-.-)
Membrane protein (Putative membrane protein)
Uncharacterized protein
Uncharacterized protein
Ketosteroid isomerase-like enzyme (Nuclear
transport factor 2 family protein) (Polyketide
cyclase) (Succinyl-CoA synthetase)
(2Fe-2S)-binding protein (Aromatic ringhydroxylating dioxygenase subunit alpha)
(Aromatic-ring-hydroxylating dioxygenase large
subunit) (EC 1.14.12.1) (Benzoate 1,2dioxygenase alpha subunit) (EC 1.14.12.10)
(Benzoate 1,2-dioxygenase subunit alpha)
(Rieske (2Fe-2S) protein) (Rieske 2Fe-2S
domain-containing protein) (Ring hydroxylating
dioxygenase, Rieske)

105

-4.57

-5.41
-89.8
-5.5
-5.22
-39.81
-4.61

-6.92
-6.91
-4.66
-6.2
-7.89
-6.18
-5.4
-4.39
-9.23
-5.42

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_1862

cbdB

ABUW_1886

cpo

ABUW_1888

ABUW_1891
ABUW_1902
ABUW_1903
ABUW_1918
ABUW_1921

sndH2

ttuB_5
rhmT_2

ABUW_1958
ABUW_1993
ABUW_2051
ABUW_2058
ABUW_2060
ABUW_2061
ABUW_2063

ABUW_2064
ABUW_2065
ABUW_2093
ABUW_2128

lpdA2 lpdA

Anthranilate dioxygenase small subunit (Aromaticring-hydroxylating dioxygenase) (Aromatic-ringhydroxylating dioxygenase beta subunit)
(Aromatic-ring-hydroxylating dioxygenase small
subunit) (EC 1.14.12.13) (Aromatic-ringhydroxylating dioxygenase subunit beta) (Putative
Aromatic-ring-hydroxylating dioxygenase small
subunit) (Ring hydroxylating beta subunit)
Alpha/beta fold hydrolase (Alpha/beta hydrolase)
(EC 1.11.1.10) (Cpo Non-heme chloroperoxidase)
(Non-heme chloroperoxidase)
Membrane protein (NAD(P)H-binding protein)
(Oxidoreductase) (EC 1.3.1.-) (Saccharopine
dehydrogenase) (Saccharopine dehydrogenase
NADP-binding domain-containing protein)
(Saccharopine dehydrogenase family protein)
ThiJ/PfpI domain protein (ThiJ/PfpI domaincontaining protein) (Type 1 glutamine
amidotransferase domain-containing protein)
L-sorbosone dehydrogenase (EC 1.1.1.-) (Lsorbosone dehydrogenase(SNDH)) (Sorbosone
dehydrogenase family protein)
Predicted membrane protein
Uncharacterized protein
MFS transporter (MFS transporter permease)
(Permease of the major facilitator) (Putative
tartrate transporter) (Tartrate transporter)
(Transporter, anion:cation symporter (ACS)
family)
Type III restriction enzyme, res subunit
Uncharacterized protein
Uncharacterized protein
Phage capsid and scaffold (Phage capsid protein)
(Uncharacterized conserved protein)
Uncharacterized protein
Uncharacterized protein
DNA glycosylase (G:T/U mismatch-specific DNA
glycosylase) (G:T/U mismatch-specific
uracil/thymine DNA-glycosylase) (Uracil-DNA
glycosylase family protein)
Uncharacterized protein
Uncharacterized protein
Citrate transporter family protein (D-betahydroxybutyrate permease) (GntP family
permease) (GntP family transporter)
Dihydrolipoyl dehydrogenase (EC 1.8.1.4)
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-5.06

-4.07
-4.53

-9.16
-5.01
-7.33
-33.81
-4.3

-4.79
-5.92
-7.61
-9.64
-30.46
-4.41
-6.41

-69.29
-4.01
-8.25
-66.05

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_2130

acoB

ABUW_2131

acoA

ABUW_2132

lipA2 lipA
lipA_2

ABUW_2133
ABUW_2143
ABUW_2156
ABUW_2187

bmr3

ABUW_2188

iucD_2

ABUW_2189

iucA

ABUW_2215
ABUW_2219
ABUW_2293
ABUW_2297
ABUW_2317
ABUW_2321

yceI

Acetoin:2,6-dichlorophenolindophenol
oxidoreductase subunit beta
ABC transporter substrate-binding protein
(Acetoin:2,6-dichlorophenolindophenol
oxidoreductase alpha subunit) (Acetoin:2,6dichlorophenolindophenol oxidoreductase subunit
alpha) (EC 1.1.1.-) (Acetoin:DCPIP
oxidoreductase alpha subunit) (Pyruvate/2oxoglutarate dehydrogenase complex,
dehydrogenase (E1) component, alpha subunit)
(Thiamine pyrophosphate enzyme, C-terminal
TPP binding domain protein) (Thiamine
pyrophosphate-dependent dehydrogenase E1
component subunit alpha)
Lipoyl synthase (EC 2.8.1.8) (Lip-syn) (LS)
(Lipoate synthase) (Lipoic acid synthase) (Sulfur
insertion protein LipA)
Transcriptional regulator (Transcriptional
regulatory protein, C terminal family protein)
Transcriptional regulator
Uncharacterized protein
DHA2 family efflux MFS transporter permease
subunit (Drug resistance MFS transporter,
drug:H+ antiporter-1) (MFS superfamily multidrug
resistance protein) (MFS transporter)
(Transporter, major facilitator family)
L-lysine 6-monooxygenase (Lysine/ornithine Nmonooxygenase) (EC 1.14.13.59) (NADPHdependent L-lysine N(6)-monooxygenase)
(Ornithine monooxygenase) (SidA/IucD/PvdA
family monooxygenase)
IucA/IucC-family aerobactin siderophore
biosynthesis component (Siderophore
biosynthesis protein) (EC 6.3.2.-)
Nucleoside-diphosphate-sugar epimerase
(Semialdehyde dehydrogenase, NAD binding
domain protein)
Uncharacterized protein
Polyisoprenoid-binding protein (Protein yceI)
(YceI-like domain protein)
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
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-88.23
-84.13

-42.7
-5.57
-4.25
-5.78
-4.34

-4.32

-5.28
-4.17
-4.4
-4.53
-5.06
-8.32
-29.9

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_2330

artP fbpC_4
fbpC_5
glnQ_2 gltL

ABUW_2345
ABUW_2372
ABUW_2388
ABUW_2390

cydB cioB
cydB1 cydB3
cydB_1

ABUW_2391
ABUW_2433
ABUW_2434
ABUW_2435

ABUW_2437
ABUW_2439
ABUW_2440
ABUW_2442
ABUW_2443
ABUW_2448

ydaD
entA_10
entA_18
yhxC

ATP-binding cassette domain-containing protein
(Amino acid ABC transporter ATP-binding protein)
(Arginine transporter ATP-binding subunit)
(Glutamate/Aspartate transport ATP-binding
protein) (Glutamate/aspartate ABC transporter
ATP-binding protein) (Glutamate/aspartate
transport system ATP-binding protein) (Glutamine
transport ATP-binding protein GlnQ) (Iron(III) ABC
transporter, ATP-binding protein)
(glutamate/aspartate transport ATP-binding
protein GltL)
Uncharacterized protein
DUF1427 domain-containing protein (DUF1427
family protein) (XapX domain protein) (XapX
domain-containing protein)
Uncharacterized protein
CydB cytochrome d ubiquinol oxidase, subunit II
(Cytochrome D Ubiquinol oxidase, subunit II)
(Cytochrome bd-I ubiquinol oxidase subunit 2)
(Cytochrome d ubiquinol oxidase subunit II)
(Putative Cytochrome bd2) (Ubiquinol oxidase
subunit II) (Ubiquinol oxidase subunit II, cyanide
insensitive) (EC 1.10.3.-)
DUF2474 domain-containing protein
KGG domain-containing protein (Putative gene 48
protein) (Stress-induced acidophilic repeat motifcontaining protein) (Stress-induced protein)
Uncharacterized protein
2,3-dihydroxybenzoate-2,3-dehydrogenase (3oxoacyl-[acyl-carrier protein] reductase) (EC
1.1.1.100) (General stress protein 39) (Glucose 1dehydrogenase) (EC 1.1.1.47) (NAD(P)dependent oxidoreductase) (Oxidoreductase) (EC
1.-.-.-) (SDR family oxidoreductase) (Short chain
dehydrogenase family protein) (Short-chain
dehydrogenase)
Heme oxygenase-like protein (Iron-containing
redox enzyme family protein)
TPR repeat containing protein
Surface antigen
Uncharacterized protein
Uncharacterized protein
DcaP-like protein (TMF family protein)
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-6.11

-7.79
-6.47
-8.44
-6.82

-4.75
-12.98
-8.33
-15.17

-17.33
-8.43
-15.85
-8.66
-6.39
-5.81

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_2449

ABUW_2450

fadD_1

ABUW_2451

fadR

ABUW_2458

ABUW_2503
ABUW_2518
ABUW_2524
ABUW_2527
ABUW_2553
ABUW_2554

yceJ_1
paaY yrdA_2
paaE paaJ
pcaF

ABUW_2594
ABUW_2604

kipI

ABUW_2605
ABUW_2606

pxpA

ABUW_2607

ycsG

Class I SAM-dependent methyltransferase
(Methyltransferase domain protein)
(Methyltransferase domain-containing protein)
(Putative SAM-dependent methyltransferase)
(SAM-dependent methyltransferase)
AMP-binding enzyme family protein (AMP-binding
protein) (Acetoacetyl-CoA synthetase/ Longchain-fatty-acid--CoA ligase) (EC 6.2.1.16) (AcylCoA synthetase (AMP-forming)/AMP-acid ligase
II) (EC 6.2.1.3) (Fatty acid--CoA ligase) (Longchain fatty-acid-CoA ligase)
Bacterial regulatory protein, tetR family protein
(Fatty acid metabolism regulator protein) (TetR
family regulatory protein) (TetR family
transcriptional regulator) (Transcriptional regulator
AcrR family)
Indolepyruvate ferredoxin oxidoreductase
(Indolepyruvate ferredoxin oxidoreductase family
protein) (MFS transporter) (Oxidoreductase)
(Pyruvate ferredoxin/flavodoxin oxidoreductase
family protein)
Cytochrome b (Cytochrome b561) (Cytochrome
b561 family protein)
Aminotransferase (Putative aminotransferase)
Gamma carbonic anhydrase family protein (PaaY)
(Phenylacetic acid degradation acetyltransferase)
(Phenylacetic acide degradation protein PaaY)
3-oxoadipyl-CoA thiolase (EC 2.3.1.174) (Betaketoadipyl-CoA thiolase)
Uncharacterized protein
DUF333 domain-containing protein (Hemolysin)
(Putative hemolysin)
Glutathione-dependent formaldehyde
dehydrogenase
5-oxoprolinase/urea amidolyase family protein
(Allophanate hydrolase) (Allophanate hydrolase 2
subunit 1 / Allophanate hydrolase 2 subunit 2) (EC
3.5.1.54) (Allophanate hydrolase subunit 1 and 2)
(Biotin-dependent carboxylase uncharacterized
domain protein)
Putative hydro-lyase AB71191_03206 (EC 4.2.1.-)
5-oxoprolinase subunit A (5-OPase subunit A)
(EC 3.5.2.9) (5-oxoprolinase (ATP-hydrolyzing)
subunit A)
Argininosuccinate synthase (Divalent metal cation
transporter) (Manganese transporter NRAMP)
(Membrane protein) (Mn2+/Fe2+ transporter)
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-13.67

-13.23

-5.99

-9.88

-6.45
-19.86
-4.38
-6.26
-9.26
-4.96
-13.83
-30.57

-34.64
-30.86
-42.24

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_2621
ABUW_2658
ABUW_2672
ABUW_2673
ABUW_2674
ABUW_2678
ABUW_2679
ABUW_2684
ABUW_2685
ABUW_2686
ABUW_2700
ABUW_2703

ABUW_2723

ABUW_2730

yhjQ

ahpF ahpF2
ahpF3
ahpF_1
ahpF_2
arfA_2

ABUW_2744
ABUW_2799

astA2 astA

ABUW_2887

nlpE cutF

ABUW_2901
ABUW_3032

pilT_2 pilT_1
pilU

Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
17 kDa surface antigen (Putative surface antigen)
DUF4142 domain-containing protein (Putative
outer membrane protein)
Phage putative head morphogenesis protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Cysteine-rich helical bundle repeat protein
(Ferredoxin) (Four-helix bundle copper-binding
protein) (Putative cysteine-rich protein) (Putative
cysteine-rich protein YhjQ)
Alkyl hydroperoxide reductase subunit F

-10.02
-6.29
-16.53
-20.36
-11.54
-30.83
-33.43

OmpA family protein (OmpA/MotB) (Outer
membrane lipoprotein omp16)
Membrane protein (Putative membrane protein)
Arginine N-succinyltransferase (EC 2.3.1.109)
(AstA arginine N-succinyltransferase)
Copper homeostasis protein (Copper homeostasis
protein cutF (Lipoprotein nlpE)) (Copper
resistance protein NlpE) (Copper resistance
protein NlpE N-terminal domain-containing
protein) (Lipoprotein) (Lipoprotein NlpE involved in
copper resistance) (Lipoprotein involved with
copper homeostasis and adhesion) (Putative
lipoprotein)
Activator of HSP90 ATPase (Activator of Hsp90
ATPase homolog 1-like family protein) (SRPBCC
domain-containing protein)
PilT/PilU family type 4a pilus ATPase (PilU)
(Twitching mobility protein) (Twitching motility
family protein) (Twitching motility protein)
(Twitching motility protein PilT) (Twitching motility
protein PilU) (Type IV pili twitching motility protein
PilT) (Type IV pilus assembly protein, pilus
retraction protein PilT) (Type IV pilus twitching
motility protein PilT)

-10.99
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-9.68
-15.22
-14.5
-4.69
-5.62

-4.14

-8.94
-5.28
-6.04

-4.67
-5.48

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_3106

lysM ygaU

ABUW_3157

ABUW_3265

ohrB

ABUW_3291

alkK

ABUW_3321

copA copA_2

ABUW_3322
ABUW_3325

copB copB_2
actP1 actP_3

ABUW_3351
ABUW_3352

nemR_1
nemR_2

ABUW_3524
ABUW_3575
ABUW_3577
ABUW_3582
ABUW_3587

ydeN

ABUW_3622

yjdC

ABUW_3702
ABUW_3777

yhjE_2

ABUW_3778

echA8_7

BON domain protein (LysM domain/BON
superfamily protein) (Peptidoglycan-binding LysM)
(Peptidoglycan-binding protein LysM) (Phage-like
element PBSX protein xkdP)
Conserved TM helix family protein
(Mechanosensitive ion channel) (Smallconductance mechanosensitive channel) (TM
helix domain protein) (TM helix protein) (TM helix
repeat-containing protein)
Ohr family peroxiredoxin (Ohr-like protein)
(Organic hydroperoxide resistance protein)
3-methylmercaptopropionyl-CoA ligase (DmdB)
(AMP-binding enzyme family protein) (AMPbinding protein) (Acyl-CoA synthase) (Acyl-CoA
synthetase) (EC 6.2.1.3)
Copper resistance protein A (Copper resistance
system multicopper oxidase)
Copper resistance protein B
Copper-translocating P-type ATPase (Coppertransporting P-type ATPase) (EC 3.6.3.4) (Heavy
metal translocating P-type ATPase)
Heme oxygenase-like protein
HTH-type transcriptional repressor NemR
(Putative transcriptional regulator) (TetR family
transcriptional regulator) (TetR/AcrR family
transcriptional regulator) (Transcriptional
regulator) (Transcriptional regulator, AcrR family)
(Transposon Tn10 tetC protein (ORFL))
Uncharacterized protein/domain associated with
GTPases
Signal peptide (EC 3.-.-.-)
Uncharacterized protein
Putative secreted protein
DNA transfer protein p32 (Epstein-Barr nuclear
antigen 1) (Glycine zipper family protein)
Bacterial regulatory protein, tetR family protein
(TetR family transcriptional regulator) (TetR/AcrR
family transcriptional regulator) (Transcriptional
regulator)
DUF2726 domain-containing protein (Putative
signal peptide-containing protein)
MFS transporter (MHS family MFS transporter)
(Major facilitator superfamily permease)
(Shikimate transporter)
3-hydroxyisobutyryl-CoA hydrolase (EC 3.1.2.4)
(Enoyl-CoA hydratase/isomerase family protein)
(EC 4.2.1.17)
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-4.27

-7.46

-4.04
-5.04

-4.82
-11.77
-9.05
-9.61
-15.25

-4.05
-7.29
-4.86
-5.69
-7.77
-6.32

-7.12
-105.76
-52.74

Table 5. Ontological Grouping of Genes with Decreased Expression in the
uspG::tn Mutant Strain (Continued)
ABUW_3780

mmgC_8

ABUW_3794
ABUW_3804
ABUW_3822
ABUW_3823
ABUW_3874
ABUW_3898

Acyl-CoA dehydrogenase (EC 1.3.8.1) (EC
1.3.99.-) (Acyl-CoA dehydrogenase family protein)
(Butyryl-CoA dehydrogenase)
RNase E inhibitor protein (Ribonuclease E
inhibitor RraB)
Zinc ribbon-containing protein
Bacterial transferase hexapeptide (Three repeats)
family protein
Putative UDP-galactose phosphate transferase
(WeeH)
Lipoprotein (Lipoprotein, putative) (Putative
lipoprotein) (Signal peptide protein)
GlsB/YeaQ/YmgE family stress response
membrane protein (Transglycosylase)
(Transglycosylase associated family protein)
(Transglycosylase-associated protein)

-105.19
-4.38
-5.28
-8.56
-11.45
-7
-7.01

Annotations and descriptions were assigned using UniProt Retrieve/ID mapping function. Annotations were
filed under gene names. Descriptions were under the category of protein names. EC value was used to
search KEGG Database. Note: some genes could be classified under multiple categories, here only one
was selected per gene. Fold: fold change comparing WT expression / uspG::tn expression x -1.

Table 6. Ontological Grouping of Genes with Increased Expression in the uspG::tn
Mutant Strain
ABUW_
Annotation
Metabolism
Carbohydrate Metabolism
ABUW_0203 gabT

ABUW_2973

mqo

Cofactor Metabolism
ABUW_1195 folE
Energy Metabolism
ABUW_1021 sbp_2 cysP
sbp_1

Description

Fold

4-aminobutyrate aminotransferase (EC 2.6.1.19)
(4-aminobutyrate transaminase) (4aminobutyrate--2-oxoglutarate transaminase)
(GabT 4-aminobutyrate transaminase) (Gammaaminobutyrate:alpha-ketoglutarate
aminotransferase)
Probable malate:quinone oxidoreductase (EC
1.1.5.4) (MQO) (Malate dehydrogenase [quinone])
GTP cyclohydrolase 1 (EC 3.5.4.16) (GTP
cyclohydrolase I) (GTP-CH-I)
ABC transporter permease (ABC-type sulfate
transport system periplasmic protein) (CysP)
(Sulfate ABC transporter substrate-binding
protein) (Sulfate ABC transporter, sulfate-binding
family protein) (Sulfate and thiosulfate binding
protein CysP) (Sulfate-binding protein)
(Thiosulfate-binding protein)
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13.95

5.85
4.81
8.2

Table 6. Ontological Grouping of Genes with Increased Expression in the uspG::tn
Mutant Strain (Continued)
ABUW_1793

Cyd operon protein YbgT (Cytochrome bd-I
oxidase subunit CydX) (Cytochrome bd-I ubiquinol
oxidase subunit X) (EC 1.10.3.10) (Cytochrome d
ubiquinol oxidase subunit X) (Membrane protein)
(Putative membrane protein)
ABUW_1794 cydB
CydB cytochrome d ubiquinol oxidase, subunit II
(Cytochrome D Ubiquinol oxidase subunit II) (EC
1.10.3.-) (Cytochrome D ubiquinol oxidase,
subunit II) (Cytochrome bd-type quinol oxidase,
subunit 2) (Cytochrome d ubiquinol oxidase
subunit 2)
ABUW_1795 cydA cydA_1 Cytochrome D Ubiquinol oxidase subunit I
(Cytochrome bd-I ubiquinol oxidase subunit CydA)
(Cytochrome d terminal oxidase subunit 1)
(Cytochrome d terminal oxidase, polypeptide
subunit I) (EC 1.10.3.-) (Cytochrome d ubiquinol
oxidase subunit 1(Cytochrome dubiquinol oxidase
subunit I)) (Cytochrome ubiquinol oxidase subunit
I)
ABUW_2379 tauD
Alpha-ketoglutarate-dependent taurine
dioxygenase (Taurine dioxygenase) (EC
1.14.11.17)
ABUW_2380 tauC
Nitrate/sulfonate/bicarbonate ABC transporter
permease (Putative aliphatic sulfonates transport
permease protein SsuC) (Taurine ABC transporter
permease TauC) (Taurine transport system
permease protein) (Taurine transport system
permease protein TauC) (Taurine transporter
subunit)
ABUW_2382 tauA tauA_2 ABC-type taurine transport system periplasmic
protein (Taurine ABC transporter substratebinding protein) (Taurine ABC transporter,
periplasmic binding protein) (Taurine-binding
periplasmic protein) (Taurine-binding periplasmic
protein TauA)
Genetic Information Processing
Translation
ABUW_0277
#N/A
ABUW_0405 rpsJ nusE
30S ribosomal protein S10
ABUW_0406 rplC l3p
50S ribosomal protein L3
ABUW_0407 rplD
50S ribosomal protein L4
ABUW_0408 rplW
50S ribosomal protein L23
ABUW_0410 rpsS
30S ribosomal protein S19
ABUW_0412 rpsC s3p
30S ribosomal protein S3
ABUW_0493 rpsI
30S ribosomal protein S9
ABUW_0494 rplM
50S ribosomal protein L13
cydX ybgT
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7.23

7.19

6.85

7.03
7.63

7.95

8.88
6.09
5.16
4.83
4.52
4.1
4.51
4.65
4.33

Table 6. Ontological Grouping of Genes with Increased Expression in the uspG::tn
Mutant Strain (Continued)
ABUW_0695
ABUW_1547
ABUW_1548
ABUW_2899

N/A
rpsR
30S ribosomal protein S18
rpsF
30S ribosomal protein S6
lysS
Lysine--tRNA ligase (EC 6.1.1.6) (Lysyl-tRNA
synthetase) (LysRS)
ABUW_3220
N/A
ABUW_3284 rplT
50S ribosomal protein L20
ABUW_3285 rpmI
50S ribosomal protein L35
ABUW_3593 rplA
50S ribosomal protein L1
Environmental Information Processing
Signal Transduction
ABUW_1525 dctA_1 dctA
C4-dicarboxylate transport protein
dctA_2
dctA_3
ABUW_1581 kdpA
Potassium-transporting ATPase potassiumbinding subunit (ATP phosphohydrolase
[potassium-transporting] A chain) (Potassiumbinding and translocating subunit A) (Potassiumtranslocating ATPase A chain)
Unclassified
ABUW_0201 gabP
Amino acid permease (Aromatic amino acid
gabP_1
transport protein AroP) (GABA permease) (GABA
permease (4-amino butyrate transport carrier))
(GabP)
ABUW_0275 lysP_1
Amino acid permease family protein (Amino acid
mmuP
transporter) (Amino-acid permease) (Arginine
permease RocE) (Putative S-methylmethionine
permease) (Putative amino acid permease, GabP
family)
ABUW_0381 deaD
ATP-dependent RNA helicase (ATP-dependent
RNA helicase DeaD) (EC 3.6.4.13) (Cold-shock
DEAD box protein A(ATP-dependent RNA
helicasedeaD)) (DEAD/DEAH box helicase)
(Helicase domain protein)
ABUW_0382
Putative membrane protein
ABUW_0409 rplB
50S ribosomal protein L2
ABUW_0603
Putative signal peptide protein (RcnB family
protein) (Signal peptide) (Signal peptide protein)
ABUW_0635
Alpha-beta hydrolase family esterase (Esterase)
(Patatin family protein) (Patatin-like phospholipase
family protein) (Phospholipase, patatin family)
ABUW_0691
Uncharacterized protein
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10.91
4.41
4.67
4.07

4.7
4.72
4.65
4

4.27
5.51

11.97

4.15

13.23

6.21
4.81
5.75
4.09
13.19

Table 6. Ontological Grouping of Genes with Increased Expression in the uspG::tn
Mutant Strain (Continued)
ABUW_0928

mltF mltF_1
yfhD

ABUW_1020
ABUW_1495
ABUW_1557
ABUW_1599
ABUW_1763
ABUW_1764

pgaA
benM_3
benM_1
metR
uspG
cdpA_6 gmr
gmr_2

ABUW_1792

ybgE

ABUW_2052

hifA

ABUW_2053

fimC fimC_1
fimC_2
papD-2
yadV_2

ABUW_2054

mrkC

ABUW_2102

ABC transporter substrate-binding protein (Lytic
transglycosylase, catalytic) (Membrane-bound
lytic murein transglycosylase F) (EC 4.2.2.-)
(Periplasmic binding protein of
transport/transglycosylase) (Soluble lytic
transglycosylase fused to an ABC-type amino
acid-binding protein) (Transglycosylase SLT
domain protein) (Transglycosylase SLT domaincontaining protein) (Transglycosylase, Slt family)
(Transporter substrate-binding domain-containing
protein)
Alpha/beta hydrolase (Alpha/beta hydrolase fold
protein) (Esterase)
Uncharacterized protein
Biofilm synthesis protein (Outer membrane
protein) (PgaA) (Poly-beta-1,6 N-acetyl-Dglucosamine export porin PgaA)
HTH-type transcriptional regulator MetR

Universal stress protein
Cyclic di-GMP phosphodiesterase (Diguanylate
cyclase) (Diguanylate cyclase (GGDEF) domain
protein) (Diguanylate cyclase/phosphodiesterase
(GGDEF & EAL domains) with PAS/PAC
sensor(S)) (EAL domain-containing protein)
(GGDEF domain-containing protein) (GGDEF
family protein) (Signal transduction protein) (EC
3.1.4.52)
Cyd operon YbgE family protein (Cyd operon
protein) (Cyd operon protein YbgE
(Cyd_oper_YbgE) family protein) (Cytochrome bd
biosynthesis protein) (Protein ybgE)
F17 fimbrial protein (Ferrous iron transporter B)
(Fimbrial protein) (Fimbrial subunit) (Type 1
fimbrial protein)
Chaperone protein mrkB (Fimbria/pilus
periplasmic chaperone) (Molecular chaperone) (P
pilus assembly protein) (Pili assembly chaperone)
(Pilin chaperone) (Pilus assembly protein)
(Putative fimbrial chaperone YadV)
Fimbria/pilus outer membrane usher protein
(Fimbrial biogenesis outer membrane usher
protein) (Outer membrane fimbrial usher protein)
(Outer membrane usher protein) (Outer
membrane usher protein mrkC)
Uncharacterized protein
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6.4

6.94
4.22
4.28
6.13
7.24
9.97

6.81

5.63
11.33

5.89

5.07

Table 6. Ontological Grouping of Genes with Increased Expression in the uspG::tn
Mutant Strain (Continued)
ABUW_2103
ABUW_2169
ABUW_2270
ABUW_2287

putA

ABUW_2316

yijE_3

ABUW_2381

tauB ssuB_2

ABUW_2387
ABUW_2513
ABUW_2516
ABUW_2517
ABUW_2680
ABUW_2690

csp2 cspE_1

cspV csp1
cspE cspE_2

ABUW_2696
ABUW_3198
ABUW_3495

ABUW_3706

trmB_2

Uncharacterized protein
Probable membrane transporter protein
Uncharacterized protein
Bifunctional protein PutA [Includes: Proline
dehydrogenase (EC 1.5.5.2) (Proline oxidase);
Delta-1-pyrroline-5-carboxylate dehydrogenase
(P5C dehydrogenase) (EC 1.2.1.88) (L-glutamate
gamma-semialdehyde dehydrogenase)]
DMT family permease (DMT family transporter)
(EamA family transporter) (EamA/RhaT family
transporter) (Permease of the drug/metabolite
transporter (DMT) superfamily)
ABC-type taurine transport system, ATPase
component (EC 3.6.3.-) (ATP-binding cassette
domain-containing protein) (EC 3.6.3.36) (Nitrate
transport ATP-binding protein nrtD) (Taurine
import ATP-binding protein) (Taurine transport
ATP-binding protein TauB) (Taurine transport
system ATP-binding protein) (Taurine transporter
ATP-binding subunit)
Uncharacterized protein
Cold shock protein CspE (Cold shock-like protein
cspG) (Cold-shock DNA-binding domain protein)
(Cold-shock protein)
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
'Cold-shock' DNA-binding domain protein (Cold
shock domain-containing protein) (Cold shock
protein) (Cold shock protein CspG) (Cold shock
protein CspV) (Cold shock protein, CSP family)
(Cold-shock DNA-binding domain protein)
Transposase
DUF1852 domain-containing protein (DUF1852
family protein) (Domain of uncharacterized
function (DUF1852))
Methyltransferase family protein
(Methyltransferase superfamily) (Putative
methyltransferase) (EC 2.1.1.33) (SAMdependent methyltransferase)
DUF2938 domain-containing protein (DUF2938
family protein)

10.92
4.07
9.99
30.39

4.86

9.02

4.13
8.91
5.37
4.82
12.26
8.23

15.19
7.04
4.01

5.48

Annotations and descriptions were found using uniport.org Retrieve/ID mapping function. Annotations were
filed under gene names. Descriptions were under the category of protein names. EC value was used to
search KEGG Pathways. Fold: Fold change calculated by comparing uspG::tn expression / AB5075
expression.
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Shifts in the Expression of Energy and Translation Involved Genes Result in
Susceptibility of the uspG::tn Mutant to Aminoglycosides. Our transcriptomic studies
uncovered a high number of ribosomal proteins with increased expression within the
uspG::tn strain as compared to the wildtype AB5075 strain (Table 6). Specifically, eight
genes encoding proteins of the 50S ribosomal subunit, six genes encoding proteins of the
30S subunit, and two genes encoding tRNA synthetases were upregulated by >4-fold in
the uspG::tn mutant strain. When reviewing the data more closely, including ribosomal
protein associated genes that did not fall within the 4-fold analysis group, we determined
that 54 out 55 ribosomal proteins of the 30 or 50S subunits were upregulated in the
absence of UspG (Figure 16). Further, other genes associated with translation, including
initiation and elongation factors and tRNA biosynthesis genes were similarly upregulated
in the uspG::tn strain, albeit at a level below our 4-fold cutoff. As shown in Figure 16,
each rps gene encoding a member of the 30S ribosomal subunit was upregulated in the
uspG::tn strain. As aminoglycosides target this component of protein translation, it was of
interest to see if susceptibility was altered in the uspG::tn mutant strain.
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Figure 16. Translational Machinery Shows Altered Transcription in the uspG::tn
Strain. Genes involved in translation are shown based on RNA-sequencing data following
3 hours of growth. Members of the 50S ribosomal subunit are outlined in green, of the
30S subunit are in blue. Initiation factors are in deep pink while the elongation factor is
light pink. Amino-acyl tRNA synthesis genes are shown in purple. Fold change was
calculated for + values using WT expression / uspG::tn expression. If fold change was
found to be <1, values were inverted by taking 1 / fold change and then multiplying by -1
(negative fold change).
Further to this, there were significant changes in cofactor production, ubiquinones and
other genes associated with electron transport, indicating a shift in energetics of the cell.
For example, the NAD(P)+ transhydrogenases pntB, pntA, and pntAA encoded by
ABUW_3312-ABUW_3314 were downregulated by greater than -4-fold in the uspG::tn
strain (Table 5). A shift was also evident by the downregulation of cytochrome bd
ubiquinol oxidase subunits encoded by ABUW_2389 and ABUW_2390 (Table 5), and
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converse upregulation of cytochrome bd ubiquinol oxidase subunits encoded by
ABUW_1792-ABUW_1795 in the uspG::tn strain (Table 6). Further, ABUW_2973 (mqo),
a malate:quinone oxidoreductase was upregulated by 5.85-fold, while several other
oxidoreductases and putative flavoproteins were downregulated in uspG::tn. Again, when
considering aminoglycosides, their uptake is influenced by changes in membrane
energetics. Specifically, lower levels of uptake are seen in cells with lower levels of
ubiquinone present[259]. It is also known that in addition to the difference in membrane
potential, the difference in transmembrane H+ concentration (ΔpH) also influences the
efficiency of aminoglycosides[260]. Further, streptomycin binding to the ribosome has
been shown to be dependent on the expression of certain ribosomal proteins, such as
RpsL. Several species with rpsL mutations, exhibit streptomycin resistance[261-263]. In
uspG::tn, rpsL and many other rps genes are upregulated leading us to suggest that the
mutant strain would instead be more susceptible to streptomycin.

Therefore, uspG::tn and AB5075 were subject to MIC testing against multiple protein
synthesis inhibitors, including: aminoglycosides targeting the 30s ribosomal subunit and
a macrolide targeting the 50S ribosomal subunit. As expected, uspG::tn was found to be
more susceptible to the aminoglycosides neomycin, streptomycin, and gentamicin, with
MICs 4-fold, 30-fold and greater than 50-fold lower in the uspG::tn mutant. Further,
uspG::tn was 4-fold more susceptible to the atypical aminoglycoside Hygromycin B and
1.5-fold more sensitive to the 50s targeting macrolide Erythromycin (Figure 17). This
confirms our RNAseq data and associated hypothesis that alterations in ribosomal protein
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expression and membrane energetics in our uspG::tn mutant is likely causative of the
phenotypic changes in response to antimicrobial agents observed herein.

Figure 17. Aminoglycoside Sensitivity Exhibited by uspG::tn Strain. Fold differences
in MIC are shown. Changes were generated comparing MIC of wildtype AB5075 and
uspG::tn based on in liquid culture inhibition. Studies were performed in biological
triplicate and repeated on at least two occasions to verify MIC values. Aminoglycosides:
blue, Macrolide: green.
Increased Susceptibility to Biocides and CCCP Indicates Significant Changes in
uspG::tn Cell Envelope Structure. In addition to the changes in membrane energetics,
many other membrane-associated genes were differentially expressed in our mutant
strain. Specifically, ABUW_3106 (lysM), ABUW_0921 (glpQ), ABUW_0304 (pilA1) and
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ABUW_2730 (arfA_2), which are known to be required for full envelope integrity[264266], were down regulated in our mutant strain. Therefore, we assessed whether agents
that target these processes revealed altered sensitivity in the mutant.

It is known that sodium dodecyl sulfate (SDS) functions as a biocide, targeting lipoproteins
as well as other proteins within the membrane[267]. Triclosan acts as a biocide at higher
concentrations leading to membrane destabilization[268]. Carbonyl cyanide mchlorophenylhydrazine (CCCP) functions to deplete ATP pools and acts to depolarize the
membranes[269]. Therefore, if the mutant does in fact possess an envelope with a
disrupted or an altered cell envelope, we would predict that the mutant strain would be
more susceptible to exposure to these agents. In order to test this, uspG::tn and AB5075
were subject to MIC testing in liquid media using various concentrations of triclosan and
SDS. As expected, uspG::tn was more susceptible to each treatment. As shown in Figure
18, uspG::tn was found to have an MIC that was 15-fold lower than AB5075 when
challenged with SDS. Further, uspG::tn was found to be 2-fold more susceptible to
triclosan treatment. These results indeed confirm the prediction that the cell envelope is
altered in the uspG::tn mutant. Finally, uspG::tn was found to be 2-fold more susceptible
to CCCP treatment. Since the requirement for an intact proton motive force is necessary
for the activity of aminoglycosides and we see increased susceptibility, it is likely that
instead the increased susceptibility of uspG::tn to CCCP exposure is due to the already
depleted ATP pools and not due to a disrupted ETC.
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Figure 18. Cell Envelope Altered in uspG::tn Strain Based on Sensitivity to Biocides
and CCCP. Fold differences in MIC are shown. Changes were generated comparing MIC
of wildtype AB5075 and uspG::tn using liquid culture inhibition. Tests were performed in
biological triplicate and repeated at least twice to verify MIC values.
Ethanol Susceptibility is Enhanced Due to Downregulation of Ethanol Metabolic
Enzymes. It is known that ethanol exposure at low levels can induce the uspG homolog
(A1S_1950) in A. baumannii ATCC17978[270]. Within our present study, a large number
of genes known to be induced following ethanol exposure were downregulated
transcriptionally within our uspG::tn strain. For example, ABUW_2132 encoding lipA2, a
lipoyl synthase was induced 17-fold by ethanol exposure in ATCC17978, but was
downregulated by -42.7-fold in the uspG::tn mutant. The same trend was seen for
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ABUW_1624 (dhaT), ABUW_1621 (ald1), ABUW_3582, ABUW_0468, and ABUW_0066
(hppD).

Based on this, we predicted that the uspG::tn mutant would be more susceptible to
ethanol exposure as it is unable to transcribe the genes necessary to protect against
ethanol toxicity. In order to test this, AB5075 WT and uspG::tn strains were tested in liquid
culture containing different percentages of ethanol and an MIC was determined. As
expected, uspG::tn cells were 1.25-fold more sensitive to ethanol treatment than AB5075
(Figure 19). The amount of ethanol needed to completely inhibit AB5075 growth was 5%
while 4% was enough to inhibit uspG::tn cells. Although a subtle change, it is clear and

MIC Ethanol (%)

reproducible, and thus represents a legitimate phenotype of uspG mutant strains.
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Figure 19. Ethanol Sensitivity Exhibited by uspG::tn Strain. MIC values are shown
for each strain. Studies were performed in biological triplicate and repeated on at least
two occasions to verify MIC values.
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Motility is Hindered in uspG::tn Likely Due to Shifts in Pili Expression.
Transcriptional indications were also present to suggest that motility is influenced by
UspG. Specifically, ABUW_3032 (pilU) encodes a type IV pilus ATPase that is associated
with twitching motility and was downregulated -5.48-fold. Further, ABUW_0304 encoding
a putative type IV pilin structural subunit, pilA, showed -7.58-fold lower transcription in the
mutant strain. Another pilus assembly system, the csu operon, was also downregulated
but has been implicated instead in adhesion and biofilm formation. Since pilA and pilU
are both involved in motility in A. baumannii[63], we would expect uspG::tn to have a
defect in motility. In order to test this assertion, uspG- (M), uspG+ (C) and wildtype 5075
(WT) were inoculated onto 0.5% LBA containing plasmid selecting antibiotics. Cells were
synchronized to ensure the samples contained live cells and cellular debris was limited.
Each strain was tested in biological triplicate by placing 10µL on the surface of LBA
containing 0.5% agar. Care was taken to ensure spreading did not occur and all strains
started at an equal diameter. Agar plates were then wrapped in parafilm and sealed with
tape to preserve moisture before being incubated in the dark at 27°C and 37°C.
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Figure 20. Motility Defect Observed in uspG-(M) Strain. Diameter of cell spread was
measured and recorded following 2 and 17 days of growth at the indicated temperatures.
WT: AB5075 empty vector control, M: uspG-, C: uspG+. Error bars represent the mean ±
SEM of three biological replicates.
As predicted, following 2 days of growth, it was clear that uspG- (M) was less motile
(Figure 20). This phenotype was observed at both temperatures and time points tested
with partial complementation seen under all conditions. Following 17 days of growth, the
motility defect was even clearer for uspG- (M). Each strain was able to grow more quickly
at 37°C as compared to 27°C, however, the greatest difference was seen at 27°C
following 17 days of growth. Due to evaporation, it was not possible to accurately quantify
the diameter of samples grown at 37°C following 17 days of incubation and therefore it is
unclear whether differences between uspG- (M) and AB5075 (WT) would be more
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significant at that temperature. Overall, it is clear that UspG is involved in controlling
factors associated with motility. This phenotype was also demonstrated by the uspG::tn
mutant and the wildtype AB5075 strain and is shown in Figure 21. These plates were
incubated at 27°C for 14 days under the same conditions as the plasmid containing
strains (in the dark, wrapped in parafilm and taped to avoid evaporation). Two of the three
biological replicates were chosen for visual representation for each strain although all
three replicates showed consistent results. These results again indicate that there is a
clear role for UspG in influencing motility within AB5075.

Figure 21. upsG::tn Strain Demonstrates Deficiency in Motility Following 2 Weeks
of Incubation at 27°C. Representative images of strains tested in biological triplicate on
0.5% LBA. Strains standardized prior to inoculation. Top row: wildtype AB5075, bottom
row: uspG::tn.
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Oxidative Stress Tolerance is Hindered in uspG::tn. Based on the downregulation of
various genes associated with oxidative stress and antioxidant defense, including
catalase encoding genes, peroxidases and multiple heme-oxygenases (Figure 22), it was
predicted that uspG::tn would be more susceptible to H2O2 exposure. Therefore, an MIC
approach was taken to determine the level of hydrogen peroxide that inhibits uspG::tn
growth. As expected, uspG::tn was found to be more sensitive to H2O2 exposure (Figure
23). Specifically, uspG::tn was four fold more susceptible when tested in MHBII media.
This is in agreeance with a variety of other Usp mutants including the paralog, UspA, in
A. baumannii[209].

Figure 22. Various Genes Involved in ROS Mediation are Downregulated in
uspG::tn Strain. Fold decrease in expression for uspG::tn vs AB5075. Data is equivalent
to that listed in Table 5.
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Figure 23. uspG::tn Strain is More Sensitive to H2O2 Exposure. The MIC was
determined for each strain in liquid culture. Tests were performed in biological triplicate
and on separate days to confirm activity. The MIC for H2O2 is represented as the
percentage of within liquid culture.
Inhibition of UspG Leads to the Inability to Resist DNA Damaging Agents. The
inability of uspG::tn cells to tolerate the same level of oxidative stress as the wildtype
strain indicates that a cells are potentially undergoing some level of ROS stress already.
In terms of toxicity, oxidative stress is known to cause DNA damage which can have lethal
effects; thus, it is reasonable to assume that the uspG mutant strain may be more
sensitive to challenge by DNA damaging agents. In order to test this, uspG::tn and
AB5075 were subject to: ethidium bromide, mitomycin C, acridine orange and methyl
methanesulfonate (MMS) exposure. As expected, uspG::tn was more sensitive to all
chemical agents tested (Figure 24). This is in line with data from mutants of other Usp
proteins[231] and indicates that UspG of A. baumannii functions to protect itself from DNA
damage.
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Figure 24. uspG::tn Strain is More Sensitive to DNA Damaging Agents. MICs were
determined in liquid culture for AB5075 and uspG::tn strains. Fold change in MIC of each
strain is represented. Strains were tested in biological triplicate and on at least two
separate days to confirm activity.
UspG Plays an Essential Role During Survival within Whole Human Blood. Given
the myriad sensitivities displayed by the uspG mutant, many of which mimic challenges
faced during disease causation, we surmised that the mutant would be less virulent within
the host. Additionally, downregulation of the paa pathway (Table 5) in the mutant
indicates the uspG::tn population has an accumulation of phenylacetate, which is a
chemoattractant for neutrophils and assists in the clearance of bacteria[271]. Therefore,
we predicted that survival within whole human blood, containing leukocytes such as
neutrophils, would be compromised in the uspG::tn mutant. Upon testing, and as
expected, uspG- (M) is displayed a survival defect in human blood (Figure 25). Quite
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strikingly, exposure to blood appeared to result in a complete loss of viability for the
mutant strain within only 30 minutes. To explore this more fully, we examined how quickly
such a loss of viability was observed. Accordingly, each strain was diluted in PBS to an
equivalent OD600 and added to blood, with samples immediately removed and plated. As
shown in Figure 25B, this short amount of time reduced the bacterial load within the
uspG- (M) significantly, although some viability was detectable. This indicates that UspG
is indisputably essential for survival within the human host. This is similar to UspA of A.
baumannii ATCC17978, which was shown to be essential for survival within two different
forms of mouse infection[209].

Figure 25. UspG Plays Critical Role in Human Blood Survival. Each strain was grown
in biological triplicate to exponential phase then normalized to a starting OD600 of 0.05.
CFU/mL was calculated based on plate counts. (A) Log10 CFU/mL of each strain
overtime in blood. (B) Log10 CFU/mL of initial samples in PBS or blood. Time from
inoculation to serial diluting and plating was less than 10 minutes. Error bars represent
mean ± SEM of three biological replicates.
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Discussion

Herein we present an analysis of a Universal stress protein produced by A. baumannii.
Universal stress proteins are produced by a variety of life forms and play a global role in
the adaption of organisms to stress via mechanisms that remain elusive. In A. baumannii
AB5075 six such proteins exist that have yet to be fully characterized. Prior to our analysis
the only studied Usp of A. baumannii was A1S_2692 (ATCC 17978), the homolog of
ABUW_0890. This protein has been annotated as UspA, therefore, to avoid confusion
and based on sequence predictions, ABUW_1763 herein is referred to as UspG.

UspG proteins are class II Usp proteins in E. coli and are known to bind ATP. The major
functions of UspG in E. coli are the ability to protect against DNA damage, to influence
motility, and to increase in abundance during starvation. All Usps of E. coli are induced
during stationary phase when nutrients become limited. Herein, we find that UspG of A.
baumannii acts in a way that is consistent with other universal stress proteins but also
has unique tendencies. For example, we see the accumulation of UspG during
exponential growth (Figure 14), We also show that uspG::tn demonstrates a growth
defect in nutrient rich media, a phenotype that is also observed in the absence of uspA in
A. baumannii but is uncommon in other bacterial species. Therefore, it is likely that Usps
in A. baumannii demonstrate a functional role during exponential phase as well as during
stationary growth. This was further highlighted by the significant differences in
transcription observed comparing uspG::tn and AB5075 strains in early exponential
growth. Specifically, following 3 hours of growth over 300 genes were differentially
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expressed to a degree greater than 4-fold, indicating that the absence of UspG is
detrimental to the population and that A. baumannii depends on UspG to function
normally during exponential growth.

The uspG::tn mutant was also found to be more susceptible to acids (data not shown),
alcohol, antibiotics and H2O2 stress, each of which are known stressors Usps generally
help protect bacteria from[209, 217, 220, 257, 272, 273]. In addition to the H2O2
phenotype, we also note an inability of the mutant to survive within whole human blood,
which could be due to a variety of factors. First, we detect alterations in the electron
transport chain (ETC) as well as the proton motive force machinery which generate ROS
naturally during electron transfer between quinones, cytochrome complexes, and other
ETC machinery. This was demonstrated by the differential expression of cytochrome bd
oxidases as well as the downregulation of a variety of genes encoding flavoproteins and
NADH/NADPH proton translocating proteins and the upregulation of malate:quinone
oxidoreductase. We tentatively suggest that the membrane energetics are altered, but
not disrupted, in the uspG::tn strain due to the increased sensitivity towards
aminoglycosides, which are dependent on a functional ETC and an intact membrane
[260, 274, 275]. Further, we predict that UspG is involved in controlling antioxidant
production, and, without uspG, the production of essential oxidative stress protection
proteins is not possible. This would then result in the accumulation of ROS and H2O2
within the cell and would lead to damage to a variety of molecules including DNA,
proteins, and lipids. It would also, consequently, explain the defects observed in whole
human blood survival.

132

There are several lines of evidence that support our hypothesis that ROS is accumulating
within the uspG::tn mutant. First, UspA of E.coli is overexpressed in a manner that is
directly correlated to the amount of ROS produced within the cell. Specifically, as ROS
levels increase within the cell, so does the transcription of upsA[276]. It is likely that our
cells are in fact producing higher levels of ROS or that ROS is accumulating based on the
downregulation of genes associated with detoxifying them, such as katE, sodC, a variety
of peroxidases, and multiple heme oxygenases but also by the 7.24-fold upregulation of
uspG observed. The upregulation of uspG within the uspG::tn mutant does not translate
into UspG due to the transposon insertion, but instead indicates that the cell is trying to
compensate for its absence by attempting to make more albeit unsuccessfully. The
increased sensitivity to H2O2 exposure is also in agreement with this notion: ROS is
accumulating in the absence of functional UspG. Further, it has been shown in other
species such as Salmonella typhimurium LT2 that UspA plays a role in protection against
H2O2 stress that is more prevalent during exponential growth[224]. Based on our
observation that UspG expression is seen during this time (Figure 14, Table 6), and
antioxidant defense genes are downregulated in uspG::tn (Table 5), it is tempting to
speculate that UspG too functions to protect against ROS production during this phase of
growth.

The control of antioxidants has also been shown for other Usps, Specifically the
overexpression of MfUSP1 of the plant species Medicago falcata leads to the
upregulation of antioxidant defense proteins such as catalase and superoxide
dismutase[277], the opposite of which is observed for A. baumannii in the absence of
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UspG. Further, proline accumulation was observed upon upregulation of MfUSP1 due to
the downregulation of proline oxidases[277], whereas the most highly upregulated
transcript in uspG::tn compared to AB5075 was putA (>30-fold), which encodes a proline
oxidase. Therefore, in A. baumannii, the regulation of antioxidant production as well as
the regulation of amino acid synthesis and degradation is influenced by UspG.

Another explanation for the presumed accumulation of ROS and proven sensitivity of our
uspG::tn mutant to H2O2 exposure is based on a likely dysregulation in metal
homeostasis. In E. coli, sensitivity to H2O2 has been attributed to increased iron uptake
within the mutant cells, due to unregulated uptake of siderophores. Iron exacerbates the
toxic effects of ROS via hydroxyl radical production in the presence of oxygen[278]. Thus,
iron dysregulation can be directly linked to an increase in ROS and therefore the system
may be overwhelmed in the presence of blood or H2O2 where more ROS occurs if
intracellular levels of iron are present. However, in our mutant, siderophore biosynthesis
is downregulated, icuA and icuD (aerobactin synthesis), by greater than 4-fold. We also
see a downregulation in transcription of a multitude of heme oxygenases that are involved
in the release of iron from heme[279] in uspG::tn, indicating that iron may not be
accumulating within the cells nor primarily responsible for death following exposure to
blood. Conversely, the downregulation of heme oxygenases strengthens our hypothesis
that ROS is accumulated within the uspG::tn strain since heme oxygenases are known
for their ability to function as antioxidants[279].
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Based on our data, instead of iron accumulation leading to ROS and downstream damage
through iron transporters, a more likely explanation is the accumulation of copper that can
induce ROS production, iron displacement and ultimately DNA and protein damage.
Similar to iron, copper can also induce ROS production in the presence of oxygen via a
reaction that is similar to Fenton-chemistry[66, 280]. Copper is an essential metal that is
necessary for the functionality of a variety of enzymes including cytochromes and
superoxide dismutase[281]. However, if levels become too high, copper can become
highly toxic. Even in the absence of H2O2 copper can displace iron from Fe-S centers and
inhibit the enzymes, many of which are responsible for maintaining the ETC[282]. Further,
it is known that copper resistance proteins can function to protect against H2O2 stress via
the expulsion of excess Cu I+ and Cu II+. This is important since Cu II+ reacting with
H2O2 can also form Cu III+ which is a strong oxidant yielding damaged macromolecules
such as proteins, lipids and DNA[283]. An example of copper resistance protecting
against H2O2 exposure was shown specifically in Lactobacillus plantarum, where copB
mutants were much more susceptible to H2O2 exposure[284]. In A. baumannii, both CopA
and CopB function to expel copper to ensure the levels are not toxic[66]. In line with the
notion that copper homeostasis is compromised in the uspG::tn strain, is a
downregulation of a variety of copper resistance genes such as copA, copB, actP1, and
nlpE observed within the uspG::tn mutant strain. Further to this, following exposure to
copper, Acinetobacter sp. have been shown to accumulate both CopA and CopB proteins
in addition to a variety of 30S and 50S ribosomal proteins[285]. In uspG::tn we see an
upregulation of ribosomal proteins and a downregulation of copA and copB, which makes
it tempting to speculate that copA and copB are indeed under the control of UspG.

135

Further, in their absence, an accumulation of copper would lead to oxidative stress
associated protein damage that would signal the cell to induce translational machinery
production in order to overcome the protein damaged caused by copper toxicity. This
response would then be exacerbated by the exposure of uspG::tn to H2O2 and blood,
leading to the increase in sensitivity that is observed. The same deductive reasoning
could be extended to the increased sensitivity observed for uspG::tn to DNA damaging
agents. If copper accumulation and increased levels of ROS has resulted in the oxidation
of macromolecules including DNA, exposure to external DNA damaging agents would
worsen this response. Within our transcriptional analysis, DNA damage response genes
were not differentially expressed to a degree greater than 4-fold. Therefore, DNA damage
is likely the result of the presence of excess ROS and further experimentation will be
necessary to determine whether UspG plays a direct role in protection against DNA
damage.

One of the most substantial conclusions of this work is the essentiality of UspG for survival
within the host demonstrated by the rapid killing of uspG::tn within 10 minutes of exposure
to whole human blood (Figure 25). The reasoning behind this phenomenon can be
attributed to multiple aspects of whole human blood. For example, blood contains a
variety of membrane targeting factors such as the membrane attack complex (MAC) that
leads to the lysis of Gram-negative organisms through pore formation[286]. It is highly
likely that the cell envelope of our mutant is altered in a way that is weakened. This was
demonstrated by the increased susceptibility to protonophores and membrane disrupting
agents along with differential expression of genes associated with lipid metabolism,
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peptidoglycan synthesis and cell envelope homeostasis. Specifically, surface antigens,
lipoproteins, and other lipid biosynthesis genes are downregulated. Some examples
include lipoproteins such as ABUW_2730 (-10.99-fold), encoding an OmpA family
lipoprotein, and the putative lipoprotein encoded by ABUW_3874 (-7.00-fold). In addition,
downregulation of lysophospholipases (ABUW_1332, -5.44-fold and ABUW_1210, -5.97fold) charged with maintaining and controlling lipid content within the bacterial membrane
was observed. This indicates that the system for maintaining membrane permeability
could be altered. Therefore, the MAC complex could be more efficient at targeting and
disassembling the membranes of the uspG::tn mutant. Further, in A. baumannii there is
evidence that poly-N-acetyl-β-(1,6)-glucosamine (PNAG) produced by the pga locus is a
target of the MAC complex[287] and pgaA is upregulated within the uspG::tn mutant.
Further, there is evidence that the uspG::tn mutant is more likely to be phagocytosed
quickly due to the downregulation of the paa operon in our mutant strain, a phenotype
which leads to the accumulation of the chemoattractant phenylacetate[271]. Therefore,
the inability of uspG::tn to survive within whole human blood is compounded by the
increased expression of MAC targets, a weakened cell envelope, a dysregulation of metal
homeostasis that leads to increased ROS damage, and the overproduction of neutrophil
chemoattractants leading to rapid killing.

Although there are similarities between UspG of E. coli and UspG of AB5057, there are
distinct differences, for example, UspG mutant strains are more susceptible to osmotic
stress whereas uspG::tn of AB5075 was able to resist exposure to 1M NaCl with effects
indistinguishable to wildtype AB5075 (data not shown). In addition, a variety of ribosomal
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proteins are shown to be downregulated transcriptionally following osmotic pressure in E.
coli while our uspG::tn strain demonstrates an upregulation in the same genes(Figure
16)[288]. The same inverse relationship in transcription is observed for copA, however
with increased expression in E. coli following osmotic stress and a downregulation in our
uspG::tn strain[288]. Therefore, it is unlikely that UspG in A. baumannii plays a role in the
protection against salt stress. This is in line with the similar lack of differential growth
observed for ΔuspA in A. baumannii ATCC17978 following exposure to 500mM of
NaCl[209]. In addition, UspG of E. coli does not play a role in protection against exposure
to H2O2 nor mitomycin C treatment[234], which are indisputably stressors that influence
uspG::tn survival (Figures 23 and 24).

Within the uspG::tn strain there were a variety of metabolic changes transcriptionally that
implicate UspG in the regulation of carbon flux. This is partially observed with the
increased susceptibility observed for uspG::tn to ethanol. In another A. baumannii strain,
ethanol exposure led to the expression of a variety of genes that were downregulated
within our uspG::tn mutant, while others induced or downregulated upon ethanol
exposure were similarly expressed within our mutant[270]. Therefore, it is unlikely that all
genes are regulated by UspG, but it is likely that some are. For example, ABUW_1624,
dhaT is responsible for the conversion of ethanol to acetaldehyde and was downregulated
by -10.71-fold in the upsG::tn mutant. Without this gene it is likely that the population is
unable to convert ethanol to acetaldehyde and other downstream cellular metabolites.
We predict that dhaT and ald1 are under the influence of UspG due to severe
transcriptional depression of genes downstream of dhaT. Namely, ald1 is responsible for
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converting the acetaldehyde produced by dhaT into acetate and is downregulated by 21.75-fold in the uspG::tn mutant. Further, ABUW_3781 encodes acs, which acts to then
convert the acetate into acetyl-CoA and is downregulated -205.98-fold in the uspG::tn
mutant. ABUW_3781 represents only one of three genes with the same function,
converting acetate into acetyl-CoA, to be downregulated in the absence of UspG. The
role in central carbon metabolism is also observed for other Usp proteins in organisms
such as E. coli[257], yet the mechanism of regulation is unclear.

Collectively, we have uncovered a global regulator within A. baumannii that has a
profound impact on the physiology and lifestyle of the organism. Future experimental
inquiries will be targeted to defining UspG ligands, interaction partners, and induction
patterns. We seek to continue to bring clarity to the complexity of the universal stress
response protein network that has remained elusive for almost 30 years[217].
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Chapter 4: The Discovery of Plant Derived Antimicrobial Peptides Using the
“PepSAVI-MS” Pipeline

Introduction

Plants have been used for centuries for their medicinal properties. Indeed, it is estimated
that four billion people around the world still rely on botanical herbs as a primary source
of medicine, making them an integral part of community structure[289]. There is, however,
very little research that defines the medicinal components of plant-derived remedies, or
how they contribute to the treatment of illness. This can be dangerous as many plants
contain toxic components that can lead to adverse effects; thus without chemical analysis
and standard dosing regimens, those taking such treatments are at risk[290]. With a lack
of research in this area and a history of potential as therapeutics, plant products pose as
an untapped resource for antimicrobial drug discovery. An underexplored area of study
in this regard is the capacity of plants to produce a vast array of antimicrobial peptides
(AMPs).

AMPs are small, amphipathic or cationic structures that are produced by almost all forms
of life[291]. This includes plants, animals, humans, fungi and bacteria. They function as
a form of protection for organisms against invading species and can be either stimulated
for production or expressed constitutively[292]. Each organism has a unique set of AMPs
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that are unlike that of any other organisms, however, the range of amino acids that make
up the peptides and mechanism of action (MOA) is relatively conserved. In general AMPs
are known to exhibit broad spectrum antimicrobial activities against bacteria, fungi and
viruses[293]. Their amphipathic and cationic nature allows them to integrate into the
membrane of target organisms through various methods, including open channel pore
formation in a barrel or toroidal conformation, or forming a layer that is dense enough to
dissolve the membrane[291, 294]. This is what elicits broad-spectrum activity, as the
cationic portions of the peptide are attracted to negatively charged membrane proteins,
lipids, and carbohydrates. After a threshold of accumulation is reached due to this
attraction, the amphipathic nature of the AMPs allows for a pore to be formed through
interaction with membrane lipids[295]. This leads to leaking of internal contents of cells,
releasing ions and metabolites that ultimately leads to cell death.

In terms of using AMPs as therapeutics, there are advantages that highlight their potential
as antibacterial treatments. Such advantages include their general bactericidal activity
with rapid killing, broad-spectrum activity, and anti-inflammatory effects[296, 297].
Towards this latter point, they are able to stimulate the immune system to recruit pathogen
clearing immune cells while suppressing tissue damaging inflammation within the
host[297]. It is also known that bacteria do not rapidly develop resistance to AMPs, which
can likely be explained by their MOA[298]. For example, a common mechanism of
resistance to antibacterial agents is the modification of a drug target within the cell. In the
case of AMPs, which target cell membranes, alterations to charge and general
physicochemical properties of this structure cannot easily be brought about to resist the
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attraction of an amphipathic natured AMP. Further, there is mounting evidence that AMPs
function to influence cellular processes in addition to pore formation, providing another
layer of activity that would need to be overcome by the pathogen[297].

The potential for AMPs as antibacterial agents was considered as early as 1939 with the
use of Gramicidin (extracted from a soil bacterium) to treat pneumococcal infections[84].
It was not long after, in 1942, that Purothionin, the first AMP from plants, was discovered
to have antimicrobial activity against fungi and bacteria[299]. Since then, numerous AMPs
demonstrating antibacterial activity have been extracted from a variety of different plants
and plant tissue types[297, 300]. With over 300,000 plant species identified[301], they
remain an untapped resource for the discovery of novel AMPs.

There are currently eight classes of plant AMPs, which include: cyclotides, knottins,
thionins,

snakins,

defensins,

hevein-like,

lipid

transfer

peptides,

and

alpha-

hairpinins[302]. Commonalities between these peptides are their amphipathic nature,
overall positive charge and cysteine-rich modifications to form disulfides, and cyclization
to increase stability[303]. All of peptides within these classes have one overarching role,
to serve as a part of the innate immune defense for the plant[304, 305]. Some of these
classes, such as the cyclotides and lipid transfer peptides, are part of a larger group of
peptides called Ribosomally-synthesized, Post-translationally modified Peptide natural
products (RiPPs).
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RiPPs are also produced across all three domains of life, and are desirable drug
candidates that differ from standard AMPs due to their target specificity[306]. The posttranslational modifications of RiPPs lead to conformational restriction of the AMP, which
aids in narrowing the target for attachment and integration while also enhancing stability
from degradation by chemical or metabolic means[306]. In humans, this reduces the
chance of RiPPs inducing off-target effects while increasing the likelihood of the RiPPs
reaching the target organism without being degraded. There is also evidence that RiPPs
have alternate MOAs, outside of non-specific membrane penetration and content
leakage, such as influencing metabolic and structural processes within target cells[303].
Examples of this are seen for Nisin and Bottromycin RiPPs, with the former, a RiPP
lanthipeptide, targeting peptidoglycan synthesis by inhibiting lipid II biosynthesis during
cell wall formation[307]. Bottromycins differentially target the bacterial 50S ribosome and
function to inhibit aminoacyl-tRNA entry into the A site of the ribosome during
translation[308].

Herein, we present work using a pipeline for the study of plant AMPs (PepSAVI-MS:
statistically-guided bioactive peptides prioritized via mass spectrometry) that was
developed by our collaborators, the Hicks laboratory at UNC-Chapel Hill. The method
was developed to isolate and identify bioactive products from complex natural product
sources such as medicinal plant extracts (Figure 26). Instead of using the typical
approach to natural product discovery through bioassay guided fractionation, PepSAVIMS provides a more efficient approach that implements a single round of crude extract
fractionation before bioassay analysis followed by mass spectrometric and statistical
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analysis. This allows one to streamline the process of AMP discovery and identify only
active peptides without the bias of size or abundance. Consequently, time and resources
are saved by omitting a major screening step and eliminating the possibility for activity
loss due to fractionation. Following years of deployment, this process has been further
adapted to rapidly evaluate plant species by combining promising fractions into single
samples for bioactivity inhibitory screening. Therefore, bioactive plant species are
prioritized for further investigation.

Figure 26. Workflow for PepSAVI-MS Pipeline and Project Goals. 1) Creation of
peptide libraries through extraction and SCX fractionation of crude samples. 2) Bioactivity
screening against ESKAPE pathogens. 3) LC-MS/MS analysis of active peptide libraries.
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4) Statistical modeling of MS vs bioactivity regions to identify leads. 5) Purification or
synthesis of lead peptides. 6) Determination of mechanism of action and cytotoxicity
profiles for lead peptides. Figure adapted from Kirkpatrick et. al. 2017.
The initial deployment of this process was to screen Viola odorata (sweet violet, VO) due
to the known abundance of cyclotides produced by this species, and previously defined
medicinal properties[309-311]. In order to identify peptides of clinical relevance, we
employed bioactivity screens of VO against the ESKAPE pathogens (E: Enterococcus
faecium, S: Staphylococcus aureus, K: Klebsiella pneumoniae, A: Acinetobacter
baumannii, P: Pseudomonas aeruginosa, E: Enterobacter cloacae). Initial exploration
showed promising inhibitory activity, uncovering the known RiPP cycloviolacin O2, which
had novel activity against E. coli and A. baumannii, thus validating the PepSAVI-MS
approach[95].

Given that the PepSAVI-MS pipeline appears to be highly effective at identifying novel
AMPs, we expanded our screen to a panel of additional plant varieties, focusing on the
bioactivity of RiPPs. Herein we report the screening of Linum spp. Solanum spp., Silybum
spp., Amaranthus tricolor (red spinach ATr), and Capsicum spp., among others. The goal
of this endeavor is to discover potential therapeutics and generate a greater
understanding of herbal medicine overall, with the examples presented herein
demonstrating clear and ongoing success in this regard.

Materials and Methods

Plant Species. All plants tested are presented in Table 7 and were grown as detailed in
Kirkpatrick, et. al. 2017[95]. Fractions for antibacterial testing were generated by the Hicks
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laboratory as detailed in[95] and shipped to the University of South Florida for testing, as
detailed herein.
Table 7. Plant Genre for Peptide Library Creation and Testing.
Genus
Amaranthus
Anchusa
Calendula
Chelidonium
Chichorium
Datura
Digitalis
Dodonaea
Echinacea
Grindelia
Houttuynia
Hyoscyamus
Hyperium
Linum
Mentha
Nasturtium
Origanum
Salvia
Silybum
Solanum
Trifolium
Urtica
Viola
Withania
Zingiber

Strains Tested*
ESKAPEE
SA
ESKAPE
ESKAPE
ESKAPE
ESKAPE
ESKAPE
ESKAPE
ESKAPE
EKA
EKA
ESKAE
EKA
ESKAPE
ESKAPE
ESKAPE
EKA
ESKAPE
KA
ESKA
ESKAPE
ESKAPE
ESKAPE
ESKA
ESKAPE

Full

Single

Strains tested are bacterial species challenged against each botanical fraction set. The acronyms represent
the following species in order: E: Enterococcus faecium, S: Staphylococcus aureus, K: Klebsiella
pneumoniae, A: Acinetobacter baumannii, P: Pseudomonas aeruginosa, E: Enterobacter cloacae E:
Escherichia coli. Samples tested against E. coli were tested against all 4 strains listed in table 8. Green: full
fraction library tested, Light Green: peptide single or pooled library sample tested

Bacterial Strains and Growth Conditions. All ESKAPE pathogen and E. coli strains are
drug resistant clinical isolates detailed in Table 8. Bacterial stocks were maintained at 80°C in tryptic soy broth (TSB) and 25% glycerol. Each isolate was struck onto tryptic soy
agar (TSA) and grown for 18 hours prior to storage at 4°C for working stocks. Plates were
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stored for no longer than 7 days at 4°C. Prior to each assay, a single colony was selected
for each species and resuspended in 5mL TSB, followed by incubation at 37°C overnight.
For screening, 1mL of overnight cultures were inoculated into 100mL TSB and grown for
3 hours with shaking at 37°C. These were then used in the assays detailed below.
Table 8. Bacterial Strains Used in This Study.
Organism
Enterococcus faecium
Staphylococcus aureus
Klebsiella pneumoniae
Acinetobacter baumannii

Strain #
1450
635
1433
5075 or 1403

Final OD 600nm*
0.1
0.1
0.035
0.0325

Antibiotic**
50µg/mL Tet
50µg/mL Gent
50µg/mL Gent
50µg/mL Tet

Pseudomonas aeruginosa
Enterobacter cloacae
Escherichia coli
Escherichia coli
Escherichia coli
Escherichia coli

1423
1454
MCC62
MCC67
MCC70
TW14359

0.03
0.03
0.1
0.1
0.1
0.1

50µg/mL Tet
50µg/mL Gent
50µg/mL Tet
50µg/mL Tet
50µg/mL Tet
50µg/mL Tet

Source
[312]
[312]
[312]
[143,
312]
[312]
[312]

This study
This study
This study

[313]

Antibiotic: Tet: Tetracycline, Gent: Gentamicin. *Final OD600 standardized based on OD600 measurement
and is equivalent to 5x107 CFU/mL which was diluted 1:5 for a starting inoculation of 1x107 CFU/mL per
organism per well. TGH: Tampa General Hospital, Tampa, FL. MCC: Moffit Cancer Center, Tampa, FL.
**Commercial antibiotic included within each assay to represent 100% inhibition of each organism.

Antimicrobial Activity Screening using Resazurin. All assays were performed in
standard 96-well polystyrene plates (Thermo Fisher Scientific). A 1:5 ratio of plant fraction
to media was achieved by supplementing the reaction with 2x media in equal volume to
the water-based fraction. Gram-positive organisms (ES) were cultured in TSB, while the
Gram-negative organisms (KAPE) were cultured using MHBI for bioactivity screening with
peptide. The addition of 2x media was used to ensure sufficient nutrients since the
fractions themselves account for 1/5 of the final volume. TSB was used for the analysis
of E. faecium and S. aureus due to their minimal growth in MHBI. Each well contained
20µL 2x media, 40µL 1x media, 20µL peptide fraction, and 20µL 5x concentrated bacteria
(5x107 equivalent OD at 600nm (OD600)) for a final starting CFU/mL of 1x107. Controls
included commercial antibiotics and media only wells in each assay. Tetracycline at
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50µg/mL was used as the control for E. faecium, A. baumannii, and P. aeruginosa, while
Gentamicin at 50µg/mL was used against S. aureus, K. pneumoniae, and E. cloacae.
Standardized cultures were incubated with plant fractions for 1.5 hours with shaking at
37°C, with the exception of P. aeruginosa, which was incubated for 3 hours due to slower
growth compared to the other organisms. The final turbidity was then recorded at an
OD600 before 10µL Resazurin was added to each well at a final concentration of 1.19mM
(30µg/mL). Plates were incubated in the dark under static conditions at 37°C for 30
minutes prior to recording fluorescent measurements. Results were recorded using an
excitation frequency of 544nm and emission of 590nm. Plates were then measured
consecutively in 15-minute increments until the maximum intensity was reached in
untreated (no-treatment) wells. Percent inhibition was calculated after background
florescence was removed using the following formula: (1-(sample intensity/average
control max intensity)) x 100. Each sample was tested in technical triplicate with at least
two biological replicates.

Antimicrobial Activity Screening using Optical Density. Bacterial cultures were
synchronized by inoculating 50µL of overnight culture into 5mL of TSB and incubating at
37°C for 3 hours. All assays were performed in 96-well flat bottom polypropylene plates
(Plate One). Like the Resazurin based screening, each well of the assay plate contained
20µL 2x MHBI broth, 40µL 1x MHBI broth, 20µL peptide and 20µL bacteria. Bacteria were
seeded in each well at a final concentration of 1x107 CFU/mL. Each organism was tested
in biological triplicate and each assay included media only controls, solvent only controls,
and commercial antibiotic controls. Plates were incubated at 37°C, 275 rpm shaking for
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4-7 hours depending on the organism’s growth characteristics. Final reads were taken
after 4 hours for S. aureus, K. pneumoniae, and E. cloacae. E. faecium and A. baumannii
had final reads taken after 5 hours and P. aeruginosa after 7 hours. OD reads were taken
using a Citation 5 plate reader (BioTek) at 600nm (OD600). Percent inhibition was
calculated for each well using the following formula: % inhibition = ((1-((OD600 of fraction
-OD600 of positive control)/(OD600 of negative control – OD600 of positive control)) x 100.

Validation of CyO2 Activity from Viola odorata. The minimum inhibitory concentration
(MIC) was determined for CyO2 against E. coli and A. baumannii. Cultures were grown
overnight as previously described in TSB before inoculation into MHBI media for a final
concentration of 1x105 CFU/mL. Assays were performed using a broth microdilution
method in triplicate starting at 10µM for E. coli (Hicks Lab) and 25µM for A. baumannii.
The peptide was tested at concentrations of 25, 20, 15, 10, and 5µM in biological triplicate
and activity was defined by the concentration in which complete clearing was observed
in wells following 20 hours of incubation at 37°C.

Minimum Bactericidal Concentration to Determine Activity of CC-AMP1. The
minimum bactericidal concentration (MBC) was determined for isolate CC-AMP1 against
E. faecium, S. aureus, and A. baumannii first by testing bioactivity using the antimicrobial
screening by OD600 method described above, and then by plating the well content of those
assays on TSA. The MBC was determined for each concentration of compound tested
including no treatment controls in biological triplicate. Following bioassay screening and
OD600 recording, 20µL from each well of the assay plate was extracted and placed into
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180µL of PBS. Samples were then serial diluted by intervals of 1:10 and 30µL was plated
in technical duplicate onto TSA and incubated overnight at 37°C for 24 hours. Colonies
were then counted to determine the CFU/mL for each sample. Percent recovery was then
calculated by comparing treated samples to no-drug controls. % recovery = ((CFU/mL
test sample)/(CFU/mL negative control)) x 100.

Results

Optimization of Resazurin Assay to Assess Antimicrobial Peptide Activity by
Quantifying Respiration. Resazurin is an oxidation-reduction indicator of respiration by
bacterial and mammalian cells alike. Resazurin itself is a non-toxic compound that is deep
blue in color and does not possess fluorescent properties. When reduced, however, it
becomes Resofurin which is pink in color and is highly fluorescent, allowing for detection
using a standard monochromatic plate reader. Further, Resofurin itself can be reduced to
Hydroresorufin, which is uncolored and non-fluorescent, therefore, if bacteria are allowed
to reduce the reagent too far, false inhibitory results can be obtained (Figure 27). Based
on our preliminary analysis, this occurs when too many bacteria are present per well in a
96-well plate. For this project, two Gram-positive organisms and four Gram-negative
organisms were assessed, each with very distinct metabolic profiles and growth rates.
Therefore, optimization was necessary to determine the proper incubation times and
inocula to obtain the most accurate and consistent results for each organism.
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Figure 27. False Positive Activity Arises with Overexposure of Resazurin. Each
sample was from the same data set with percent inhibition calculated using either
resazurin values or the final OD600 measurements from the same wells. C represents a
well where overgrowth and overreduction did not occur and good correlation is seen.
Samples 1-5 represent wells where overreduction of resazurin resulted in false positive
inhibition.
In order to accomplish this, generation times were determined for each of the organisms
by synchronizing and standardizing each bacterial species to a range of OD600s and
recording the respective OD600 at various timepoints under conditions that mimic the
bioassays to be performed. OD600s were then connected to a precise CFU/mL by serial
diluting and plating each sample onto TSA (Figure 28). Based on this, we were able to fit
a linear regression to various OD600 measurements vs CFU/mL counts to calculate the
OD600 in which each organism produces 5x107 CFU/mL, the desired starting OD600 prior
to dilution for bioactivity screening (Table 8). Each starting OD600 was generated based
on technical replicates of each organism in biological triplicate. For each assay, the OD600
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equal to 5x107 CFU/mL was diluted 1:5 to obtain a starting CFU/mL of 1x107 per well for
each organism (Table 8).
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Figure 28. Determination of Differences in ESKAPE OD600 vs CFU/mL. Each ESKAPE
pathogen was synchronized and standardized to the shown optical densities to determine
the ideal seeding OD600 for each resazurin bioassay. Error bars represent ±SEM of three
biological replicates.
The PepSAVI-MS Approach to Antimicrobial Peptide Discovery. With the approach
for bioactivity screening optimized for each organism to be tested, plant samples were
prepared by the Hicks Laboratory at UNC-Chapel Hill following the PepSAVI-MS
approach (Figure 26, adapted from Kirkpatrick et al. 2017[95]). Our novel approach is
implemented, initially by growing specific plant species to a pre-flowering stage and then
immediately flash-freezing the aerial plant tissue using liquid nitrogen prior to peptide
extraction. Frozen tissue is then ground and treated with protease inhibitors prior to
pelleting and centrifugation to fractionate samples using strong cation exchange (SCX)
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chromatography. This method of fractionation allows for the isolation of specific AMPs,
which are RiPPs. Plant samples containing RiPPs are then separated into 47 fractions,
forming libraries to be screened for bioactivity against the ESKAPE pathogens. The crude
samples are then tested at a ratio of 1:5 in biological triplicate against the ESKAPE
pathogens. Plants tested in this manner are highlighted in Table 7 in dark green. Under
certain circumstances not all ESKAPE pathogens could be tested due to the amount of
test material collected and therefore, pathogens were prioritized for testing. These are
also highlighted in Table 7.

Following the Resazurin based antimicrobial assay to detect inhibition, bioactivity is
calculated based on percent inhibition of each crude extract fraction and is converted to
a scaled score that directly represents the inhibitory activity. Specifically, if a peptide
fraction inhibits 100% of the bacteria within a test well, a scaled score of 10 is given for
that sample. Scaled scores are calculated based on the average score of three replicates.
Peptide fractions that are found to be most promising based on bioactivity are then
analyzed via mass spectrometry (LCMS/MS) to determine which peptides are present
and at what concentrations. These peptides are then purified and subjected to further
bioactivity screening.

Assessing the Activity of Viola odorata (VO) to Validate the PepSAVI-MS Approach
Reveals Novel Antimicrobial Activity. To implement this approach and prove its
potential, a known RiPP AMP producing plant was selected: Viola odorata (VO),
commonly known as the Sweet Violet plant[310]. As previously described, plants were
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grown, and fractionated libraries were created for bioactivity screening against the
ESKAPE pathogens (Figure 29). From this data, fractions 18-22 represented a peak in
bioactivity and therefore underwent LCMS/MS analysis to detect levels of the known
RiPP: cycloviolacin O2 (CyO2)[310]. Previous work has shown minimal activity of CyO2
against Gram-positive organisms such as S. aureus[311], which is in line with our study
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Figure 29. Bioactivity of Viola odorata Fraction Library. Data is represented as a
stacked scaled score (% inhibition/10) for simplicity with all ESKAPE pathogens.
Fractions 1-10 and 41-47 were excluded leaving only the samples expected to contain
RiPPs. Data points represent the average of 3 biological replicates per species.
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To validate the activity of our sample and our approach to AMP discovery using the
pipeline, the CyO2 found within fractions 18-22 was purified and subject to bioactivity
assessment via screening for its inhibitory potential against two select pathogens:
Escherichia coli and A. baumannii. For this screen, each strain was challenged with pure
CyO2 and the MICs were determined. E. coli was found to have an MIC of 5µM
(conducted by our collaborators) which was expected based on a previous study that
demonstrated inhibition of a different strain of E. coli by CyO2[311]. A. baumannii was
inhibited following 15µM of CyO2 treatment. These findings serve as proof of principle for
the pipeline and uncovered novel activity for CyO2 against the Gram-negative, multi-drug
resistant A. baumannii strain. This data was published in[95].

Bioassay Screening of Fractionated Ethnobotanical Plant Species Against the
ESKAPE Pathogens. Based on the success of our pilot study in VO, multiple species of
ethnobotanical plant were subject to the same rigor of testing (Table 7). The most active
fractions of select samples are shown in Figures 30-32. Due to the need to protect
intellectual property in our ongoing efforts, only the genera of each plant are revealed
herein. Fraction sets of 47 crude samples that contain potentially active RiPPs were
tested against the ESKAPE pathogens. Fractions 11-40, most likely to contain the RiPPs
were graphed to evaluate their bioactivity. Specifically, fractions 1-10 contain small
molecules that could be bioactive and fractions 41-47 contain high levels of salt, which
can be toxic to bacteria, therefore, each are omitted from the PepSAVI-MS analysis.
Further, high salt concentrations and highly abundant small molecules can lead to
instrument contamination during downstream MS/MS peptide quantification. Identifying

155

fractions containing the most bioactive AMPs is achieved by looking for peaks or small
bell curve trends of activity within the data sets since the same AMP is eluted across
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Figure 30. Bioactivity of Linum spp. Fraction Library. Data is represented as a
stacked scaled score (% inhibition/10) for simplicity with all ESKAPE pathogens.
Fractions 1-10 and 41-47 were excluded leaving only the samples expected to contain
RiPPs. Data points represent the average of 3 biological replicates per species.
Figure 30 shows the bioactivity of Linum spp. where modest peaks of activity are present
within fractions 23-26, 28-30, and 32-34. The most abundant activity was seen against E.
cloacae demonstrating around 20% inhibition when challenged with fractions 26 and 33.
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Due to low levels of bioactivity recorded across multiple ESKAPE species, these samples
were not pursued further, however, Linum spp. would be a candidate to consider
investigating to find AMPs specifically targeting E. cloacae. Although ±20% may seem
low, it is possible and even likely that the fractions responsible for this activity contain
AMPs that are in low abundance and therefore are highly potent themselves against E.
cloacae. Therefore, isolating and purifying the peptide(s) responsible for the bioactivity
observed against E. cloacae and re-testing for inhibitory activity would be a viable
approach to determine therapeutic potential of AMPs produced by Linum spp.

Another example yielding the characteristic peak of activity was found for Solanum spp.
(Figure 31), which was tested against ESKA of the ESKAPE panel. It was clear that
fractions 18-25 contained AMP(s) that are effective to inhibit and thus target K.
pneumoniae and A. baumannii. The content of fraction 20 demonstrated the highest
amount of inhibition against each species and therefore likely contained the highest
concentration of bioactive peptide(s). In addition, this fraction is likely to contain an AMP
with broad-spectrum activity. Specifically, this fraction contained a peptide or peptides
that inhibited K. pneumoniae by an average of 37%, A. baumannii by 26.5%, and E.
faecium by 15.4%. These bioactive fractions (18-25) did not undergo further analyses and
therefore it is unclear which peptide(s) led to the inhibitory activity observed, however, the
broad-spectrum activity highlights Solanum spp. as a candidate for future analysis.
Specifically, by investigating the peptides present within fraction 20 and the surrounding
elution products would allow us to determine whether a single peptide was responsible
for the cross-species activity or if a group of AMPs were responsible.
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Figure 31. Bioactivity of Solanum spp. Fraction Library. Data is represented as a
stacked scaled score (% inhibition/10) for simplicity with all ESKA pathogens. Fractions
1-10 and 41-47 were excluded leaving only the samples expected to contain RiPPs. Data
points represent the average of 3 biological replicates per species.
The next plant that underwent bioactivity assessment comes from the genus Silybum. For
this sample set, activity was seen against two Gram-negative species as shown in Figure
32. Fractions 18-23 show a peak of activity against K. pneumoniae and A. baumannii
suggesting that bioactive AMPs are present within those samples. The activity was found
to be Gram-negative specific as S. aureus and E. faecium were not influenced by
treatment with these fractions. However, relatively low levels of inhibition were observed
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against A. baumannii and K. pneumoniae. The maximum level of inhibition was observed
for fraction 19, inhibiting A. baumannii by 17.5% compared to no-treatment controls. K.
pneumoniae was inhibited by a maximum of 9% when challenged with fraction 23.
Activity, however small, prompted us to investigate this plant species further. Seeing the
highest levels of activity against each species in different fractions suggests that different
peptides are contributing to the antibacterial activity.

Figure 32. Bioactivity of Silybum spp. Fraction Library. Data is represented as a
stacked scaled score (% inhibition/10) for simplicity with all ESKAPE pathogens.
Fractions 1-10 and 41-47 were excluded leaving only the samples expected to contain
RiPPs. Data points represent the average of 3 biological replicates per species.
Repeating the assay with more concentrated samples allowed us to confirm this. Thus,
to understand which of the fractions were contributing to the bioactivity observed, another
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library from Silybum spp. containing 3-times the peptide concentration per fraction was
generated. K. pneumoniae and A. baumannii were then subject to bioactivity screening
using the concentrated library. As shown in Figure 33, activity against K. pneumoniae
and A. baumannii was observed across the same fractions (18-23) highlighting the
reliability of our pipeline to aptly replicate our findings across different plant harvests.
Despite this, however, the degree of activity was not 3-fold that of the initial library created.
Against A. baumannii, the second, more concentrated library, yielded similar inhibitory
activity while the samples inhibited K. pneumoniae to a higher degree albeit less than 3fold. Therefore, although we are able to confidently isolate the same peptides based on
the reflective bioactivity patterns observed, the concentration of bioactive peptides is likely
to vary between harvests. Despite this, we have identified fractions containing AMPs
capable of targeting two important pathogens and further studies will allow for their
identification and structure elucidation. Thus, Silybum spp. serves an example plant
species, producing multiple bioactive AMPs that are worth isolating and characterizing
further utilizing the PepSAVI-MS approach.
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Figure 33. Bioactivity of Silybum spp. 3x Fraction Library. Data is represented as a
stacked scaled score (% inhibition/10) for simplicity with KA pathogens. Fractions 1-10
and 41-47 were excluded leaving only the samples expected to contain RiPPs. Data
points represent the average of 3 biological replicates per species.
Throughout this process we were able to screen 19 different ethnobotanical species
(Table 7), with the select examples discussed, further demonstrating the validity and
power of the PepSAVI-MS approach to AMP discovery. This screening effort has led to
the identification of multiple plant species with antimicrobial activity against multi-drug
resistant microorganisms. Further, it has allowed for the bioassay guided identification of
sample fractions containing AMP pools that likely contain novel AMPs capable of
targeting these microorganisms.
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Fast-Tracking Screening Procedure via Assessing Single Fraction Isolates Against
the ESKAPE Pathogens. Although the process for screening fraction libraries proved
successful, a majority of libraries did not yield noteworthy results and thus there were no
subsequent investigation into the AMPs present. This is not surprising as the panel of
bacteria used within these assays are the most clinically relevant based on their isolation
locations and ability to resist multiple commercial antibiotics. When considering AMPs of
therapeutic relevance, activity against multi-drug resistant organisms will likely translate
to activity against other strains of the resistant species. Therefore, hits identified are of
high value, however, this means fewer plant species will be identified throughout this
process including plants that may produce AMPs with inhibitory activity against less drugresistant strains of the organisms tested. The high value (smaller) hit identification rate,
coupled with the labor and time-intensiveness of screening 47 peptide fractions against
six species of bacteria in biological triplicate, led us to modify the initial steps in the
screening process to increase efficiency. To do so, the fractionation step for peptide
library creation was eliminated creating a single pooled fraction containing all of the plant
material and AMPs. This allowed us to save time and resources by rapidly eliminating
plant species without bioactivity and identifying bioactive plant species to be assessed
fully via fractionated library creation and screening. From this approach we were able to
promptly test multiple species of plant simultaneously. These are shown in Table 7
highlighted in light green. The bioactivity of these concentrated fractions is shown in
Figure 34.
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Figure 34. Bioactivity of Single Fraction Libraries. Data is represented as a stacked
scaled score (% inhibition/10) for simplicity with all ESKAPE pathogens. Data points
represent the average of 3 biological replicates per species. Due to issues with ongoing
intellectual property, originating plant species names are abbreviated.
The plant sample of the Mentha genus demonstrated the highest bioactivity with inhibitory
activity against all six ESKAPE pathogens (Figure 34). In addition to this, the
Hyoscyamus sample showed inhibitory activity against Gram-positive (E. faecium and S.
aureus) and Gram-negative species (A. baumannii). Silybum and Calendula genre also
demonstrated inhibitory potential albeit to a lesser degree. Based on these results, full
fraction libraries of the Mentha and Hyoscyamus genera are queued for future testing
against the ESKAPE panel to identify and isolate fractions containing the peptides
contributing to the activity observed in the single fraction screen shown in Figure 34. The
retesting of Silybum using this approach serves as proof of principle for identifying
bioactive AMP producing plant varieties even though the activity does not specifically
mirror that of the fully fractionated library screen.
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Overcoming Colorimetric Interferences via Turbidity-Based Assessment. The
concentrated fraction approach revealed promising candidates for full fractionation and
ESKAPE panel challenge, however, there were still limitations to this approach. Certain
plant extracts possess components with visible color, which is not ideal for a colorimetric
based assay such as Resazurin screening. Specifically, the color of the samples was
found to interfere with the spectrometer readings of Resazurin and resulted in
measurements that could not reliably be used to calculate the inhibitory effect of the
peptide samples. In the fractionated library screens, the colorimetric components of the
plants were eluted into factions collected early and were not considered in the inhibitory
data (within fractions 1-10). To overcome this in the pooled single fractions, an OD600based approach was employed using the same parameters and seeding concentrations
as previously used but modifying the amount of time each bacterial species within the
ESKAPE panel was grown in the presence of peptide samples. To find the optimal time
to allow for growth and detect statistically significant inhibitory data solely utilizing OD600,
growth curves were performed using no-treatment controls and antibiotic-treated controls
as the baseline for inhibitory activity (Figures 35-40).

As shown in Figure 35, it was found that an optimal time for assaying activity was
between 4 and 7 hours for E. faecium. An optimal time is defined as the condition(s) in
which the difference in OD600 of the treated sample and the OD600 of the non-treated
sample are most significantly separated. For example, it is known that our control
antibiotic (treated sample) is able to inhibit the population and represents 100% inhibition.
However, the OD600 does not change throughout the timepoints since the organism is
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inhibited throughout all tested timepoints. So, if percent inhibition is calculated at each
point, the highest level of inhibition is seen for the timepoints at which the highest level of
separation is present between the treated and non-treated samples. Specifically, for E.
faecium, using raw OD600 values without subtracting background, percent inhibition at
hour 2 is 34%, whereas nearly 70% inhibition is calculable at hour 7.

Using this logic, the ideal time ranges were determined for the remainder of the ESKAPE
pathogens. The ideal time for S. aureus was found to be between 3 and 8 hours (Figure
36), while for K. pneumoniae the ideal range was between 4-8 hours (Figure 37). The
ideal time range was found to be between 5-8 hours and 7-11 hours for A. baumannii
(Figure 38) and P. aeruginosa (Figure 39) respectively. Finally, the ideal range of time
for incubation of E. cloacae was determined to be between 4-9 hours (Figure 40).
Following this analysis, it was determined that the ideal time of inhibitory quantification
was after 5 hours of incubation with peptides for E. faecium and A. baumannii, 4 hours
for S. aureus, K. pneumoniae, and E. cloacae, and 7 hours for P. aeruginosa. These time
points were chosen to represent a time within the established ideal range that also
allowed for an efficient high-throughput screening approach. By assessing multiple
organisms at the same timepoint, data of statistical significance could be generated more
quickly and efficiently. For example, E. faecium and A. baumannii could be seeded within
the same assay plate and measured together instead of the alternative combination of E.
faecium and S. aureus. Incubating E. faecium and S. aureus together would result in a
disruption in incubation time for E. faecium when S. aureus samples needed to be
measured whereas E. faecium and A. baumannii could be incubated for 5 hours without
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interruption. Thus, more consistent results could be generated. Keeping these timepoints
consistent also established a baseline to serve as a control and ensured that peptide
samples across different plant species and preparations could be reliably compared.
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Figure 35. Growth of E. faecium Reveals 5 Hours to be Optimal Assay Point. Data
was collected using a BioTek Plate reader following synchronizing and standardizing to
a starting OD600 of 0.1. Each data point represents the OD600 of three biological replicates
of the organism in MHBI with or without antibiotic treatment. Error bars represent the
mean ± SEM of the three replicates. P-vales for each time point were determined for the
antibiotic treated and non-treated samples. Asterisks represent P vales using Student’s
t-test : 0.05<*, 0.01<**, 0.001<*** relative to controls.
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Figure 36. Growth of S. aureus Reveals 4 Hours to be Optimal Assay Point. Data
was collected using a BioTek Plate reader following synchronizing and standardizing to
a starting OD600 of 0.1. Each data point represents the OD600 of three biological replicates
of the organism in MHBI with or without antibiotic treatment. Error bars represent the
mean ± SEM of the three replicates. P-vales for each time point were determined for the
antibiotic treated and non-treated samples. Asterisks represent P vales using Student’s
t-test : 0.05<*, 0.01<**, 0.001<*** relative to controls.
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Figure 37. Growth of K. pneumoniae Reveals 4 Hours to be Optimal Assay Point.
Data was collected using a BioTek Plate reader following synchronizing and standardizing
to a starting OD600 of 0.035. Each data point represents the OD600 of three biological
replicates of the organism in MHBI with or without antibiotic treatment. Error bars
represent the mean ± SEM of the three replicates. P-vales for each time point were
determined for the antibiotic treated and non-treated samples. Asterisks represent P vales
using Student’s t-test : 0.05<*, 0.01<**, 0.001<*** relative to controls.
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Figure 38. Growth of A. baumannii Reveals 5 Hours to be Optimal Assay Point. Data
was collected using a BioTek Plate reader following synchronizing and standardizing to
a starting OD600 of 0.0325. Each data point represents the OD600 of three biological
replicates of the organism in MHBI with or without antibiotic treatment. Error bars
represent the mean ± SEM of the three replicates. P-vales for each time point were
determined for the antibiotic treated and non-treated samples. Asterisks represent P vales
using Student’s t-test : 0.05<*, 0.01<**, 0.001<*** relative to controls.
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Figure 39. Growth of P. aeruginosa Reveals 7 Hours to be Optimal Assay Point.
Data was collected using a BioTek Plate reader following synchronizing and standardizing
to a starting OD600 of 0.03. Each data point represents the OD600 of three biological
replicates of the organism in MHBI with or without antibiotic treatment. Error bars
represent the mean ± SEM of the three replicates. P-vales for each time point were
determined for the antibiotic treated and non-treated samples. Asterisks represent P vales
using Student’s t-test : 0.05<*, 0.01<**, 0.001<*** relative to controls.
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Figure 40. Growth of E. cloacae Reveals 4 Hours to be Optimal Assay Point. Data
was collected using a BioTek Plate reader following synchronizing and standardizing to
a starting OD600 of 0.03. Each data point represents the OD600 of three biological
replicates of the organism in MHBI with or without antibiotic treatment. Error bars
represent the mean ± SEM of the three replicates. P-vales for each time point were
determined for the antibiotic treated and non-treated samples. Asterisks represent P vales
using Student’s t-test: 0.05<*, 0.01<**, 0.001<*** relative to controls.
Amaranthus tricolor (ATr) has Limited Activity Against ESKAPE Pathogens but
Shows Enhanced Activity Against Escherichia coli. Initially, A. tricolor (ATr) was
tested against 3 of the 6 ESKAPE pathogens (S. aureus, K. pneumoniae, and A.
baumannii) using the fully fractionated library PepSAVI-MS approach, but little activity
was observed (Figure 41). The highest level of activity was found against A. baumannii
with around 15% inhibition recorded when treated with ATr fraction 21. Alternatively,
preliminary activity was generated against a laboratory strain of E. coli and inhibition was
observed (Hick’s lab, data not shown). Based on this data, the PepSAVI-MS approach
was implemented and revealed a novel short chain proline-rich AMP (ATr-AMP1) that has
been previously described as possessing activity against laboratory strains of E. coli and
S. aureus[314].
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Figure 41. Bioactivity of Amaranthus tricolor Fraction Library. Data is represented
as a stacked scaled score (% inhibition/10) for simplicity with SKA pathogens. Fractions
1-10 and 41-47 were excluded leaving only the samples expected to contain RiPPs. Data
points represent the average of 3 biological replicates per species.
This success led us to reevaluate the potential of ATr against the ESKAPE pathogens
and therefore a concentrated single fraction of ATr was tested against the ESKAPE panel
as well as multiple strains of E. coli (Figure 42). The E. coli isolates used for this screen
came from a spinach outbreak (TW14359) or were collected from infected patients at the
Moffit Cancer Center (MCC) (Tampa, FL), giving clinical relevance to the findings.
Specifically, over 50% inhibition was observed against all three clinical isolates of E. coli
(MCC62, MCC67, and MCC70) as well as the TW14359 isolate. This finding is in line with
the previous inhibitory activity observed by our collaborators when testing a laboratory
strain of E. coli and highlights this species of plant as a valuable source of AMPs capable
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of targeting multiple strains of E. coli. This data also revealed inhibitory activity of AMPs
produced by A. tricolor that target other Gram-negative organisms. The pooled single
fraction was most active against P. aeruginosa and resulted in over 70% inhibition.
Further, A. baumannii was inhibited by over 60% and E. cloacae by over 45% (Figure
42). K. pneumoniae was the least susceptible Gram-negative isolate tested and exhibited
inhibition by close to 20% when challenged with ATr. It should be noted that the
concentrated fraction again showed activity against K. pneumoniae and A. baumannii at
levels higher than any specific fraction. This indicates that there are potentially multiple
AMPs to isolate that are effective against these pathogens and harnessing the products
produced by this plant would require a different approach to identify them. These findings
also indicate that the AMPs produced by A. tricolor are specific to Gram-negative
microorganisms as no activity was observed against E. faecium nor S. aureus (Figure
42).
E. coli - MCC70
E. coli - MCC67
E. coli - MCC62

Strain

E. coli - TW14359
E. coli - DH5α
E. cloacae
P. aeruginosa
A.baumannii
K. pneumoniae
S. aureus

Scaled Score

10

5

0

E. faecium

Figure 42. Bioactivity of Amaranthus tricolor Concentrated Fraction Against
ESKAPE and E. coli Isolates. Data is represented as a stacked scaled score (%
inhibition/10) for simplicity. Data points represent the average of 3 biological replicates
per species. Error bars represent the mean ±SEM of the three replicates.
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Transcriptome Mining Reveals Potential Antimicrobial Peptide Candidates
Effective Against Select ESKAPE Pathogens. The absence of substantial inhibition
observed against S. aureus, K. pneumoniae and A. baumannii when challenged with the
fully fractionated peptide library of ATr, coupled with Gram-negative specific inhibition
observed for the ATr single pooled fraction, prompted us to take an alternate approach to
peptide identification for this plant species. Instead of identifying the AMPs responsible
for the bioactivity seen for the pooled sample of ATr using the PepSAVI-MS approach,
translated transcriptome mining through in silico analysis was performed. Specifically,
181 AMPs have been predicted to be present within this plant species based on in silico
analyses leaving much room for discovery[314, 315]. Using a top-down and bottom-up
mass spectrometry approach, our collaborators were able to identify 127 proteins within
ATr, seven of which were predicted AMPs[316]. Amongst those seven was a lipopeptide
(ATr-LTP1) which was partially purified and tested against the ESKAPE panel as shown
in Figure 43. Specifically, this peptide demonstrated activity against both Gram-positive
organisms; S. aureus was inhibited by nearly 35% while E. faecium was inhibited by over
20%. However, the highest activity was seen for K. pneumoniae, where partially purified
ATr-LTP1 inhibited the population by over 40%. Conversely, the remaining Gramnegative organisms (A. baumannii, P. aeruginosa, and E. cloacae) were less impacted
by ATr-LTP1 and demonstrated inhibition values of less than 20% when challenged with
the peptide sample.
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Figure 43. Bioactivity of Amaranthus tricolor Partially Purified Lipopeptide ATrLTP1 Against ESKAPE. Data is represented as percent inhibition compared to no drug
controls following treatment with 50µM LTP1. Data points represent the average of 3
biological replicates per species. Error bars represent the mean ±SEM of the three
replicates. Asterisks represent P-value using Student’s t-test. P-value <0.05 *, <0.01 **,
<0.001 ***.
Based on the promising activity against K. pneumoniae, the peptide was further purified
and retested against K. pneumoniae at 50µM and 25µM as shown in Figure 44. At 50µM,
the peptide was able to inhibit growth by greater than 40% while 25µM challenge resulted
in 32% inhibition. Therefore, the MIC was found to be higher than the tested range. Due
to the difficulty in isolating this peptide, testing at higher concentrations could not be
performed and an MIC could not be determined.
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Figure 44. Bioactivity of Amaranthus tricolor Purified Lipopeptide ATr-LTP1
Against K. pneumoniae. Data is represented as percent inhibition compared to no drug
controls following treatment with 50µM and 25µM ATr-LTP1. Data points represent the
average of 3 biological replicates per species. Error bars represent the mean ±SEM of
the three replicates. Asterisks represent P-value using Student’s t-test. P-value <0.05 *,
<0.01 **, <0.001 ***.
When looking further within the transcriptome of A. tricolor, a defensin (ATr-Def1) was
identified[316] and a truncated version was synthesized for bioactivity screening. This
truncated peptide showed activity against the ESKAPE pathogens as depicted in Figure
45. Against S. aureus, ATr-Def1 led to over 50% inhibition at 50µM. The inhibition was
not considered Gram-positive specific, but S. aureus specific, as E. faecium was inhibited
by less than 10%. Further, the next highest amount of inhibition was observed against P.
aeruginosa where nearly 20% inhibition was reported. ATr-Def1 challenge resulted in less
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than 15% inhibition of K. pneumoniae and E. cloacae, while A. baumannii was completely
resistant to treatment at the concentration tested. This targeted approach led to a host of
AMPs being identified some of which showed antimicrobial activity against members of
the ESKAPE panel. Specifically, we observed K. pneumoniae specific activity for AMPLTP1 and S. aureus specific activity for ATr-Def1. This highlights the value of combining
the PepSAVI-MS pipeline with bioinformatics-based approaches to find promising AMP
candidates for therapeutic characterization.

Figure 45. Bioactivity of Amaranthus tricolor ATr-Def1 Against ESKAPE. Data is
represented as percent inhibition compared to no drug controls following treatment with
50µM ATr-Def1. Data points represent the average of 3 biological replicates per species.
Error bars represent the mean ±SEM of the three replicates. Asterisks represent P-value
using Student’s t-test. P-value <0.05 *, <0.01 **, <0.001 ***.
Capsicum chinense x frutescens (CC) a Hybrid Ghost Pepper Plant Displays GramNegative Specific Activity. Another plant, C. chinense x frutescens (CC), was evaluated
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using the same approach to AMP discovery as ATr, combining top-down and bottom-up
proteomics coupled with in silico predictions to identify potential AMPs for testing.
Through this, 14 potential AMPs with characterized sequences were identified in the
aerial tissue of CC out of the 115 predicted from the closely related C. chinense
proteome[317]. Through this, two AMPs termed CC-AMP1 and CC-AMP2 were identified.
CC-AMP1 was partially purified and was found to have activity against laboratory strains
of E. coli and K. pneumoniae based on testing by our collaborators. Because of this, CCAMP1 was suspected to have anti-Gram-negative activity and was therefore tested
against three of the multi-drug resistant pathogens (A. baumannii, P. aeruginosa, and E.
cloacae). There were high levels of inhibitory activity found for each pathogen as shown
in Figure 46. Specifically, when challenged with 70.16µM of CC-AMP1, E. cloacae was
inhibited by 75%. This was the lowest amount of inhibitory activity recorded, with CCAMP1 inhibiting A. baumannii and P. aeruginosa populations by 92% and 97%
respectively.
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Figure 46. Bioactivity of Capsicum chinense x frutescens CC-AMP1 Against APE.
Data is represented as percent inhibition compared to no drug controls following
treatment with 70.16µM CC-AMP. Data points represent the average of 3 biological
replicates per species. Error bars represent the mean ±SEM of the three replicates.
Asterisks represent P-value using Student’s t-test. P-value <0.05 *, <0.01 **, <0.001 ***.
Based on the substantial activity against A. baumannii and P. aeruginosa, the peptide
was then tested in a dose dependent manner against ESKAP isolates (Figure 47). It was
clear that the Gram-negative isolates were inhibited in a dose dependent manner,
however, for the Gram-positive isolates challenged, a similar level of activity was
observed at all concentrations tested. This further solidified our prediction that CC-AMP1
was specifically targeting Gram-negative organisms. The highest level of activity was
observed against A. baumannii and P. aeruginosa with over 90% inhibition recorded at
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the highest concentration tested (71µM). K. pneumoniae was also significantly influenced
by CC-AMP1 at the highest concentration tested with 83.7% inhibition observed. CCAMP1 was able to inhibit A. baumannii by greater than 90% at concentrations as low as
8.875 µM.

Figure 47. Bioactivity of Capsicum chinense x frutescens CC-AMP1 Peptide
Against ESKAP. Data is represented as percent inhibition compared to no drug controls
following treatment with CC-AMP at various concentrations. Data points represent the
average of 3 biological replicates per species. Error bars represent the mean ±SEM of
the three replicates. Asterisks represent P-value using Student’s t-test. P-value <0.05 *,
<0.01 **, <0.001 ***.
This led us to perform an MBC against A. baumannii to gain an understanding of the MOA
of the peptide, distinguishing if it functions as a bactericidal or bacteriostatic peptide. From
this data it was determined that the peptide was acting as a bactericidal agent against the
Gram-negative isolates as demonstrated by A. baumannii in Figure 48. From the dose
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dependent testing shown in Figure 47, the MIC against A. baumannii was defined as
8.875µM. As shown in Figure 48, at this concentration (between 17.2µM and 8.6µM), 0%
recovery is observed and therefore at the MIC, CC-AMP1 is acting as a bactericidal
peptide and killing the bacterial population. The peptide was able to eradicate over 90%
of the bacterial cells at concentrations ranging from 68.8µM-4.3 µM, further validating this
bactericidal MOA. Based on the similar levels of inhibition observed for K. pneumoniae,
P. aeruginosa and E. cloacae when compared to A. baumannii, it is reasonable to predict
that CC-AMP1 is also acting as a bactericidal peptide against the remaining Gramnegative ESKAPE pathogens. Within the CC plant, using the PepSAVI-MS approach, we
have identified an AMP that specifically targets Gram-negative microorganisms and acts
bactericidally at low concentrations. This provides another example of the power of using
bioinformatics and the PepSAVI-MS approach to discover AMPs from ethnobotanical
plant species and demonstrates how downstream biological testing can help define the
MOA of those peptides.
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Figure 48. Bactericidal Activity of CC-AMP1 Against A. baumannii. Data is
represented as percent recovery following treatment with CC-AMP at various
concentrations. Data points represent the average of 3 biological replicates. Error bars
represent the mean ±SEM of the three replicates. Asterisks represent P-value using
Student’s t-test comparing CFU/mL of treated samples to no-drug controls. P-value <0.05
*, <0.01 **, <0.001 ***.
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Discussion

Plants have been used since ancient times to treat human ailments, some of which are
still used today, such as garlic and honey. For example, in the fifth century B.C.
Hippocrates documented nearly 400 medicinal plants in detail[318]. Further, it is
estimated that there are between 250,000-500,000 species of plant on earth[301] leaving
many/most to be explored for medicinal purposes. Although there are currently no plantderived commercially available antibiotics, there are various plant-based compounds
used to treat human disease. Arguably, the most widely known is aspirin, isolated from
willow bark.

Antimicrobial peptides (AMPs) are small polymers consisting of amino acids that are
produced by all forms of life and possess antimicrobial activity. AMPs have served
therapeutically as a defense against invading bacterial pathogens since the introduction
of Gramicidin in 1939. Since then, various antimicrobial agents have been sourced from
natural materials including soil bacteria, plants, humans, and all forms of multicellular life.
For this study, we have attempted to harness the medicinal properties from plant species
in the form of AMPs in an attempt to combat the high levels of drug resistance seen for
the ESKAPE pathogens in the post-antibiotic era[319, 320].

Herein we have investigated the antibacterial potential of over 20 species of plant using
a novel PepSAVI-MS approach that has evolved over the past five years. The approach,
validated in 2017, has revealed multiple species of plant that contain novel RiPPs. The
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advantage to using this approach is highlighted when it is compared to other approaches
to natural product drug discovery. For example, bioassay guided fractionation is
considered a gold standard for natural products drug discovery. This approach initially
involves the isolation of material followed by bioactivity testing[321]. The bioactive
samples are then scaled up and re-tested for bioactivity. If still active, the sample is
subject to numerous rounds of chromatographic fractionation and subsequent bioactivity
testing until a single compound is deemed responsible for the activity[321]. The structure
of this compound is then deciphered, and the compound is further characterized for an
MOA. In theory, this is an excellent approach, however, multiple rounds of fractionation
are time consuming and result in the loss of sample each round. Further, many times the
activity of the compound is lost following fractionation due to the necessity of certain
compounds to interact with others to become toxic to the target organism, or the effects
of two compounds are additive and lead to the activity observed. Finally, the tedious effort
often results in the isolation of a compound that has already been discovered. The
PepSAVI-MS approach differs in that the initial isolation and testing step is eliminated.
Samples are initially fractionated and therefore bioactivity can be assigned to a smaller
pool of peptides very rapidly. There is also a lesser chance for false positive results due
to interacting or codependent peptides.

Over time our approach has evolved to become more efficient in identifying plant species
containing novel AMPs. This came in the form of screening pooled single fractions against
the ESKAPE pathogens and led to rapidly identifying plant species of interest prior to
implementing the full power of the PepSAVI-MS system. For example, during our
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investigation, the samples from the Mentha, Hyoscyamus, Silybum, and Calendula genre
demonstrated broad-spectrum antibacterial properties and are considered plants of
interest for the PepSAVI-MS pipeline. Conversely, samples from the genre Nasturtium,
Trifolium, Chichorium, Dodonaea, and Urtica yielded negligible bioactivity and could be
eliminated from further investigation. The categorization of nine plant species based on
bioactivity was therefore possible within one day. This can be compared to the minimum
of two weeks necessary to screen all nine species of plant against all six ESKAPE
pathogens if libraries of 47 fractions were initially tested.

The validated PepSAVI-MS pipeline was used to identify a novel peptide of the
Amaranthus tricolor (ATr) plant species which was published in 2019[314]. This peptide
is a proline rich RiPP AMP that exists in multiple peptidoforms in ATr. Proline-right AMPs
are unique in that many are able to inhibit microorganisms without membrane disruption
and instead have targets within the cell that ultimately lead to cell death[89, 322]. The
identification of proline-rich AMPs within plants is relatively new, as the first one was
identified in Brassica napus in 2015[323]. The proline-rich AMP of ATr, ATr-AMP1, was
found to exist as heterogeneous population with multiple isoforms that were partially
purified and demonstrated inhibitory activity against E. coli and S. aureus[314]. ATr-AMP1
is the second known AMP of ATr to be isolated and to demonstrate antimicrobial activity.
The PepSAVI-MS approach allowed for an unbiased look at this species that confirmed
the therapeutic potential of this plant. The MOA of ATr-AMP1 has yet to be characterized,
although this is a point of interest in our ongoing efforts. We will investigate whether the
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peptide indeed acts as other proline-rich AMPs to influence bacterial cells internally
without inducing membrane lysis.

The investigation that led to the identification of ATr-AMP1 then led us to consider this
species in more depth via transcriptome mining and proteomic validation. This resulted in
the identification of seven AMPs[315] and included one unclassified AMP, two snakins, a
defensin, and three lipid transfer proteins[316]. These were identified via bottom-up and
top-down proteomics. Bottom-up proteomics works to enumerate all peptides within the
plant sample, which are then compared to in silico predicted AMPs of ATr. Following this,
top-down proteomics enables the visualization of post-translational modifications (PTMs)
and full-length peptides in various isoforms. Two of the AMPs identified through these
studies were evaluated for bioactivity against the ESKAPE pathogens. Specifically, ATrLTP1, a lipopeptide, was determined to have activity against K. pneumoniae, however,
an MIC was not able to be established. This level of activity was not surprising, however,
based on previous studies investigating homologs of this lipopeptide reporting similarly
low levels of bioactivity[324, 325].

The other peptide identified via top-down proteomics was a defensin (ATr-Def1) however
the concentration of peptide was too low to isolate and purify in its native form. Therefore,
a truncated version containing the gamma core region of the peptide was synthesized
and assessed for bioactivity. It has been shown that the gamma core of defensins alone
are less effective at inhibiting target organisms than their full-length parent peptides, but
they do function as a predictor of antimicrobial activity[326]. Thus, screening the gamma-
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core region alone would allow us to determine whether the full-length peptide was worth
pursuing further without the difficulty of extracting the lowly expressed peptide possessing
PTMs. Screening of ATr-Def1 revealed activity against S. aureus which prompted us to
attempt to determine whether the peptide would be stable in human serum and therefore
a good candidate for in vivo applications. In order to do this, purified peptide was added
directly to human serum and evaluated via mass spectrometry at various timepoints.
Although purified peptide in buffer could be detected on the mass spectrometer, there
was no detection within the serum/peptide mixture indicating that either that peptide itself
is degraded very rapidly in serum (within 10 minutes) or it is aggregating with other
peptides or proteins within the human serum (data not shown). Therefore, although we
see Gram-positive activity, ATr-Def1 in its truncated form is not an ideal candidate and
further testing with the native peptide is necessary to fully understand the potential of this
AMP as a therapeutic.

A similar approach to peptide identification was implemented in C. chinense x frutescens
(CC) and revealed yet another AMP candidate with potential. Transcriptome mining of the
translated proteome of the closest relative, C. chinense, in silico led to the validation of
15 AMPs present within CC via bottom-up proteomics[317]. In addition to this, two novel
AMPs were identified with little homology to known AMPs. One of those, CC-AMP1 was
tested and found to be Gram-negative specific and to function as a bactericidal agent.
Based on these results, our collaborators further characterized the MOA of CC-AMP1 by
performing membrane permeability assays and determined that the bactericidal activity
was due to a membrane permeabilizing event of both the outer and inner
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membranes[317]. Future studies to characterize this AMP will be aimed at determining
whether this AMP is effective at inhibiting fungal isolates as well. Members of the
Capsicum genus have been described as having medicinal properties most widely due to
the production of capsacin. It is not a peptide itself, but has been shown to have
antibacterial

activity

against

Bacillus

subtilis

functioning

through

membrane

disruption[327] similar to CC-AMP1. The Capsicum chinense x frutescens species
specifically is able to relieve pain associated with arthritis, gastritis, indigestion, and many
other disorders[327]. Further, although most treatments involve the use of the fruit or the
entire plant, where capsaicins are produced, leaves of the C. frutescens species have
been used to treat boils, abscesses and wounds in the Fijian culture[328]. This
antibacterial activity is in line with the antibacterial activity we observe from the CC-AMP1
peptide isolated from the aerial tissue of the pre-fruiting plant. Thus, the healing properties
within the leaves of C. frutescens used by the Fijians could be due to the presence of
bioactive AMPs.

Over the years our collaboration with the Hicks Laboratory at UNC-Chapel Hill has
provided the data necessary to prove the usefulness and versatility of the PepSAVI-MS
pipeline to identify RiPP AMPs effective against multi-drug resistant bacteria.
Consequently, this contributes to the knowledge and diversity in which this pipeline can
be applied. We have also worked to troubleshoot and enhance the efficiency of the
pipeline through more targeted approaches which implement bioinformatics and full
coverage forms of mass spectrometry to identify leads. Allowing for this system to evolve
has led to the identification of novel bioactive peptides that are now ready for full
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characterization as potential therapeutics. Throughout this process we have identified
various plant species with a plethora of unclassified AMPs that simply need investigating.
This project serves as a foundation for future studies, generating leads for the next phase
of success using PepSAVI-MS. Ongoing investigations will continue to unveil novel
peptide products that will contribute to the ongoing fight against multi-drug resistant
bacteria while contributing legitimizing knowledge to our understanding of medicinal
plants.
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Chapter 5: Concluding Remarks and Future Directions

Final Discussion

Chapter 2. Acinetobacter baumannii is a multi-drug resistant pathogen responsible for a
variety of diseases, but it is most known for its ability to resist carbapenem and its high
transmissibility in hospitals. This organism is responsible for thousands of deaths yearly
within the United States alone. The difficulty in treating A. baumannii infections of multidrug resistant strains is exacerbated when the infection manifests in the form of a biofilm.
Bacterial biofilms are known to be 1000x more resistant than their planktonically growing
counterparts due to innate tolerance. This is in the form of an extracellular matrix (ECM)
produced during biofilm formation that consists of polysaccharides, eDNA and proteins,
all creating a seemingly impenetrable barrier of protection for the bacterial population
dwelling within.

In order to identify factors important for biofilm formation in A. baumannii, a variety of
transposon mutants were screed for their ability to form biofilms. We were able to
randomly select 2,648 mutants out of a pool of 10,000 and categorize them
phenotypically. Categories consisted of putative positive effectors of biofilm with tn
mutants exhibiting decreased biofilm formation and putative negative effectors of biofilms
formation that were unable to produce biofilms with substantial biomass. This analysis
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led to the identification of over 100 strains, nearly 50 of which were verified to generate a
biofilm biomass that was either 2-fold greater or 2-fold lesser than the biofilm formed by
the wildtype AB5075 strain. From this group, 16 were pursued for ECM characterization.

Of these mutant strains, eight are presumed negative effectors and eight were presumed
positive effectors of biofilm formation. Specifically, each was assessed for their adherence
capacity through real-time tracking of impedance. In addition to this, eDNA composition
of mature biofilms was quantified and protein and polysaccharide content was assessed
at late and early-stage biofilm formation. Each mutant exhibited a unique ECM profile
based on these results that was then used to implicate their roles in the biofilm formation
process of A. baumannii.

Our approach was validated in part by the observation that four different tn insertion
mutants of the biofilm associated protein Bap, were deficient in biofilm formation. Further,
we observed a decrease in eDNA within the bap::tn mutant strain. Due to the essentiality
of Bap in stabilizing mature biofilms formed by A. baumannii, we predict that Bap could
serve as a scaffold for eDNA binding within mature biofilms and contribute to biofilm
stability, in part, through this mechanism.

We have also identified an uncharacterized lysogenic phage within AB5075 that
contributes to biofilms formation likely through cell lysis as a means of contributing ECM
components to strengthen the biofilm as has been shown in other organisms[182-184].
Further, we show that peptidoglycan editing as well as amino acid transport contribute to
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the formation and maintenance of A. baumannii biofilms. We also reveal a variety of
metabolic enzymes that positively and negatively influence biofilms produced by AB5075.
Specifically, it was found that gapN::tn, typically expressed when levels of free phosphate
ions are low, formed a weakened biofilm. Therefore, it is probable that phosphate
limitation and resulting metabolic shifts induce biofilm formation. Alternatively, the gene
adjacent to gapN, gntK, is involved in producing intermediates of the Entner-Doudoroff
pathway of carbon metabolism and negatively influences biofilm formation likely through
the indirect downregulation of polysaccharide production.

This work has also implicated a necessity for an intact SOS response system for proper
biofilm formation. Conversely, we have shown that a member of the DNA damage
response negatively impacts biofilm formation, likely through the repression of another
biofilm effector (ddrR) that positively regulates biofilm associated genes. A similar
mechanism is proposed for an uncharacterized transcription factor that is adjacent to a
gene that is upregulated in A. baumannii biofilms. We were also able to demonstrate that
the over initiation of translation and dysregulation of replication lead to increases in biofilm
biomass. Finally, we have begun to characterize a component of a putative type IV
secretion system that when disrupted, alters the biofilm architecture, and likely leads to
bacterial aggregation instead of adherence.

Out of over 2,600 mutants investigated, the biofilm formed by the uspG::tn mutant
(referred to as usp::tn in Chapter 2) was the most substantial. Specifically, this strain was
able to form a biofilm with over 8-fold more biomass than the wildtype AB5075 strain. This
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prompted a full investigation into the functionality of this newly discovered universal stress
protein of A. baumannii and served as the topic of Chapter 3. In doing so, we have
uncovered links between UspG and some of the tn mutants characterized in this chapter
that may help to better explain the biofilm phenotypes demonstrated and will be discussed
in brief in the following section.

There are still many questions that remain concerning the mechanism behind biofilm
formation and maintenance in A. baumannii due to the complexity, however, this work
has uncovered key proteins that influence this system. It is the hope that these findings
will contribute to our ability to fight these infections through our contribution of new
molecular targets for biofilm eradication.

Chapter 3. Universal stress proteins are as the name suggests, universally expressed
following exposure to a variety of different stresses. Our initial investigation into biofilm
effectors of A. baumannii led to the identification of an uncharacterized member of the
Usp (UspA) family (Pfam PF00582). Our results indicated the role of UspG as a negative
effector of biofilm formation based on the increase in biofilm formation of over 8-fold in
the tn mutant strain. This was surprising due to the demonstration of other organisms
such as P. aeruginosa showing an increase in Usp expression in biofilms[210, 211].
Arguably, the most drastic phenotype observed was the defect in growth accompanied
by a large spike in adhesion. Within the uspG::tn mutant, we see the upregulation of pgaA,
which is involved in polysaccharide formation and is an important structural component
of biofilms, particularly during the earlier stages of adherence[44]. In addition, we see an
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upregulation in a variety of ribosomal genes, which is also observed in biofilms formed by
A. baumannii[44]. However, genes shown to be upregulated in biofilms of A. baumannii
were conversely downregulated in our uspG::tn strain following 3-hours of growth. For
example, the paa operon as well as the csu operon are upregulated in biofilms but were
downregulated in our study[44]. Therefore, UspG may be influencing certain components
within the cell that lead to the dysregulated production of biofilm products without
necessarily directly influencing the system overall. However, the csu operon is
upregulated nearly 200-fold in the biofilm population of some A. baumannii strains
compared to their planktonic counterparts[44] indicating that their downregulation in our
planktonic population may be a result of the growth arrested state instead of UspG
specific influence.

Another important phenotype observed was the inability of uspG::tn strain to survive in
the presence of blood. This indicates that survival within the host is dependent in some
part to this regulator. In an assessment of A. baumannii virulence and survival within
Galleria mellonella, a tn mutant of ABUW_1763 (UspG herein, annotated as UspA in the
cited work) was unable to survive[150], which supports this prediction.

Chapter 4. Plants serve as a valuable source for the discovery of novel AMPs with
antibacterial properties due to their diversity, abundance, and previously described
medicinal properties. RiPPs in particular are advantageous due to their target specificity,
novel MOAs and natural origin[303, 329]. There are currently 41 classes of RiPPs across
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the three domains of life and these numbers are projected to continue to rise[306] as
more investigations such as ours are conducted.

In this study, we were able to identify a variety of plant species that conferred antibacterial
activity against both Gram-positive and Gram-negative multi-drug resistant organisms.
Further, the PepSAVI-MS approach allowed us to narrow in on specific peptide fractions
containing RiPPs that are likely novel. It will be important to continue our investigation
into these fractions.

Through the use of a rapid single fraction screening approach we were able to identify
plant species from the genre Mentha, Hyoscyamus, Silybum, and Calendula as AMP
producing plants of interest. The Mentha genus was found to be the most bioactive with
inhibition observed against all members of the ESKAPE panel. There are nearly 30
species within this genre, many of which are known to possess medicinal qualities.
Members of the Mentha genus have been tested for antibacterial activity following
essential oil extraction. The major components within the essential oils were found to be
phenolic compounds. To our knowledge, this is the first instance for AMP screening within
this genus.

Future Directions

Chapter 2. The investigation into the biofilm forming mechanics of A. baumannii has
revealed nearly 50 genes that influence biofilm formation in a statistically substantial way.
Of these, only 16 underwent ECM and attachment profiling and one was subject to
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classical molecular function assessment. This highlights the endless opportunities for
future exploration based on the findings of this chapter. However, there are experiments
that will validate a few of the presumed influences of the top genes that will further our
understanding of biofilm formation.

We were able to uncover genes involved in the regulation of carbon metabolism and
demonstrated that gluconate kinase gntK is a negative effector of biofilm formation in A.
baumannii and its involvement leads to a decrease in polysaccharide production, perhaps
though the accumulation of D-gluconate. Therefore, measuring levels of this metabolite
will be implemented.

Alternatively, gapN, a non-phosphorylating NADP+ dependent glyceraldehyde-3phosphate dehydrogenase positively influences biofilm formation. Specifically, GapN
leads to the production of 3-phosphoglycerate through a modified Entner-Doudoroff
pathway that can produce NADH when levels of inorganic phosphate are low. Therefore,
levels of free phosphate within A. baumannii biofilms will be evaluated.

Additionally, mmsA1, encoding methylmalonate semialdehyde dehydrogenase that is
involved in the citrate cycle as well as other metabolic pathways was found to be a positive
regulator of surface-liquid interface biofilm formation but also a negative regulator of
pellicle formation, in effect, acting as a metabolic switch to induce changes in population
behavior based on changes to metabolism. This was exhibited within the mmsA1::tn
mutant in which a hypermucovisous pellicle was formed at the expense of surface
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attachment. We predict that the pellicle is composed of polysaccharides due to the
consistency of the culture pellicle and previous literature on the subject, but this is yet to
be verified experimentally. However, in Chapter 3, when investigating the influence of
uspG::tn on exponential growth, we observed a substantial decrease in mmsA1
transcription (downregulation of over 100-fold) as well as an upregulation of pgaA,
responsible for polysaccharide production in the uspG::tn mutant strain. This is
accompanied by the observation of increased biofilm formation by the uspG::tn mutant
that was found to be in part due to the overproduction of polysaccharides, particularly in
the initial stages of biofilm formation.

Chapter 3. First, it will be important to understand and address the lack of full
complementation in the uspG+ (C) strain. This inability to complement wildtype
phenotypes fully is observed for other Usp genes in A. baumannii such as UspA in
ATCC17978 but was also demonstrated in a study of virulence within AB5075[150]. This
inability to complement the same gene (ABUW_1763) in the same background (AB5075)
using an alternate vector highlights a universal problem. However, ways to combat this
will be to explore other vectors, for example multi-copy plasmids or a plasmid with an
inducible promoter that can be overexpressed. Further, the construct designed in this
study contains a histidine tag that could be interfering with the ability of the protein to form
dimers or interact with other proteins that elicit its function. To investigate this, different
techniques for tag attachment will be explored. For example, adding the histidine marker
to the other end of the protein. A tag is important because of our next set of future
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directions that include the investigation of interaction partners, ligands, and dimerization
activity.

Specifically, it will be of great interest to determine interaction partners of UspG through
in silico predictions followed by protein purification and pull-down experiment to determine
the interaction partners using LCMS/MS. The in silico analysis will identify proteins within
the translated genome of AB5075 that contain a Usp domain. It will also be important to
determine whether, like Usps of E. coli, heterodimerization occurs between different Usp
paralogs of A. baumannii. Further, although it is highly likely, it will be necessary to confirm
the interaction of UspG with itself. These interaction studies can be performed using a
bacterial two-hybrid (BATCH) approach. Following the pull-down experiments to identify
interaction partners, the BATCH approach can be implemented to confirm these
interactions. Further, specific residues of UspG responsible for the interactions will be
assessed through the use of site-directed mutagenesis on both UspG and the defined
interaction partner.

Purified UspG will also be used to assess ligand partners, in particular whether
phosphorylation occurs and if ATP or AMP binding is possible. Further, identifying the
exact conditions of stress that induce transcription will be determined. This can be
achieved through qPCR analysis following exposure to a variety of stressors. In particular,
oxidative stress, aminoglycoside exposure, biocide exposure, and heat exposure.
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It will be of interest to investigate the role of UspG in desiccation survival, which is a major
contributor of A. baumannii infection rates and transmission. We predict that UspG is
upregulated under these conditions and likely under the control of BfmR. This is partly
due to evidence that BfmR, a response regulator that mediates desiccation tolerance,
also regulates stress responses such as nutrient starvation and oxidative stress[74], each
of which are influenced by UspG.

Long-term studies would be aimed at investigating the regulators of UspG. Based on our
findings, these are likely linked to other regulators of oxidative stress. This includes
investigating the implication of Zur and zinc limitation in controlling the expression of
uspG. This hypothesis is based on the observation that Δzur is unable to resist oxidative
stress and has higher levels of ROS produced[330]. Levels of glutathione were also
increased along with ratios of NAD+/NADH and ADP/ATP, which could be similar to our
uspG::tn strain.

Finally, evaluating the protein composition of the uspG::tn mutant strain as compared to
AB5075 using proteomics during early and late exponential phase will uncover insights
into the influence of UspG. In particular we will further understand the unique role UspG
plays during exponential phase, which is unique to this species. Evaluating the
metabolome of uspG::tn and AB5075 will also validate some of our questions concerning
the metabolic and energetic state of the cell in the absence of UspG. We can evaluate if
ATP pools or cofactor ratios are skewed to reflect a state of oxidative stress in the mutant
strain. We will also be able to detect whether acetate is accumulated. ROS levels, which
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we predict to be upregulated will also be quantified using the 2′,7′-dichlorofluorescin
diacetate or hydroxylpheyl fluorescein dyes[331]. Antioxidant tracking kits are also
available and could be used to validate the lower levels of catalase and superoxide
dismutase observed transcriptionally in the uspG::tn mutant. By evaluating the
transcription and production of these factors in the uspG::tn mutant following exposure to
a variety of stresses that induce uspG expression we will determine whether these
components of the oxidative stress response are under the control of UspG.

To understand the role of UspG in biofilm regulation and the increase in biofilm formation
observed in the uspG::tn strain, levels of glutamate should will be assessed, as this could
hold the key to better biofilm formation. Glutamate is necessary for the formation of
peptidoglycan and may influence the cell envelope as a whole. We predict that glutamate
is accumulated within our uspG- (M) based on the upregulation of putA, which converts
proline to L-glutamate in addition to the upregulation of pgaA.

Diguanylate cyclase is also a contributor to biofilm formation through the formation of
cyclic di-GMP which accumulates to signal biofilm formation in a variety of bacteria. A
gene encoding diguanylate cyclase is located directly adjacent to uspG, and was
upregulated nearly 10-fold in the uspG::tn mutant following 3 hours of growth. Therefore,
it is probably that expression is translated to cyclic di-GMP production and thus the
increased biofilm phenotype observed. Specifically, diguanylate cyclase is accumulated
within biofilms and acts as a secondary messenger to induce a variety of biofilm promoting
factors that promote motility, adhesins and capsule production[23]. Based on the
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upregulation of this gene, we will investigate the cyclic di-GMP levels within the uspG(M) strain with the prediction that levels will be elevated.

Chapter 4. Investigating the components of species of plant that exhibited bioactivity will
be important to continue our efforts of AMP discovery. In particular, investigating the
Mentha, Hyoscyamus, and Calenula genre samples for antibacterial activity through
generating and screening fully fractionated libraries against the ESKAPE panel. From
this, we will be able to isolate and purify leads similar to the approach taken for ATr and
CC samples. Identifying the bioavailability of the lead AMPs identified within this work will
also be a goal of this project. Through determining the stability within serum as well as
their toxicity towards human cell lines and hemolytic properties we will have a better
understanding of their therapeutic potential.

We have also uncovered fractions within the fractionated libraries that require follow up
screening to identify the RiPPs contributing to the antibacterial activity observed. For
example, antibacterial activity against A. baumannii and K. pneumoniae was isolated to
fractions 18-23 of the Silybum spp. library. Further, fractions 26 and 33 of the Linum spp.
library contain RiPPs with activity against E. cloacae. These samples should be integrated
back into the pipeline for statistical analysis to quantify abundance via LCMS/MS. This
should then be followed up with purification of the bioactive peptide or peptides and finally
sequence and structure elucidation. Throughout this process, peptides will be screened
for their inhibitory activity.
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Long term goals of this project include upscaling the scope of ethnobotanical species to
enter the pipeline. By increasing the number of plant species tested using the pooled,
single fraction screening approach, we will have more opportunities to uncover novel
AMPs more quickly. For example, up to 18 species of plant can be tested in biological
triplicate against a single species of bacteria using a 96-well plate format that includes
anti-evaporation measures and the proper controls. Another approach could be the
generation of single fraction plant libraries containing 56 different AMP samples to be
screened in a high-throughput manner against the EKSAPE pathogens. In essence, a 96well plate-based library of plant species could further fast-track the bioactive plant
identification process and would reveal which are effective against which of the ESKAPE
pathogens. Without screening in biological triplicate, material would be saved, however
variations in bioactivity due to bio replicate variability would need to be considered when
analyzing results. This variability could be calculated using the average variation of a
single species across biological replicates using all previous screens. Therefore, the
PepSAVI-MS approach would be employed more efficiently, only generating fully
fractionated libraries for the plant species with the most potential based on the target
organism of interest.
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Appendix I: Supplemental Figures for Chapter 2

Supplementary Figure A1. Transposon Mutants of A. baumannii Demonstrating
Increased Biofilm Formation. Shown are the Z-scores (see methods) for each mutant
demonstrating an increase in biofilm formation with a cutoff of ≥ 12.5th percentile for each
plate assayed.
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Supplemental Figure A2. Transposon Mutants of A. baumannii Demonstrating
Decreased Biofilm Formation. Shown are the Z-scores (see methods) for each mutant
demonstrating an increase in biofilm formation with a cutoff of ≤ 12.5th percentile for each
assay plate.
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Supplemental Figure A3. Lead Mutants Demonstrate Significant Changes in Biofilm
Biomass. Each mutant was seeded in sextuplicate with biofilms assessed after 24 hours
of growth. (A) Blue indicates samples that had an increase in biofilm formation, (B) pink
indicates mutants that had a decrease in biofilm formation; both as compared to wildtype
using CV assays. Error bars are shown ±SEM. Statistical significance was assessed
using Student’s t-test, P-value: * =0.01 ; ** =0.001 ; *** = 0.0001.

Supplemental Figure A4. Verification of Screen Integrity by Complementation
Analysis. Each strain was seeded in sextuplicate into 96-well plates, with biofilms
assessed after 24 hours of growth via CV staining. Empty vector: pMQ557 in tn strain
background. Error bars are shown ±SEM. Statistical significance was assessed using
Student’s t-test, P-value: * =0.01 ; ** =0.001 ; *** = 0.0001. WT = Wild-Type, M = Mutant,
C = Complemented strain. The wild-type and mutant strains all contained an empty copy
of the pMQ557 complementing vector.
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Supplemental Figure A5. Real-Time Profiling of Biofilm Formation for Mutants
Exhibiting Enhanced Biomass in CV Screens. Each mutant was seeded into the wells
of gold-plated 96-well plates in biological triplicate and technical duplicate at an OD600 of
0.05. Reads were taken every five minutes over a 72h growth period. Blue indicates
mutants with increased biofilm formation during CV staining, whilst the wildtype is shown
in black in each case. Error bars are shown ±SEM.
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Supplemental Figure A6. Real-Time Profiling of Biofilm Formation for Mutants
Exhibiting Diminished Biomass in CV Screens. Each mutant was seeded into the wells
of gold-plated 96-well plates in biological triplicate and technical duplicate at an OD600 of
0.05. Reads were taken every five minutes over a 72h growth period. Pink indicates
mutants with decreased biofilm formation during CV staining, whilst the wildtype is shown
in black in each case. Error bars are shown ±SEM.
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Supplemental Figure A7. Growth Assessment of All Mutants. Each mutant was
seeded into the wells of a 96-well plates in biological triplicate at an OD600 of 0.05. Reads
(OD600) were taken every fifteen minutes over 15h. Blue indicates strains with increased
biofilm formation during CV staining, whilst pink indicates strains that had a defect in
biofilm formation. Wildtype is shown in black in each case. Error bars are shown ±SEM.
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Supplemental Figure A8. Pellicle Formation and Hypermucoviscosity of
mmsA1::tn. (A) Viscosity test for the mutant using a sterile tip. (B) Samples were
inoculated with a single colony prior to incubation under static conditions at 37°C for 24
hours.
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Appendix II: Supplemental Tables for Chapter 2
Supplemental Table A1. Bacterial Strains and Plasmids.
Strain Name
Gene
ID/Description
tnab1_kr130917p01q113 ABUW_0133 tnab1_kr121119p01q189 ABUW_0201 gabP
tnab1_kr121119p04q148 ABUW_0570 tnab1_kr130913p07q112 ABUW_0885 bap
tnab1_kr130913p04q101 ABUW_0983 hda
tnab1_kr121210p04q115 ABUW_0999 ruvB
tnab1_kr121204p05q144 ABUW_1189 ldtJ
tnab1_kr121213p03q109 ABUW_1763 uspA
tnab1_jr130919p01q142 ABUW_2431 umuDAb
tnab1_kr130916p04q169 ABUW_2655 tnab1_kr121119p04q136 ABUW_3390 gapN
tnab1_kr130917p09q181 ABUW_3391 gntK
tnab1_kr121203p04q142 ABUW_3421 folA
tnab1_kr121119p04q144 ABUW_3783 mmsA1
tnab1_kr121203p04q151 ABUW_3809 tnab1_kr130913p04q147 ABUW_4114 traH
AB5075
Wildtype Strain
JLA2878
ABUW_1763 ABUW_1763::tn with pMQ557 EV
JLA2879
ABUW_1763 ABUW_1763::tn with complement
pMQ557::ABUW_1763
JLA2887
AB075 with pMQ557 EV
Plasmid
pMQ557 cloning vector
Gift: Dr. R. Shanks, University of
for complementation
Pittsburg
EV: empty vector
Supplemental Table A2. Primers Used in This Study.
Primer
Sequence
OL5750
ATGTCTCGAGTGGCGATAATATAACCATA
ABUW_1763 F ACGATAACAAG
OL5751
ABUW_1763 R
OL4163
pMQ557 F
OL4164
pMQ557 R
T261

ATGTGGTACCTTAGTGGTGGTGGTGGTG
GTGTTCAGTTACGACCAATACTGGCAC
ATCTTCTCTCATCCGCCAAA

Source
[144]
[144]
[144]
[144]
[144]
[144]
[144]
[144]
[144]
[144]
[144]
[144]
[144]
[144]
[144]
[144]
[143]

This study
This study
This study

Enzyme
XhoI

Ref.

KpnI

This study

This study

This study

CTGTTTCTCCATACCCGTAG

This study

CAAATCCTATTGTATGGATTAGTCGAGC

This study
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Supplemental Table A2. Primers Used in This Study. (Continued)
T262
GTATGCTATACGAAGTTATGGCGC
T263

TGAGCTTTTTAGCTCGACTAATCCAT

This study

[144]

Enzyme: Restriction enzyme used. Ref.: reference. Restriction sites are underlined. His6 tag is bold and italicized.
Supplemental Table A3. Mutant Strains Identified as Producing Significantly
Greater Biofilm Biomass from Crystal Violet Screens.
ID
Gene
Description
ZScore
ABUW_3607 putative general secretion pathway protein
10.54
ABUW_3391 gntK
shikimate kinase
6.58
ABUW_2819 hypothetical protein
4.46
ABUW_0989 tRNA/rRNA methyltransferase
4.17
ABUW_3470 N-acyl-phosphatidylethanolamine -hydrolysing
4.11
phospholipase D
ABUW_3017 integrase
3.76
ABUW_2276 transcriptional regulator, ArsR family
3.75
ABUW_1595 ion transport protein
3.65
ABUW_3595 nusG
transcription termination/antitermination factor
3.64
NusG
ABUW_2699 hypothetical protein
3.63
ABUW_0133 ribosomal protein S30EA/sigma 54 modulation
3.61
protein
ABUW_0218 aldo-keto reductase
3.61
ABUW_1816 aro1
3-deoxy-7-phosphoheptulonate synthase
3.50
ABUW_2368 transcriptional regulator, LysR family
3.50
ABUW_0625 sporulation related domain-containing protein
3.33
ABUW_3809 transcriptional regulator, GntR family
3.31
ABUW_0739 hypothetical protein
3.16
ABUW_2367 chromate transporter
3.14
ABUW_1637 oxidoreductase short-chain
3.12
dehydrogenase/reductase family
ABUW_1300 stress-responsive protein Ish1
3.01
ABUW_0585 two-component system histidine kinase sensor
2.98
component
ABUW_3563 transcriptional regulator, IclR family
2.96
ABUW_1791 hypothetical protein
2.96
ABUW_3439 hypothetical protein
2.92
ABUW_0601 hypothetical protein
2.89
ABUW_4100 conjugative transfer system protein TraK
2.88
ABUW_0574 phage-related tail completion protein (GPR-like)
2.88
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Supplemental Table A3. Mutant Strains Identified as Producing Significantly
Greater Biofilm Biomass from Crystal Violet Screens. (Continued)
ABUW_4102 protein-disulfide isomerase
2.87
ABUW_2131 acoA
acetoin:2,6-dichlorophenolindophenol
2.87
oxidoreductase alpha subunit
ABUW_0981 purM
phosphoribosylformylglycinamidine cyclo-ligase
2.85
ABUW_0097 serB
phosphoserine phosphatase
2.81
ABUW_0105 phoR
phosphate regulon sensor kinase PhoR
2.74
ABUW_1184 ABC transporter, ATP-binding protein
2.70
ABUW_1078 major facilitator family transporter
2.65
ABUW_1808 hypothetical protein
2.65
ABUW_1466 hypothetical protein
2.64
ABUW_0912 glpD
glycerol-3-phosphate dehydrogenase
2.61
ABUW_0539 hypothetical protein
2.51
ABUW_3228 pcoA
copper resistance protein A
2.50
ABUW_0192 hypothetical protein
2.50
ABUW_1806 ilvA1
threonine dehydratase
2.49
ABUW_2932 hypothetical protein
2.48
ABUW_1754 acetyltransferase gnat family
2.47
ABUW_3105 thiD
putative phosphomethylpyrimidine kinase
2.46
ABUW_2188 L-lysine 6-monooxygenase/L-ornithine 52.45
monooxygenase
ABUW_3127 ligA
DNA ligase, NAD-dependent
2.44
ABUW_0914 diaglycerol kinase catalytic domain-containing
2.42
protein
ABUW_1649 hypothetical protein
2.41
ABUW_2090 4-hydroxybenzoate transporter
2.41
ABUW_2278 permease
2.36
ABUW_2941 thiamine pyrophosphate enzyme domain protein
2.36
TPP-binding
ABUW_2320 transcriptional Regulator, LysR family
2.35
ABUW_3512 glutathione-regulated potassium-efflux system
2.34
protein KefB
ABUW_0983 hda
DnaA family protein
2.33
ABUW_0491 sspB
stringent starvation protein B
2.32
ABUW_2988 transcriptional regulator, LysR family
2.31
ABUW_3702 hypothetical protein
2.28
ABUW_2194 acyl-CoA dehydrogenase, middle domain protein
2.27
ABUW_1974 adeA
multidrug efflux protein AdeA
2.26
ABUW_2933 aldose 1-epimerase
2.21
ABUW_2095 transcriptional regulator, LysR family
2.20
ABUW_0088 hypothetical protein
2.16
ABUW_0136 dsbD
thiol:disulfide interchange protein
2.16
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ABUW_0070 fahA
fumarylacetoacetase
2.15
ABUW_0385 ttg2C
toluene tolerance efflux transporter
2.14
ABUW_2261 MotA/TolQ/ExbB proton channel
2.13
ABUW_0029 transcriptional regulator, LysR family
2.10
ABUW_1658 hypothetical protein
2.01
ABUW_0724 membrane protein involved in aromatic
2.01
hydrocarbon degradation
ABUW_2819 hypothetical protein
1.99
ABUW_2431 umuDAb DNA damage response transcriptional regulator
1.99
ABUW_4114 traH
TraH family protein
1.98
ABUW_3333 DnaJ/SEA domain-containing protein
1.97
ABUW_2528 paaC
3-hydroxyacyl-CoA dehydrogenase
1.97
ABUW_2655 hypothetical protein
1.96
ABUW_1244 mrdB
rod shape-determining protein RodA (EsvE3)
1.91
ABUW_3302 relA
GTP pyrophosphokinase (ppGpp synthetase I)
1.90
ABUW_2216 rpsT
ribosomal protein S20
1.81
ABUW_1763 usp
Universal stress protein A domain
1.56
Supplemental Table A4. Mutant Strains Identified as Producing Significantly Less
Biofilm Biomass from Crystal Violet Screens.
ID
Gene
Description
ZScore
ABUW_3421 folA
dihydrofolate reductase
-1.19
ABUW_0138 est
esterase
-1.24
ABUW_0188 GGDEF family protein
-1.25
ABUW_0443 prlC
oligopeptidase A
-1.26
ABUW_0263 hypothetical protein
-1.27
ABUW_3133 coaX
pantothenate kinase, type III
-1.29
ABUW_3387 leucine carboxyl methyltransferase
-1.31
ABUW_0976 comA
competence factor involved in DNA uptake
-1.32
ABUW_2372 hypothetical protein
-1.36
ABUW_2843 NADH pyrophosphatase
-1.37
ABUW_2626 neuraminidase domain-containing protein
-1.41
ABUW_3242 fadL
FilD
-1.43
ABUW_0876 sucD
succinyl-CoA synthetase, alpha subunit
-1.43
ABUW_2917 yhgI
IscR-regulated protein YhgI
-1.44
ABUW_0698 flavodoxin/nitric oxide synthase
-1.45
ABUW_3694 protein YegH
-1.45
ABUW_1555 ppsA
phosphoenolpyruvate synthase
-1.46
ABUW_2288 hypothetical protein
-1.47
ABUW_0117 hypothetical protein
-1.47
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ABUW_0879 hypothetical protein
-1.49
ABUW_1828 hypothetical protein
-1.50
ABUW_0229 transcriptional regulator, AraC family
-1.50
ABUW_2769 acetyl-hydrolase
-1.52
ABUW_2878 ureJ
urease accessory protein J
-1.52
ABUW_3806 acnD
2-methylisocitrate dehydratase, Fe/S-dependent
-1.53
ABUW_2925 pit
phosphate transporter
-1.56
ABUW_0250 hisB
imidazoleglycerol-phosphate dehydratase
-1.56
ABUW_3439 hypothetical protein
-1.56
ABUW_3389 proA
glutamate-5-semialdehyde dehydrogenase
-1.57
ABUW_3385 prc
carboxy- protease
-1.58
ABUW_0182 two-component system hybrid histidine
-1.58
kinase/response regulator
ABUW_1068 slyD
peptidyl-prolyl cis-trans isomerase, FKBP-type
-1.59
ABUW_2549 GntR-type transcription regulator HTH
-1.59
ABUW_1058 2-nitropropane dioxygenase
-1.59
ABUW_3390 gapN
aldehyde dehydrogenase
-1.61
ABUW_0093 nusB
transcription antitermination factor NusB
-1.62
ABUW_2503 cytochrome B561
-1.62
ABUW_3025 hypothetical protein
-1.65
ABUW_0346 hypothetical protein
-1.66
ABUW_0390 hydrolase, NUDIX family protein
-1.66
ABUW_0722 cysH
phosphoadenosine phosphosulfate reductase
-1.66
ABUW_0643 cysI
sulfite reductase
-1.67
ABUW_2921 formylglycine-generating sulfatase enzyme domain- -1.67
containing protein
ABUW_0487 acyl-CoA dehydrogenase
-1.72
ABUW_3725 transporter, drug/metabolite exporter family
-1.72
ABUW_0932 non-ribosomal peptide synthetase
-1.74
ABUW_3639 gacA
response regulator
-1.74
ABUW_0711 intracellular protease, PfpI family
-1.75
ABUW_3862 ileS
isoleucyl-tRNA synthetase
-1.76
ABUW_3326 copC
copper resistance protein CopC
-1.76
ABUW_0885 biofilm-associated protein
-1.76
ABUW_0885 biofilm-associated protein
-1.77
ABUW_0835 hypothetical protein
-1.77
ABUW_1002 purL
phosphoribosylformylglycinamidine synthase
-1.79
ABUW_2717 3-oxoacyl-(acyl carrier protein) synthase
-1.80
ABUW_2874 hypothetical protein
-1.80
ABUW_1552 cyoB
cytochrome O ubiquinol oxidase, subunit I
-1.81
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ABUW_1862 aromatic-ring-hydroxylating dioxygenase beta
-1.81
subunit
ABUW_0999 ruvB
Holliday junction DNA helicase RuvB
-1.83
ABUW_3902 trmE
tRNA modification GTPase TrmE
-1.84
ABUW_0980 purN
phosphoribosylglycinamide formyltransferase
-1.86
ABUW_1016 cbl
transcriptional regulator, LysR family
-1.87
ABUW_1228 lipA1
lipoic acid synthetase
-1.87
ABUW_3783 mmsA1 methylmalonate-semialdehyde dehydrogenase
-1.87
ABUW_2246 putative enoyl-CoA hydratase/isomerase
-1.87
ABUW_0570 phage-related baseplate assembly protein (GPJ-1.88
like)
ABUW_1272 hypothetical protein
-1.89
ABUW_1140 lysine 2,3-aminomutase family protein
-1.93
ABUW_1340 hisQ
histidine transport system permease protein HisQ
-1.94
ABUW_1352 ygiW1
bacterial OB fold domain-containing protein YgiW
-1.99
ABUW_4086 Transposase
-2.03
ABUW_2198 hup
DNA-binding protein HU
-2.07
ABUW_2076 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase -2.07
ABUW_0201 gabP
GABA permease
-2.11
ABUW_0355 astE
succinylglutamate desuccinylase
-2.13
ABUW_3305 cysM
cysteine synthase B
-2.13
ABUW_3393 eda
khg/kdpg aldolase
-2.13
ABUW_0797 lipoprotein, putative
-2.17
ABUW_0715 mreB
rod shape-determining protein MreB
-2.20
ABUW_0885 biofilm-associated protein
-2.22
ABUW_3340 prtN
transcriptional regulator PrtN
-2.22
ABUW_0885 biofilm-associated protein
-2.25
ABUW_3705 transcriptional regulator SoxR-family
-2.41
ABUW_1189 ldtJ
ErfK/YbiS/YcfS/YnhG family
-2.47
ABUW_3263 hypothetical protein
-2.47
ABUW_1216 sodB
superoxide dismutase (Fe)
-2.51
ABUW_2634 mutS
DNA mismatch repair protein MutS
-2.53
ABUW_1929 hypothetical protein
-2.56
ABUW_3060 tuf
translation elongation factor Tu
-2.58
ABUW_2239 pyrF
orotidine 5'-phosphate decarboxylase
-2.80
ABUW_0582 phage-related capsid scaffolding protein (GPO-like) -2.92
ABUW_2922 hypothetical protein
-3.09
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